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ABSTRACT 
Adipose tissue exists in three shades: White adipose tissue (WAT), the site of energy 
storage, brown adipose tissue (BAT), which burns nutrients to generate heat and maintain 
body temperature, and brown in white adipose tissue (brite AT), which represents WAT 
adapting BAT features in cold exposure. Thermogenically active BAT has been discovered in 
adult humans and inversely correlates with obesity and insulin resistance. The link between 
impaired insulin sensitivity and the browning of adipose tissue has not been clear however. 
While the necessity for insulin for normal development of adipose tissues is well recognised, 
the dependence of the recruitment of brite adipocytes in functional insulin signalling has not 
been investigated before. We show that β3-adrenergic stimulation can overcome insulin 
deficiency and fully activate the brown program in WAT. Vice versa, while it is known that the 
presence of brite AT allows enhanced glucose clearance, it has not previously been 
investigated whether this tissue is more insulin sensitive than white. Surprisingly we found 
that brite cells and tissues demonstrated markedly elevated glucose uptake even in the 
absence of insulin, and while insulin augmented glucose uptake to both white and brite AT, 
the degree of this response did not differ between the two types of adipose tissue. In line with 
these findings, we observed a marked induction of the insulin independent glucose 
transporter solute carrier family 2 (GLUT-1) upon browning of WAT. Thus we demonstrate for 
the first time that insulin signalling is dispensable for brite recruitment and not improved in 
browned cells or tissues. 
The nuclear receptor co-regulator Transducin (beta)-like 1 X-linked receptor 1 (TBLR) is a 
known transcriptional master-regulator that carries out distinct metabolic roles in liver and 
WAT. We show that, being part of the machinery of a general regulatory mechanism, the 
actions of TBLR depend largely on its environment, since TBLR deficiency in BAT lead to a 
distinct phenotype compared to other tissues and its role in mature cells differs from its role 
during adipogenic differentiation. During differentiation, TBLR balanced growth versus 
differentiation cues and its depletion reduced glucose import and metabolic activity of mature 
adipocytes. In thermogenically active mature brown adipocytes or BAT, Tblr expression was 
found to be cold-inducible downstream of the MAPK pathway. BAT-specific knock out of 
TBLR could be largely compensated for, since gene expression, adiposity, lipid or glucose 
handling and respiration in these mice (BATKO mice) were normal. However, BATKO mice 
had impaired maximal thermogenic capacity upon acute β3-adrenergic stimulation. 
Surprisingly, BAT-specific TBLR KO had systemic effects on gene expression and lead to 
reduced serum very low density lipoprotein (VLDL) both in the cold and at thermoneutrality. 
After excluding altered hepatic production or loss to feces, we observed elevated lipid 
deposition to WAT. Based on our findings, we hypothesise that BATKO mice differentially 
secrete factors that affect peripheral metabolism. 
Understanding the recruitment and regulation of different shades of adipose tissue is a 
crucial step towards pharmaceutically targeting a disadvantageous metabolic state. This 
thesis offers new insights on the dependence of whole body metabolism on the function of 
thermogenically active adipose tissue. 
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ZUAMMENFASSUNG 
Fettgewebe kommt in drei Formen vor: Klassisches weißes Fettgewebe (white adipose 
tissue, WAT), ein Energiespeicherorgan, braunes Fettgewebe (brown adipose tissue, BAT), 
das im Gegensatz zu WAT Nährstoffe verbrennt um Wärme zu erzeugen und die 
Körpertemperatur aufrecht zu erhalten, und sogenanntes „brite“ (brown in white) Fett, 
welches sich wie BAT verhält und in der Kälte in WAT rekrutiert wird („browning“). Wärme-
erzeugendes BAT wurde kürlich entgegen früherer Annahmen in Erwachsenen 
nachgewiesen und korreliert negativ mit Adipositas und Typ 2 Diabetes, jedoch war 
unbekannt, welche Verbindung zwischen verringerter Insulin-Sensitivität und WAT 
„browning“ besteht. Wir zeigen hier, dass es durch β3-adrenerge Stimulation möglich ist, die 
Auswirkungen von Insulindefizienz auf „brite“ Fett zu kompensieren und das braune 
Programm in WAT zur Gänze zu aktivieren. Weiters wurde nie spezifiziert ob „brite“ Fett per 
se insulin-sensitiver ist als weißes. Überraschenderweise konnten wir nachweisen, dass 
„browned“ Fett bereits ohne Insulin mehr Glukose aufnimmt. Insulinstimulation führte zur 
Steigerung der Aufnahmerate, jedoch war das Ausmaß dieser Antwort jeweils gleich stark. 
Im Einklang dazu beobachteten wir einen substanziellen Anstieg des insulin-unabhängigen 
Glukosetransporters „solute carrier family 2“ (GLUT-1) beim „browning“ von WAT. Wir zeigen 
also erstmals, dass WAT „browning“ nicht von Insulin-Signalen abhängt, und dass 
Insulinsensitivität von „browned“ gegenüber weißen Zellen und Gewebe nicht verbessert ist. 
Der Kernrezeptor Koregulator Transducin (beta)-like 1 X-linked receptor 1 (TBLR) ist als 
Master-Regulator bekannt, der in Leber und WAT metabolische Aufgaben übernimmt. Wir 
zeigen, dass TBLR in seiner Funktion stark von seiner Umgebung abhängt, da sich TBLR 
Defizienz in BAT anders auswirkte als in anderen Geweben, und in differenziertem BAT 
anders als während der Adipogenese. Während der Differenzierung balancierte TBLR 
Wachstums- gegen Differenzierungssignale aus und das Ausschalten („knock out“, KO) von 
TBLR hatte zur Folge, dass diese Zellen zu metabolisch weniger aktiven Fettzellen reiften 
und weniger Glukose importierten. In differenziertem BAT war Tblr Expression 
kälteinduzierbar. Mäuse ohne TBLR im BAT (BATKO) konnten den Verlust großteils 
kompensieren und zeigten normale Genexpression, Adiposität, und Fett- und 
Glukosestoffwechsel. Die akute β3-adrenerge Stimulation der maximalen BAT Kapazität von 
BATKO Mäusen war jedoch beeinträchtigt. Überraschenderweise hatten diese Tiere 
reduzierte Spiegel von very low density lipoprotein (VLDL) im Serum, sowohl in der Kälte als 
auch unter thermoneutralen Bedingungen. Dieser Unterschied rührte weder von 
unterschiedlicher hepatischer VLDL Produktion noch von Energieverlust an Fäces her, 
allerdings kommt es zu vermehrter Lipidablagerung in WAT. Basierend darauf vermuten wir, 
dass BATKO Mäuse sich von Kontrolltieren bezüglich der BAT-mediierten Sekretion von 
Faktoren unterscheiden, die periphäre Gewebe beeinflussen. 
Um einen nachteilhaften metabolischen Status verbessern zu können, ist eine 
vielversprechende Strategie, die Regulierung verschiedener Formen von Fettgewebe zu 
verstehen und zu beeinflussen. Diese Arbeit eröffnet neue Erkenntnisse zur Abhängigkeit 
des Stoffwechsels eines ganzen Organismus von der Funktion von braunem Fettgewebe. 
7 
 
ACKNOWLEDGEMENTS 
Looking back on the last 4 years, I can only say that it was a fantastic experience. None of 
this would have been possible without the help of all those people constantly supporting me. 
I want to thank you, Stephan, for accepting me into your lab, and despite it consisting of so 
many and so different members that sometimes we greeted new faces every week, never 
losing touch to the individual members and their project. Not only did I never feel doubt that 
you were interested in the people and projects, but also your optimism is incredibly 
containgious, leading me to walk out from every meeting filled with new enthusiasm. Alex, 
thank you for having been incredibly patient with me when introducing me to the lab, topic 
and methods, I think there could not have been a single person from whom I could have 
learned more, not only because of your patience, but also your dedication to detail. Of course 
the whole group was amazing. This bunch of brilliant people not only helped me more than I 
deserve, but also created this positive atmosphere in which it was a pleasure to work. 
Oksana, I was always looking forward to our preps just because it gave us the time to talk. 
Kati, you fought like a lion with all the hassles we encountered with breeding of our mice, 
thank you. Thank you Mauricio, for never being as annoyed as you would have every right to 
be with my never ending stupid questions. I want to thank all the technicians, you are the 
foundation pillars of all of our success and without you not a single project would have been 
possible. Thanks Ashley and Adriano for reading my thesis and putting up with my English. 
Thanks Maria, you made my transition to TBLR so smooth, even just by email from the 
island. And thank you all A170ies! I also want to thank my TAC committee members, Marcel 
Scheideler, who crossed the alps every time just to be here and support me, and Aurelio 
Teleman, who gave me so much useful input. Thanks also to our collaborators, Carsten 
Sticht who analysed microarray data galore for me and always took time to explain its 
meaning, and Anne Loft for the patient support with ChIPseq and a million of questions. 
Thank you, Prof. Rüdiger Hell, Prof. Peter Angel and Prof. Karin Müller-Decker for taking the 
time and effort to constitute my defense commission. Thank you Lindsay and the Graduate 
School for being so supportive during my time in the Student Council. 
Whom I probably owe most to is my family, who never stopped believing in me and gave me 
all I need and so much more. Papa, you are the one that lighted the spark of fascination for 
wisdom and science in me, since as early as I can think back. Mama, you know me better 
than I know myself, and the knowledge that you will always be there if I fall gives me the 
courage to try flying high. Stefan, Omas, Opas, thank you for believing in me! Thanks to the 
crazy bunch I left in Austria, but who never stopped travelling here just to see me. Who 
would have thought that I’d be Doctor Miss Commander one day? At the same time, I found 
incredible people here that are at the same time friends and family and more. I do not want to 
imagine Heidelberg without our 10-girls-in-a-room cooking sessions. Thank you Chiara, my 
sister in caffeine and Nutella! Ece, health to your hands! Anna, thanks for the szarlotka! 
Thanks for being fed your mums in Italy, Turkey and Poland! And finally, thank you so much, 
Angelo, for even in your pixelated form being able to make every bit of stress go away and 
make me laugh like a moron with just a word and a smile. 
8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“Whether you succeed or not is irrelevant - there is no such thing. 
Making your unknown known is the important thing - and keeping the 
unknown always beyond you.” 
 
Georgia O’Keeffe 
 
 
9 
 
INDEX 
Abstract....................................................................................................................................... 5 
Zuammenfassung ....................................................................................................................... 6 
Acknowledgements .................................................................................................................... 7 
Index ........................................................................................................................................... 9 
Introduction ............................................................................................................................... 12 
Obesity is a pandemic .......................................................................................................... 12 
Obesity leads to the metabolic syndrome and to diabetes .................................................. 13 
Fat does not equal fat: Multiple shades of adipose tissue ................................................... 13 
Brown and white adipocytes differ morphologically ............................................................. 14 
Brown and white adipocytes have different origins.............................................................. 15 
Brown and white adipocytes differ functionally .................................................................... 16 
UCP-1 is regulated both transcriptionally and functionally  .................................................. 18 
Brown and brite fat are glucose sinks burning away nutrients ............................................ 19 
TBLR and TBL are co-regulators with known metabolic roles............................................. 22 
Aim of the projects ................................................................................................................ 24 
Results ...................................................................................................................................... 25 
Browning of White Adipose Tissue uncouples glucose uptake from insulin signalling........... 25 
C57Bl6 is a robust strain to investigate white adipose tissue browning .............................. 25 
Lack of insulin does not impair browning capacity of primary adipocyte progenitors ......... 26 
Osmotic pumps are a valuable tool for constant-flow administration of browning agents to 
mice....................................................................................................................................... 27 
Browning of white adipose tissue is functional in diabetes mouse models ......................... 29 
Browning of white adipose tissue increases systemic glucose clearance in an insulin-
independent manner............................................................................................................. 32 
Browning of white adipose tissue induces GLUT-1 expression .......................................... 34 
Brown Adipose Tissue is one of the checkpoints for the metabolic master-regulator TBLR .. 38 
TBLR localises to the nucleus in vitro, but to the cytosol in vivo ......................................... 38 
Tblr expression in BAT is inducible in vitro .......................................................................... 40 
Tblr expression in BAT is inducible in vivo........................................................................... 45 
Tblr1 is involved in the adipogenic program and in mature adipocyte function .................. 48 
Tblr1 ablation in vitro can distinguish between role during differentiation and role in mature 
adipocytes ............................................................................................................................. 55 
BAT-specific TBLR ablation in vivo is strong and specific ................................................... 64 
TBLR ablation in vivo hardly affects BAT gene expression ................................................. 65 
10 
 
TBLR ablation does not affect adiposity in HFD feeding ..................................................... 69 
Absence of TBLR in BAT does not affect systemic glucose handling................................. 71 
TBLR-deficient BAT is capable of normal lipolysis .............................................................. 73 
Acute stimulation reveals a defect in maximal capacity of TBLR KO BAT.......................... 74 
BATKO mice have reduced serum VLDL at different temperatures.................................... 78 
TBLR-deficient BAT differentially expresses secreted proteins .......................................... 84 
iWAT browning and TBL potentially compensate for TBLO KO .......................................... 86 
Discussion ................................................................................................................................ 90 
Conclusion and outlook .......................................................................................................... 101 
Methods .................................................................................................................................. 103 
Molecular and Biochemical Methods ................................................................................. 103 
Determination of Nucleic Acid Concentration ................................................................. 103 
RNA Isolation and Quantitative RT-PCR ........................................................................ 103 
Microarray Analysis ......................................................................................................... 103 
Chromatin Immunoprecipitation DNA-Sequencing......................................................... 103 
RNA-Sequencing............................................................................................................. 105 
Cloning ............................................................................................................................ 105 
Luciferase assays............................................................................................................ 106 
Protein Analysis............................................................................................................... 107 
Immunohistochemistry .................................................................................................... 108 
Quanification of Mouse Serum Metabolites .................................................................... 109 
Quantification of Tissue Triglyceride Levels ................................................................... 109 
Fast‐protein liquid chromatography ................................................................................ 109 
Bomb calorimetry of feces .............................................................................................. 109 
Cell Biology ......................................................................................................................... 110 
Cell Cultivation ................................................................................................................ 110 
In vitro differentiation ....................................................................................................... 110 
Cell stimulation for mRNA expression analysis .............................................................. 111 
Progenitor Isolation and Cell Culture .............................................................................. 111 
Transfection..................................................................................................................... 112 
Adenoviral Transduction ................................................................................................. 113 
GLUT-1 Inhibition ............................................................................................................ 114 
Lipolysis Assay ................................................................................................................ 114 
Lipogenesis Assay .......................................................................................................... 114 
In Vitro Glucose Uptake Assay ....................................................................................... 115 
Seahorse Metabolic Flux Analysis .................................................................................. 116 
11 
 
Animals ............................................................................................................................... 117 
Obesity Models................................................................................................................ 117 
Genetic Models ............................................................................................................... 117 
CL316243 injections........................................................................................................ 118 
Osmotic Pumps ............................................................................................................... 118 
Glucose Tolerance Test .................................................................................................. 118 
ITT and in Vivo Glucose Uptake Assay .......................................................................... 118 
Oral Lipid Tolerance and Trioleate Uptake Test............................................................. 120 
Hepatic output assay....................................................................................................... 121 
Metabolic Phenotyping in the TSE System .................................................................... 121 
Adipose Tissue Explants................................................................................................. 122 
Ethics Statement ............................................................................................................. 122 
Statistical Analysis .............................................................................................................. 122 
Material ................................................................................................................................... 123 
Buffers ............................................................................................................................. 123 
Oligonucleotides .............................................................................................................. 124 
Plasmids .......................................................................................................................... 126 
Antibodies........................................................................................................................ 127 
Enzymes .......................................................................................................................... 127 
Instruments...................................................................................................................... 128 
Software .............................................................................................................................. 129 
Kits ................................................................................................................................... 130 
Chemicals ........................................................................................................................ 130 
Consumables .................................................................................................................. 133 
Appendix ................................................................................................................................. 136 
Adenovirus Sequences....................................................................................................... 136 
Glossary .............................................................................................................................. 138 
Literature................................................................................................................................. 140 
 
Introduction 
 
12 
 
INTRODUCTION 
Obesity is a pandemic 
For the first time in the history of mankind, over-nutrition accounts for a higher death toll than 
under-nutrition. An imbalance in energy intake over energy expenditure causes excessive 
accumulation of fat, which is classified as overweight if the body mass index (BMI,the body 
weight in kilograms (kg) divided by the square of body height in meters, kg/m2), exceeds 25, 
and as obesie if the BMI exceeds 30. Roughly 40 % of the world’s population is overweight 
and more than 1 out of 10 individuals is obese, numbers that have doubled in the last 30 
years. This correlates with an increased risk for the globally leading source of death, 
cardiovascular disease, as well as for diabetes and certain cancers (WHO (2015) Fact sheet 
No. 311, Obesity and overweight). 
 
 
In order to identify strategies to counteract the deleterious consequences of obesity, the 
underlying causes need to be understood as well as the mechanisms by which, upon onset 
of obesity, systemic adverse effects are mediated. It is widely accepted that lifestyle, namely 
Figure 1. Worldwide prevalence of  overweight . The percentage of overweight (BMI > 25 kg/m2) 
inhabitants age 20+ (male and female) in 2008 is shown. © Copyright World Health Organization 
(WHO), 2015. 
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diet or nutritional status and physical activity, translate to body composition and as such 
there is a strong correlation between socioeconomic status and obesity [10, 11]. Additionally, 
genetic predispositions contribute to the development of obesity [12, 13], making it clear that 
adipose tissue biology needs to be correctly regulated to maintain a healthy status. 
 
Obesity leads to the metabolic syndrome and to diabetes 
As a consequence of being overweight or obese, a plethora of deleterious health conditions 
are described. These co-morbidities comprise the so-called metabolic syndrome, which is 
defined by glucose intolerance or insulin resistance, accompanied by further factors such as 
obesity, hypertension or an altered serum lipid profile (dyslipidemia) [14]. One of the 
underlying causes of insulin resistance are toxic by-products of metabolic overload [15]. 
Mainly this equates to elevated levels of circulating fatty acids (FAs), either produced by 
lipolysis in lipid stores in adipose tissue, or by lipoprotein lipolysis in other tissues through the 
action of lipoprotein lipase (LPL) [16]. This in turn leads to FA-mediated dampening of insulin 
signalling [17-19] and to adipocyte death followed by chronic inflammation and macrophage 
infiltration [20, 21]. Furthermore, the abundance and composition of triglyceride and 
cholesterol-rich lipoproteins, which transport lipids through the bloodstream, is disturbed [14], 
due to both fatty acid induced elevated production of very low density lipoprotein (VLDL) in 
the liver [22], and due to diminished clearance of peripheral cholesterol following a reduction 
in levels of high density lipoprotein (HDL) [23, 24]. 
The metabolic syndrome is a strong determinant for the subsequent development of type 2 
diabetes [25, 26]. 
Fat does not equal fat: Multiple shades of adipose tissue 
When examining obesity and overabundance of fat, it is crucial to clearly define the location 
and nature of lipid depots. 
The major site of fat storage in mammals is white adipose tissue (WAT) [27], most of which is 
located either intra-abdominally (also referred to as visceral), embedding inner organs, or 
subcutaneously in the form of inguinal (around the hips) or intrerscapular (between the 
shoulder blades) fat [28]. Over-abundance of subcutaneous fat bears less risk for the 
development of diabetes than excessive accumulation of intra-abdominal fat [29]. 
This can to some extent be attributed to the fact that adipose tissue acts as an endocrine 
organ in a depot-specific manner [30]. Adipose tissue secretes factors that act either in a 
paracrine manner, on neighbouring cells, or in an endocrine manner, being secreted into the 
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circulation. Among those factors are cytokines such as leptin and tumor necrosis factor alpha 
(TNFα), complement factors such as adipsin and adiponectin or proteins involved in lipid 
homepstasis such as lipoprotein lipase (LPL) or apolipoproteins [31]. 
In addition to the location, the composition of adipose tissue can vary between individuals. 
Adipose tissue is comprised not only of adipocytes (mature fat cells), but also connective 
tissue and the stromal vascular fraction of cells, which containins stem cells that can 
differentiate into mature adipocytes [32]. Excess of nutrients leads to expansion of adipose 
tissue, and while in adult-onset of obesity this mainly means filling of already present 
adipocytes with lipids (hypertrophy), in early onset obesity this is accompanied by increased 
cell number, termed hyperplasia [33]. 
Finally, in contrast to energy storing white adipose tissue, brown adipose tissue comprises a 
functionally diverse fat depot, dissipating nutrients to generate heat via the mitochondrial 
pore protein uncoupling protein 1 (UCP-1) [34]. The recent discovery that brown adipocytes 
can be detected in adult humans [35-37] has drawn interest to elucidate its therapeutic 
potential in the setting of obesity. While most of the conventional approaches to 
pharmaceutically target obesity have shown only limited success, such as inhibition of 
intestinal nutrient uptake [38] or of white adipose tissue (WAT) formation [39, 40], the 
activation of brown adipose tissue (BAT) is a promising approach, having been proven to 
help maintain normal glucose homeostasis [41-43]. 
Brown and white adipocytes differ morphologically 
Brown adipocytes differ morphologically from classical white adipocytes, having small 
multilocular lipid droplets rather than one large droplet, and by possessing and increased 
number and size of mitochondria [44], which can be seen in Figure 2. Brown adipocyte 
mitochondria are numerous, ovoid in shape and densely packed with laminar cristae [2]. 
Also, BAT is highly vascularised [45, 46], conferring its darker colour compared to white 
adipose tissue, which is visible even upon gross inspection [2]. Finally, brown adipocytes, in 
contrast to white, are characterised by the expression of uncoupling protein 1 (UCP-1, also 
thermogenin) [47, 48], which is the basis of their differential function as will be explained 
below. 
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Figure 2. Differential morphology of brown 
and white adipose t issue. Adjacent brown 
and white adipose tissu depots stained 
with an antibody against the brown fat-
specific protein uncoupling protein 1 (UCP-
1) [1, 2] 
 
Brown and white adipocytes have different origins 
Brown adipose tissue, although being rich in lipids just like white, is not a fat depot in the 
classical sense. Instead, it shares more common features with muscle, as it is designed for 
lipid catabolism rather than storage, it is innervated by the sympathetic nervous system and 
is rich in mitochondria [49]. 
In general, brown as well as white adipocytes differentiate from mesodermal stem cells 
(MSCs) into adipocytes in two steps, first committing either to the white or the brown 
preadipocyte lineage, followed by terminal differentiation [27]. Each of these steps is 
controlled by individual subsets of regulatory proteins. The commitment step is mainly 
regulated by bone morphogenic proteins (BMPs) [50, 51], the hedgehog pathway [52] and 
the Wnt pathway [53, 54], while terminal differentiation is regulated by insulin [55], cAMP 
responsive element binding (CREB) [56], and in response to insulin and CREB subsequently 
by CCAAT/enhancer-binding protein beta and delta (C/EBPβ, C/EBPδ) [57, 58] and after that 
by C/EBPα and peroxisome proliferator-activated receptor gamma (PPARγ) [59-62]. 
It was recently confirmed that brown fat cells and muscle cells, in contrast to white fat cells, 
derive from a common myogenic factor 5 (Myf5) expressing precursor and they can be inter-
converted during differentiation under the control of PRD1-BF1-RIZ1 homologous domain 
containing 16 (PRDM16) [63, 64]. 
In addition to classical brown adipose tissue, white adipose tissue can respond to the 
demand for thermogenesis upon cold exposure by so called “browning”, that is, the 
emergence of adipocytes with brown properties within classical WAT depots [65-68]. While 
the morphology and function, including UCP-1 expression, of these “brite” (brown in white, 
sometimes also referred to as beige) adipocytes resembles that of brown, they differ from 
brown adipocytes found in classical BAT depots as they do not descend of Myf5 expressing 
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precursors [69-71]. It is currently not resolved whether brite cells exclusively arise exclusively 
from brite precursor cells residing in white fat depots [72, 73], or if, as numerous studies 
suggest [2, 74-77], even fully differentiated white adipocytes can trans-differentiate into brite 
cells [8]. 
 
 
Brown and white adipocytes differ functionally 
Higher vascularisation of BAT compared to WAT is necessary, since the function of BAT is to 
use the energy from food intake for the production of heat if challenged by cold-exposure 
[78], as opposed to white adipose tissue that stores excess energy as triglyceride depots 
[79]. This allows animals to adapt to cold challenges and switch from shivering to more 
Figure 3. White,  brite and brown adipocytes  arise f rom dif ferent  precursors . While brown 
adipocytes arise, like muscle cells, from Myf5 expressing precursors and can be acutely activated 
by cold exposure (a), white and brite adipocytes derive from adipocyte precursors (b). Different 
mechanisms were suggested to influence the fate determination between white and brite 
adipocytes, such as cold and dietary stimuli during differentiation (b). [8] 
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energy-conserving non-shivering thermogenesis, a process dependant on the mitochondrial 
pore protein UCP-1 [47, 48]. 
In general, to gain energy from food, nutrients are oxidised and electrons resulting from this 
breakdown are gradually transferred to oxygen (O2). This process allows for the generation 
of adenosine triphosphate (ATP) from adenosine diphosphate (ADP) and inorganic 
phosphate (Pi), a process referred to as oxidative phosphorylation. The breakdown of 
nutrients leads to the production of reduction equivalents by transferring electrons (e-) to 
NAD+, reducing it to NADH. In the mitochondria of each cell, those electrons are then step-
wise handed through a chain of protein-complexes in the inner mitochondrial membrane. 
Those complexes consist of 
• Complex I (NADH:ubiquinone oxidoreductase, transfers e- from NADH to 
ubiquinone, reducing it to ubiquinol) 
• Complex II (succinate:ubiquinone oxidoreductase, alternative entry point for 
succinate-derived e- directly from the citric acid cycle) 
• Complex III (ubiquinone:cytochrome c oxidoreductase, transfers e- from 
ubiquinol to cytochrome c) 
• Complex IV (cytochrome c oxidase, transfers e- from cytochrome c to O2) 
• Complex V (ATP synthase, creates ATP from ADP and Pi powered by the 
proton (H+) gradient over the inner mitochondrial membrane) 
Complex I, III and IV pump protons from the mitochondrial matrix into the intermembrane 
space between the permeable outer and the impermeable inner mitochondrial membrane, 
which creates a gradient and thus force, both in concentration and charge. The last step of 
this process limits the reaction as an equilibrium is reached until ATP is again hydrolysed to 
ADP + Pi. [80]. 
Brown adipocyte mitochondria however possess a unique feature, as they express a protein, 
uncoupling protein 1 (UCP-1) that permeabilises the inner mitochondrial membrane, thereby 
dissipating the electrochemical gradient and uncoupling respiration from the need of ATP 
synthesis and use. By disrupting the equilibrium and releasing heat rather than ATP, the 
reaction allows the continual breakdown of nutrients, which, in the absence of uncoupling, 
would require ATP to be hydrolysed (for example by powering muscle contraction) [81, 82]. 
Phrased simply, in the cold BAT burns energy stores without requiring physical activity. 
The events occurring during oxidative phosphorylation and uncoupled respiration are 
illustrated in Figure 4. 
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UCP-1 is regulated both transcriptionally and functionally 
Without control, the existence of brown adipose tissue would, in a futile cycle, lead to 
depletion of energy and consequently death. Thus brown adipose tissue function, in 
particular UCP-1 meadiated events, are tightly controlled to assure uncoupling only takes 
place when required. This control is exerted on the one hand transcriptionally, allowing 
adipocytes to gradually express increasing amounts of UCP-1 during the course of cold 
adaptation, and on the other hand on protein activation levels, allowing for acute UCP-1 
activation upon β-adrenergic stimulation [78]. 
In both cases, the initial steps are the same. Cold exposure leads to norepinephrine (NE, 
equal to noradrenalin) release [83] and activation of the adipose β3-adrenergic receptor (β3-
AR) [84, 85]. The β3-AR is a G-protein coupled receptor (GPCR) and upon activation of the 
membrane bound G-protein GS [86], adenylyl cyclase is activated which triggers an increase 
in the second messenger molecule cyclic adenosine monophosphate (cAMP) [87] and 
subsequent activation of protein kinase A (PKA) [88]. 
PKA can then mediate both the transcriptional response required for cold adaption, and 
acute UCP-1 activation. The former is achieved by phosphorylating and activating cAMP 
response element binding (CREB) and subsequent gene expression programs [89, 90]. 
Figure 4. Ucp1 uncouples respiration by dissipating the proton gradient . Gradual electron transport 
through the complexes of the electron transport chain in the inner mitochondrial membrane lead to 
the buildup of an electrochemical gradient, which is the driving force of ATP production. 
Dissipation of this gradient through the pore protein UCP-1 uncouples respiration from ATP 
generation and leads to the production of heat (Figure adapted from [7] 
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Those include direct Ucp1 binding by CREB [91] and also phosphorylation and activation of 
the p38 mitogen-activated protein kinase (MAP kinase) pathway [92] and subsequently the 
PPARγ co-regulator PGC-1α [93], which can again bind the Ucp1 promoter [94]. 
Even in the presence of high UCP-1 expression, mitochondria in BAT stay coupled and UCP-
1 inactivated until stimulated, which can occur in a matter of minutes [78]. In the physiological 
state, UCP-1 is maintained inactive through inhibition by purin nucleotides such as GDP and 
ADP [46, 95]. However in the cold, upon activation of PKA as described above, lipolysis is 
induced and free fatty acids are produced [96-98]. Those fatty acids do not only serve as fuel 
to power the electron transport chain as described above, but also activate UCP-1 [82, 99]. 
In fact, despite the fact that fatty acids possess, to some degree, even UCP-1-independent 
capability to drive respiration, by acting as fuel or even as detergents with inherent 
uncoupling capability [100], the activation of thermogenesis is still fully dependent on UCP-1. 
This is proven by the findings that FAs fail to induce thermogenesis in UCP-1 knockout cells 
[101] and that on the other hand unmetabolisable FA analogues are still capable of UCP-1 
induction [102]. 
Brown and brite fat are glucose sinks burning away nutrients 
The function of thermogenically active adipose tissue, as explained above, together with the 
discovery of its presence in adult humans, make it an interesting candidate for counteracting 
nutrient overload, obesity and diabetes. There are speculations that one of the physiological 
functions of BAT is to prevent obesity [103, 104]. High fat diets have been shown to activate 
thermogenesis [105], however it is not fully understood whether defects in BAT function have 
the potential to facilitate obesity. While some previous reports suggest that BAT-deficient 
animals are obese [106], other studies found that UCP-1 knockout animals were not 
overweight or obese [107]. In humans, BAT activity negatively correlates with adiposity [108], 
and despite the small amount of BAT present in humans, it is estimated that brown fat could 
contribute up to 20% of daily energy expenditure [109]. 
Upon cold-induced activation of BAT, glucose uptake is increased [110], and this has the 
potential to systemically clear glucose and thereby improve insulin sensitivity in humans [42, 
43], which makes targeting of BAT a promising strategy in the prevention and treatment of 
obesity-induced diabetes [41]. 
Additionally, recent studies demonstrated that BAT has the potential to correct another 
hallmark of the metabolic syndrome, hypertriglyceridemia, by clearing triglyceride rich 
proteins from the circulation via on LPL activity [111]. 
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Transcriptional co-regulation of gene expression depends on multiprotein 
complexes 
Gene expression is coordinated depending on cell type, developmental stage or specific 
requirement in response to environmental changes. The latter is largely possible by 
regulating gene expression programs through nuclear receptors (NRs), proteins that can be 
activated by ligand binding, translocate to the nucleus and regulate target gene expression 
[112]. These ligands are often lipophilic hormones, such as steroids and thyroids, that 
instead of binding to surface receptors enter the cell and bind to NRs. In addition to hormone 
activated nuclear receptors, there are so-called orphan receptors for which their ligands have 
not yet been identified [113, 114]. NRs, once in the nucleus, bind as homo- or heterodimers 
to palindromic response elements (REs) [115]. The structure of NRs is modular and outlined 
in Figure 6. 
Figure 5. Brown fat is existent in humans and c lears  glucose and fat . (A) 18F-fluorodeoxiglucose 
(18F-FDG) uptake studies revealed sites of high glucose uptake in adult human subjects, confirmed 
to being adipose tissue by computed-tomography coupled positron emission tomoscintigraphy 
(PET-CT) scans in follow up studies. (B) Brown fat cells import glucose which is broken down by 
glycolysis or converted to lipids. Upon adrenergic activation, intracellular lipolysis creates free fatty 
acids, serving both as activators and as fuel for thermogenesis. (Figure adapted from [9]) 
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In addition to being controlled by the presence and absence of ligands, NRs interact with co-
regulators, proteins that mediate activation (co-activators) or repression (co-repressors) of 
NR target genes [116]. The latter is achieved by recruiting proteins that interact with un-
bound NRs and form a co-repressor complex at target gene promoters. The two best 
characterised co-repressors are the nuclear receptor co-repressor NCoR [117], and SMRT 
(Silencing Mediator of Retinoid and Thyroid Receptors [118]. Those proteins interact with 
NRs [119] and exert repressive function [120]. Diverse interactions have been described, in 
which NCoR or SMRT form complexes with histone deacetylase 3 (HDAC3), transducin-β-
like 1X-linked (TBL1X, or also TBL) and its related protein transducin-β -like 1 X-linked 
receptor 1 (TBL1XR1, or also TBLR). In these complexes, HDAC3 is responsible for the 
repressing function by deacetylating chromatin, which causes heterochromatin formation and 
shut down of gene expression [121-123]. This complex is illustrated in Figure 7. 
 
 
Figure 7. Co-repressor complexes consis t  of  mult iple proteins . NRs not bound by ligands recruit 
co-repressor complexes to mediate silencing of target gene repressors. Co-repressors such as 
NCoR and SMRT interact with further proteins such as HDAC3, TBL or TBLR to mediate 
heterochromatin formation and gene repression (figure adapted from[5]). 
Figure 6. Nuc lear receptors  are modular proteins . Apart from a N-terminal receptor specific 
activating domain (AF-1), NRs consist of a C-terminal ligand dependent activating domain (AF-2), 
those two being separated by a DNA binding domain [6]. 
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Finally, co-regulators themselves are target of regulation, and a variety of post-transcriptional 
modifications has been reported to being able to transmit signals by activating or inactivating 
NR co-regulators. For example mitogen triggered activation of the MAPK pathway can lead 
to co-repressor phosphorylation and export from the nucleus, thereby activating gene 
expression [124]. Also acetylation [125] or ubiquitinylation [126] have been described. 
Intriguingly, this allows a common co-repression machinery to being activated or de-activated 
for specific targets in a tissue-specific way. One example is the co-activator PGC-1α that in 
brown fat is described as to interact with PPARγ and TR to activate Ucp1 transcription [127]. 
The same factor however in liver is known to, upon cAMP signalling-mediated CREB 
phosphorylation, facilitate glucocorticoid signalling-dependent expression of gluconeogenic 
genes [93]. Thus, not only differential expression but also distinct regulation of NR co-
regulators can determine tissue-specific responses. It is even speculated that co-regulators, 
being amplifiers of gene expression responses, are the missing link to explain how small sets 
of genetic mutations can give rise to a wide-spread spectrum of phenotypes [112]. 
TBLR and TBL are co-regulators with known metabolic roles 
As outlined above, NRs work in cooperation with multiprotein-complexes mediating 
repressive or activating function and those co-regulators can be targeted and modified in 
order to change their function. 
Two proteins sharing roughly 90 % sequence homology, TBLR and TBL, together with 
HDAC3, are part of the NCoR or SMRT co-repressor complex. They are, like HDAC3, 
essential for NCoR repressive function [128]. However, NCoR repressive function depends 
on HDAC3 but not on TBLR/TBL, suggesting that they regulate the co-repressor complex in 
a different way than the actual de-acetylating function [129]. One way they do so seems to 
be targeting of the NCoR complex to histones, in order to, upon initial weak de-acetylation 
capability, recruit the complex to its site of action and thereby enhance its potency [130]. 
Further, both proteins harbour an F-box/WD40 repeat motif, which is known to allow for 
target protein poly-ubiquitinylation and degradation [131], suggesting that they can function 
by altering the stability of the NCoR complex. In fact, TBLR and TBL do not only mediate 
gene repression, but have also been shown to activate gene expression. TBLR and TBL can 
serve as nuclear exchange factors, recruiting the ubiquitin conjugating/19S proteasome 
complex, which leads to the exchange of co-repressors (NCoR or SMRT) for co-activators 
[132]. 
While both factors have been described as functionally redundant [128], subsequent 
research showed they differ in 5 phosphorylation sites, which allows for differential 
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regulation. TBL possesses unique sites phosphorylated by glycogen synthase kinase 3 
(GSK3), while TBLR harbours a unique site targeted by protein kinase C-δ (PKCdelta) [3]. 
Figure 8 illustrates the action of TBLR and TBL in the NCoR or SMRT co-repressor complex. 
 
 
Conceivably, being part of the machinery that exerts one very common mechanism of gene 
regulation, both TBLR and TBL have been associated with disease development if aberrantly 
expressed. TBLR mutations are associated with autism and mental disabilities [133-135]. 
Further, they regulate the balance between pro- and anti-proliferative effects, depending on 
their interaction partners. For example, TBLR was recently demonstrated to interact with the 
androgen receptor (AR) in order to switch from pro- to anti-proliferative programs, 
suppressing prostate cancer growth [136]. In the setting of cervical cancer however, TBLR 
was found to promote metastasis [137]. TBL was demonstrated to interact with nuclear factor 
κB (NF-κB), thereby activating pro-proliferative programs and enhancing breast cancer 
invasiveness [138]. 
Finally, metabolic roles were reported for both TBLR and TBL, and notably, depending on the 
tissue, they can mediate specific roles without being completely functionally redundant, 
leading to strong phenotypes upon deletion of TBLR-only in adipose tissue or of TBL-only in 
the liver. Our group demonstrated that in white adipose tissue, TBLR interacts with PPARγ 
and retinoid X receptor alpha (RXRα) to allow cAMP-mediated activation of lipid mobilization, 
Figure 8. TBLR and TBL can be phosphory lated to mediate nuc lear co-regulator exchange. 
Activating signals lead to kinase mediated phosphorylation of TBLR and / or TBL on distinct sites. 
In turn they recruit the ubiquitin conjugating/19S proteasome complex, thereby eliminating co-
repressors and exchanging them for co-activators (figure adapted from [3]). 
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thus potentially being protective against the development of obesity [139]. In the liver, TBL, 
together with TBLR and PPARα, is responsible for fatty acid oxidation, its absence inducing 
hypertriglyceridemia and hepatic steatosis (“fatty liver”) [140]. In embryonic stem cells, TBL 
deletion blocks adipogenic differentiation [132]. 
Aim of the projects 
This thesis is comprised of two related projects, the first focusing on insulin signalling and the 
browning of white adipose tissue, the second elucidating the role of nuclear receptor co-
regulator TBLR in brown adipose tissue. 
Due to the potential of brown and brite fat to counteract obesity, it is crucial to understand 
how brown adipocytes can be recruited and how they are regulated. The first part of this 
thesis will describe the interplay between insulin signalling and the recruitment of brite 
adipocytes. It is known that insulin and insulin-like growth factor (IGF)-1 are indispensable for 
adipogenic differentiation [141, 142], their absence leading to reduced adipose depots and 
basal brown fat thermogenesis in vivo [143]. Interestingly, the capability of β3-adrenergic 
stimulation was maintained regardless of insulin [143]. These studies did however not cast 
light on the influence of insulin signalling on brite recruitment within white adipose tissue. We 
hypothesised that in states of impaired insulin signalling, white adipose tissue browning may 
be impaired, which may partially explain lower BAT abundance in obese and thus insulin 
resistant patients. Further we speculated that, from the opposing point of view, recruitment of 
brite adipocytes might improve insulin sensitivity. While it is known that browning increases 
glucose clearance, it is not described whether brite cells and tissues are more insulin 
sensitive, that is, reacting stronger to insulin stimulation than white adipose tissue. 
The second part of this thesis will focus on nuclear receptor co-regulator-mediated regulation 
of brown adipose tissue function. Based on the known metabolic roles of TBL [140] and 
TBLR [139] we hypothesised that also other metabolically active tissues may be hotspots for 
TBLR- or TBL-mediated regulation. Since previous studies failed to distinguish between 
different fat depots, it was not previously clear if and which effects of ablation of TBLR in total 
adipose tissue [139] are attributable to brown fat function. In order to understand the role of 
TBLR in this functionally distinct adipose depot, in vitro and in vivo studies were employed to 
examine the role of TBLR and TBL in brown adipocytes and subsequent implications on 
systemic metabolic homeostasis. 
With these two approaches this study aims to enhance the understanding of the regulation of 
the function of thermogenic active brown adipocyte cells and tissues by hormones such as 
insulin and by transcriptional regulators such as TBLR. 
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RESULTS 
The goal of this project was to broadly contribute to the understanding of the functional 
regulation of thermogenic active brown, as well as brite (brown in white) adipose cells and 
tissues. The first part of this thesis will provide insights on the complex interplay between 
glucose uptake, insulin signalling and white adipose tissue browning, while the second part 
will investigate how the metabolic master-regulator Transducin (beta)-like 1 X-linked 
Receptor 1 (TBL1XR1, or also TBLR) integrates brown adipose tissue-specific mechanisms 
and systemic metabolic regulation. 
BROWNING OF WHITE ADIPOSE TISSUE UNCOUPLES GLUCOSE 
UPTAKE FROM INSULIN SIGNALLING 
C57Bl6 is a robust strain to investigate white adipose tissue browning 
In the beginning of this project the role of mouse strain and gender was tested in regard of 
their effect on browning potential. Primary inguinal white adipose tissue (iWAT) stromal 
vascular fraction (SVF)-derived Lin-Sca1+ [144] adipocyte progenitors from C57Bl6 (BL6) and 
129S6/SvEvTac (SV129) male and female mice were differentiated in vitro in the presence or 
absence of carbaprostacyclin (cPGI2), which had previously been reported to induce 
browning of white adipocytes by acting downstream of β-adrenergic signalling. This resulted 
in “white” (ethanol (EtOH) vehicle-treated) or “brite” (cPGI2-treated) adipocytes. The brite 
state of white adipocytes was defined based on the elevated mRNA expression of 
uncoupling protein 1 (Ucp1). SV129-derived adipocytes expressed higher levels of Ucp1 
even in the absence of cPGI2, indicating an already brite state in basal conditions. In both, 
BL6- and Sv129-derived adipocytes, basal Ucp1 expression was lower in cells from females, 
and in all samples Ucp1 expression was inducible by chronic cPGI2 treatment. Based on the 
largest relative change by browning cues, female BL6 mice were chosen for further studies 
(Figure 9). 
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Lack of insulin does not impair browning capacity of primary adipocyte 
progenitors 
To address the question of whether insulin signalling during adipocyte differentiation is 
required for brite recruitment, iWAT SVF-derived primary adipocyte progenitors were isolated 
from BL6 female mice. Differentiation was induced in the absence or presence of cPGI2 
and/or insulin, and the cells were harvested 24 hours later. The capability of adipocyte 
progenitors to respond to insulin at this timepoint of differentiation was confirmed by Western 
Blot analysis, detecting phospho-AKT (Figure10.A,B). RNA of harvested cells was subjected 
to microarray analysis with Affymetrix chips. As expected, bioinformatic analysis of gene 
expression data revealed that cPGI2 induced distinct gene expression patterns, resulting in 
the samples from brite-induced cells to group clearly in a hierarchical clustering analysis on 
correlations. However the presence or absence of insulin during the first 24 hours of 
differentiation hardly affected gene expression in white as well as in brite-induced cells 
(Figure 10.C). Next, primary adipocyte progenitors were differentiated for 8 days into mature 
white or brite adipocytes with insulin present or absent in the medium. The role of insulin in 
the differentiation to the respective adipocyte type was assessed based on the expression 
patterns of marker genes. In general, the activation of the adipogenic program, as judged by 
the expression of the early adipogenic genes peroxisome proliferator activated receptor 
Figure 9. iWAT adipocytes of BL6 mice are white and can turn brite.  Ucp1 mRNA expression of 
primary iWAT SVF-derived adipocyte progenitors from BL6 and SV120 male and female mice 
differentiated in vitro into white (EtOH treatment) or brite (cPGI2 treatment) adipocytes. All values 
are expressed as means ± SEM, n = 3 mice for cell isolation. Three way ANOVA proved, both in 
basal and in NE stimulated state, p<0.001 for white (EtOH-treated) vs. brite (cPGI2 treated) cells, 
for BL6 vs. SV129, and for male vs. female. 
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gamma (Pparg) [145] and its co-factor peroxisome proliferator activated receptor gamma 
(Ppargc1a), was not largely compromised by the lack of insulin (Figure 10.D). However, 
insulin appeared to be essential for full differentiation into mature adipocytes, since cells 
differentiated without insulin exhibited lower levels of the white adipogenesis marker resistin 
(Retn) and of the late adipogenesis marker fatty acid binding protein 4 (Fabp4) (Figure 10.E). 
Fabp4 levels could only be partially rescued by the stimulating effect of cPGI2 on 
adipogenesis in the absence of insulin (Figure 10.E). The brite adipogenesis markers Ucp1 
and Cell death-inducing DNA fragmentation factor, alpha subunit-like effector A (Cidea) were 
only marginally affected by the lack of insulin in the white state (Figure 10.F). cPGI2 was still 
capable of inducing their expression, albeit to a compromised extent, in line with impaired 
general adipogenesis (Figure 10.F). Altogether, this data show that insulin is crucial for 
regular adipocyte differentiation while it does not arrest the browning process. 
Osmotic pumps are a valuable tool for constant-flow administration of 
browning agents to mice 
For in vivo studies of recruitment of brite adipocytes, the standard method used previously in 
our lab was daily intraperitoneal (i.p.) injection of 1 mg/kg bodyweight of the β3-adrenergic 
sympathomimetic agonist CL316243 (CL) for 10 consecutive days. However we chose to 
apply CL by a constant flow administered by implanted osmotic pumps (equal daily dose and 
duration) after comparing both methods. We found that mice reacted to both administration 
methods with browning of WAT as indicated by increased food intake (Figure11.A) without 
changes in body weight (Figure11.B), while magnetic resonance imaging (MRI) analysis 
even showed a trend to decreased body fat content (Figure11.C). Likewise, with both 
methods WAT weight was decreased to a similar extent while BAT weight was unaffected 
(Figure11.D). Finally, mRNA expression levels of marker genes for WAT browning (Ucp1, 
Cidea and the mitochondrial factors cytochrome c oxidase subunit VIIa 1 (Cox7a1) and VIIIb 
(Cox8b)) were found to be induced equally by either application method, while the 
expression of the WAT marker gene Retn was unaffected (Figure11.E, inguinal white 
adipose tissue (iWAT), the same was found in abdominal WAT (aWAT), data not shown). 
Further, pump-implanted animals did not suffer from any adverse side effects as compared 
to injected animals. On the contrary, i.p.-injected animals exhibited signs of higher stress 
levels, such as slight browning even in the basal state (indicative of a generally elevated 
adrenergic tone) (Figure11.E), as well as a larger relative liver weight (Figure11.F) compared 
to pump-implanted animals. Based on these results we chose to continue using osmotic 
pump implantation as a method of inducing browning of WAT in vivo. 
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Figure 10. Lack of insulin does not impair browning capacity of primary adipocyte progenitors .  (A) 
Western Blot and (B) corresponding quantification with ImageJ of iWAT SVF-derived primary 
adipocyte progenitors at 80% confluency, stimulated with the indicated doses of insulin for 15 
minutes. (C) Heatmap showing differential mRNA expression between confluent iWAT SVF-derived 
primary adipocyte progenitors differentiated for 24 h with white (EtOH-treated) or brite (cPGI2 
treated) differentiation cocktail and between absence or presence of insulin (Ins) in the medium. 
Higher and lower expression is displayed in red and blue, respectively. (D) mRNA expression of 
Pgc1a and Pparg or (E) Fabp4 and Retn or (F) Ucp1 and Cidea in iWAT SVF-derived primary 
adipocyte progenitors differentiated into white or brite adipocytes for 8 days with insulin present or 
absent in the differentiation medium. All values in bar graphs are expressed as means ± SEM, n = 
3 animals for cell isolation, #p<0.05, ##p<0.01, ###p<0.001 white (EtOH-treated) vs. brite (cPGI2 
treated) cells, *p<0.05, **p<0.01, ***p<0.001 normal conditions vs. insulin deprived conditions. 
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Browning of white adipose tissue is functional in diabetes mouse models 
Analogously to the in vitro data shown above, the importance of insulin signalling on the 
recruitment of brite adipocytes in vivo was studied in established experimental models of 
insulin insufficiency. We used streptozotocin (STZ)-induced β-cell ablation to create mice 
lacking insulin, mimicking Type I diabetes [146], and high fat diet (HFD) versus low fat diet 
(LFD) feeding to generate obese, insulin resistant mice, mimicking Type II diabetes [147]. 
The pathological settings were confirmed by measuring blood glucose and insulin levels, 
revealing high blood glucose levels accompanied by a lack of insulin in STZ-treated mice as 
well as high blood glucose levels despite elevated insulin levels typical for HFD-fed mice 
(Figure12.A, B). Metabolic abnormality in these animals was further confirmed by 
demonstration of weight and adipose tissue loss in the STZ and gain of weight and adiposity 
in the HFD model (Figure12.C, D). 
Figure 11. Drug delivery by osmotic pumps induces WAT browning equally  ef f ic ient  as  by  i.p.  
injec t ions. Female BL6 mice were subjected to recruitment of brite adipose tissue by administering 
1 mg/kg body weight CL for 10 days either by i.p. injections (i.p.) or by implanted osmotic pumps 
(s.c.). (A) Food intake, (B) body weight, (C) body fat mass as assessed by MRI, (D) iWAT weight, 
(E) mRNA expression of brite and white marker genes and (F) liver weight in response to CL-
treatment. medium. All values in bar graphs are expressed as means ± SEM, n = 5, #p<0.05, 
##p<0.01, ###p<0.001 white (NaCl-treatment) vs. brite (CL-treatment), *p<0.05, **p<0.01, ***p<0.001 
i.p. injections vs. osmotic pumps. 
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Upon implantation of osmotic pumps to recruit iWAT browning by CL administration, all 
groups responded to the cue by a loss of fat mass (Figure13.A) and reduced WAT weight, 
while the masses of BAT and other tissues were not affected (Figure13.B), with the 
exception of STZ-injected animals that hardly had any body fat mass even before the 
induction of browning (Figure13.D). Also serum insulin levels were reduced in response to 
CL-treatment (Figure13.C). Gene expression analysis of iWAT and aWAT depots of STZ-
treated animals showed that in the white (no CL) state, brite marker genes (Ucp1, Cidea, 
carnitine palmitoyltransferase 1b (Cpt1b), Cox7a1, Cox8b) were expressed at lower levels in 
insulin-deficient animals (Figure13.D, E). However, CL-treatment could fully overcome the 
defect, leading to brite marker genes expressed at high levels regardless of the presence of 
insulin in the serum of the mice (Figure13.D, E). Given the markedly lowered basal 
expression, the fold change of brite marker mRNAs in response to CL was even higher in 
STZ-treated mice. Analogously in HFD-fed animals iWAT and aWAT gene expression 
analysis showed lowered basal levels of brite markers in insulin resistant animals which 
could be strongly induced by CL-treatment, albeit still not fully reaching the same levels as in 
LFD-fed controls (Figure13.F, G). Still, also in the Type II diabetes model, the fold induction 
Figure 12. STZ treated mice show a Type1 I diabetic phenotype while HFD-fed mice show a Type 
II diabet ic  phenotype.  (A) Random fed blood glucose levels and (B) serum insulin levels of 
streptozotocin (STZ, 60 µg/day/g bw) injected and control (upper panels) or 12 weeks low fat diet 
(LFD) or high fat diet (HFD) fed (lower panels) mice. (C) Body weight over time and (D) inguinal 
and abdominal white or brown adipose tissue (iWAT, aWAT and BAT, respectively) weights at time 
of sacrifice of STZ-injected and control (upper panels) or LFD and HFD-fed (lower panels) mice. All 
values in bar graphs are expressed as means ± SEM, n = 7-10, *p<0.05, **p<0.01, ***p<0.001 
control vs. STZ and LFD vs. HFD-fed animals. 
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of brite markers was even stronger in animals with impaired insulin signalling. To confirm 
these results, immunohistological analysis of UCP-1 expression in iWAT and aWAT of LFD 
and HFD-fed animals was performed, the results reflecting the gene expression data, namely 
that while HFD-fed animals expressed lowered basal UCP-1 levels, CL-treatment was able to 
increase the amount of UCP-1 protein also in the insulin resistant animals (Figure13.H, I). 
 
 
Figure 13. CL mediated browning occurs largely independant from insulin signalling status. (A) 
ECHO-MRI body composition analysis, change in fat mass in STZ-injected and control (upper 
panel) or LFD and HFD-fed (lower panel) mice during the 10 days of CL or control treatment. (B) 
Tissue weights of iWAT, aWAT, BAT, liver and gastrocnemius skeletal muscle (GC) and (C) 
random fed serum insulin levels of STZ-injected and control (upper panel) or LFD and HFD-fed 
(lower panel) mice treated with CL or NaCl for 10 days. (D) mRNA expression of Ucp1, Cidea, 
Cpt1b, Cox7a1, Cox8 in iWAT and (E) aWAT of STZ-injected and control mice or (F) iWAT and (G) 
aWAT of LFD and HFD-fed mice treated with CL or NaCl for 10 days.  (H) UCP-1 stained iWAT 
and (I) aWAT slices of mice fed LFD or HFD mice treated with CL or NaCl for 10 days. All values 
are expressed as means ± SEM, n = 7-10, #p<0.05, ##p<0.01, ###p<0.001 white (NaCL-treatment) 
vs. brite (CL-treatment), *p<0.05, **p<0.01, ***p<0.001 control vs. STZ and LFD vs. HFD-fed 
animals. 
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Altogether, these findings indicate that while unstimulated WAT depots display lower brite 
marker expression as a result of aberrant insulin signalling status, β3-adrenergic stimulation 
still could efficiently induce the browning program. Even if a slightly compromised brite end-
state apparently was achieved in the disease models, it is still obvious that recruitment of 
UCP-1 positive adipocytes within WAT depots can efficiently take place independently of 
insulin signalling. 
Browning of white adipose tissue increases systemic glucose clearance in an 
insulin-independent manner 
After elucidating that the browning mechanism in WAT can take place largely independently 
of insulin, we prompted the converse question whether brite adipocytes and depots are more 
insulin sensitive than white. It is established that cold exposure increases glucose uptake of 
brown adipocytes [78, 110], therefore enhancing the number of UCP-1 positive adipocytes 
increases the mass of target tissue for stimuli enhancing glucose uptake. It was not clear 
however, whether brite adipocytes and tissue per se are more sensitive to insulin than white 
cells. Therefore, primary iWAT SVF-derived adipocyte progenitors were differentiated into 
white or brite adipocytes as described above and glucose uptake in response to increasing 
doses of insulin was determined. The cells, whose white or brite identity was confirmed 
based on their marker gene expression profile in comparison to white or brown primary 
adipocytes (Figure14.A), were treated for 20 minutes with 0 – 100 nM of insulin in the 
presence of the radiolabelled non-metabolisable glucose derivative 3H-2-deoxyglucose (3H-
2DOG). Brite adipocytes incorporated markedly higher amounts of 3H-2DOG even in the 
basal (not insulin-treated) state. Upon insulin treatment, 3H-2DOG uptake increased in a 
dose dependant manner in both cell types (Figure14.B). However normalizing 3H-2DOG 
uptake in response to any administered dose of insulin to the differential basal levels 
revealed that the fold increase in response to insulin was the same in brite as in white 
adipocytes (Figure14.C), indicating that both cell types are equally insulin sensitive. This was 
also confirmed by Western Blot analysis, detecting a comparable degree of insulin-induced 
AKT (Protein Kinase B) or GSK3β (Glycogen synthase kinase 3) beta phosphorylation in 
white or brite differentiated adipocytes (Figure14.D, E). 
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To confirm our results on glucose uptake in an in vivo setting, we induced brite recruitment in 
female BL6 mice by CL administration via subcutaneous implantation of osmotic pumps as 
described above. As seen in previous experiments, indicators of CL-induced elevated 
metabolism could be observed, such as markedly reduced weight gain (Figure15.A), reduced 
body fat mass (Figure15.B) and WAT weight (Figure15.C) as well as lowered blood glucose 
levels (Figure15.D) in CL-treated mice (no gene expression analysis could be performed in 
this experiment due to the radioactive nature of the assay performed and described below). 
In these animals, we performed an intraperitoneal insulin tolerance test (ITT). The lowered 
blood glucose level in CL-treated “brite recruited” animals compared to “white” animals was 
Figure 14. Brite adipocytes are not more insulin sensitive than white despite elevated glucose  
uptake. (A) mRNA expression of Ucp1, Cidea, Cpt1b, Cox7a1, Cox8, Fabp4, Retn in primary iWAT 
SVF-derived adipocyte progenitors differentiated into white (EtOH-treated) or brite (cPGI2-treated) 
adipocytes or in primary BAT SVF-derived adipocyte progenitors differentiated into adipocytes. 
Values are shown as relative to expression in white adipocytes, except for Ucp1 which was not 
detectable in white adipocytes and is expressed as relative to levels in brite adipocytes. (B, C) 3H-
2-deoxy-D-glucose (3H-2DOG) uptake by primary iWAT SVF-derived adipocytes (B) absolute or 
(C) relative to unstimulated basal uptake. Cells stimulated with different doses of Insulin for 20 
minutes. (D) Western Blot and (E) corresponding quantification with imageJ (relative to VCP) of 
iWAT SVF-derived primary adipocyte progenitors differentiated into white (EtOH-treated) or brite 
(cPGI2-treated) adipocytes and stimulated with 100 nM insulin (ins) for 15 minutes. All values are 
expressed as means ± SEM, n = 5–15 animals for cell isolation #p<0.05, ##p<0.01, ###p<0.001 white 
(EtOH-treated) vs. brite (cPGI2 -treated). 
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maintained throughout the assay both in basal and in insulin stimulated conditions 
(Figure15.E). Normalizing blood glucose levels to non-insulin-treated levels revealed that the 
relative decrease in blood glucose in response to insulin was comparable between the white 
and the brite group (Figure15.F). Next, glucose uptake into various tissues was assessed. 
The enrichment of the 3H-2DOG tracer in blood did not differ between groups, confirming that 
differences in total blood glucose levels did not dilute the tracer, thus allowing comparison of 
amounts of tracer incorporated into tissues between groups (Figure15.G). Gererally, both 
insulin and CL affected tissue glucose uptake as expected, with insulin treatment increasing 
uptake into WAT and heart and CL-induced browning increasing uptake into WAT, 
regardless of insulin (Figure15.H). The overall contribution of each depot to systemic glucose 
utilization per mouse was calculated from the respective uptake rate and weight of each 
tissue. In the white state, iWAT and aWAT roughly utilize only a third of the amount of 
glucose taken up by BAT, despite its higher mass. In the brite state, the amount of whole-
body glucose uptake attributable to WAT increases to the level contributed by the heart and 
almost to the level contributed by BAT when treated with insulin (Figure15.J). Notably, while 
total 3H-2DOG uptake into WAT was substantially elevated upon browning, the relative fold 
increase glucose uptake as an effect of insulin stimulation did not differ between the two 
groups (Figure15.I). In summary, our data show that brite recruitment in WAT increases 
systemic clearance of glucose from the bloodstream. However, the effect could not be 
attributed to improved insulin sensitivity of adipose tissue after browning. 
Browning of white adipose tissue induces GLUT-1 expression 
To address the mechanism of the elevated glucose uptake of white adipocytes induced by 
browning, after ruling out enhanced insulin sensitivity, and upon the observation that 
glycolysis genes were not differentially regulated (data not shown), insulin-independent 
glucose-transport via glucose transporter 1 (GLUT-1) was examined. In primary iWAT SVF-
derived adipocyte progenitors differentiated into white (EtOH-treated) or brite (cPGI2-treated) 
adipocytes, browning induced slightly elevated mRNA (Figure16.A) and markedly elevated 
protein levels (Figure16.B, C) of GLUT-1. To address the physiological relevance of GLUT-1 
induction, female BL6 mice were exposed to cold (5 °C). Induction of the thermogenic 
program was confirmed by elevated UCP-1 levels (Figure16.D), and analogously to in vitro 
experiments, browning induced strong upregulation of GLUT-1 protein levels (Figure16.D, E). 
To validate this observation in an independent in vivo setting, we tested GLUT-1 induction 
upon browning induced by chronical CL-treatment. Whereas Glut-1 mRNA levels were not 
substantially affected by CL (Figure16.F), immunohistochemical analysis revealed that 
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multilocular adipocytes arising upon CL-induced browning were GLUT-1 positive, whereas 
white cells displayed hardly any detectable GLUT-1 staining (Figure16.G). 
 
 
Figure 15. Browning of WAT increases systemic glucose clearance without being at t ributable to  
higher insulin sens it iv ity .  (figure legend continued on next page) 
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To demonstrate that the observed increase of GLUT-1 expression is insulin-independent, 
GLUT-1 induction was investigated in the pathological setting of insulin deficiency caused by 
β-cell ablation as described above. Consistent with our finding  that functional browning 
occurs despite lack of insulin in the STZ mouse model (Figure13.C upper panel, D, E), we 
found GLUT-1 protein to be significantly elevated upon CL administration in iWAT of STZ-
treated mice (Figure16.H, I). 
To functionally validate the role of GLUT-1 in browning-stimulated glucose uptake, GLUT-1-
dependent 3H-2DOG uptake by adipocytes was blocked with the specific inhibitor STF-31. 
GLUT-1 inhibition significantly decreased basal glucose uptake in white adipocytes 
(Figure16.J). Expectedly, insulin-stimulated glucose uptake was still functional with chemical 
inhibition of GLUT-1. Notably, also browning almost fully rescued the decrease in 3H-2DOG 
uptake by GLUT-1 inhibition (Figure16.J), indicating that compensatory mechanisms control 
elevated glucose uptake during browning in the absence of GLUT-1 activity. 
In summary, our data indicate that browning is accompanied by augmentation of GLUT-1 
expression, thereby increasing glucose uptake into adipose tissue in an insulin-independent 
manner. Nevertheless, given that browning was able to compensate for the impaired glucose 
uptake caused by specific GLUT-1 inhibition, GLUT-1 induction only partially explains the 
enhanced glucose uptake of brite compared to white adipocytes. 
Figure 15. Browning of WAT increases systemic glucose clearance without being at t ributable to  
higher insulin sens it iv ity .  (figure legend continued from previous page) 
 (A) Change in body weight and (B) fat mass of mice during the 10 days of CL or control treatment. 
(C) iWAT and aWAT weights at time of sacrifice. (D) Basal blood glucose values upon 10 days of 
CL or control treatment. (E, F) Intraperitoneal insulin (Ins) tolerance test (ITT) (0.5 U/kg body 
weight insulin) of mice treated with CL or control for 10 days. (E) Absolute blood glucose levels and 
(F) levels relative to non-insulin-stimulated are shown. (G) Relative enrichment of the 3H-2-deoxy-
D-glucose (3H-2DOG) tracer in blood of mice treated with CL or control for 10 days, over the 45 
minutes course of the experiment. (H, I) 3H-2DOG uptake rate into iWAT, aWAT, BAT and heart of 
the same mice as in A-G. (H) Absolute uptake and (I) uptake relative to non-insulin-stimulated 
conditions is shown. Uptake rates were measured 45 minutes after intraperitoneal injection of 
insulin or vehicle. (J) Total 3H-2DOG uptake by each tissue of the mice shown in (F), calculated 
from the 3H-2DOG uptake rate and from the weight of each tissue. All values are expressed as 
means ± SEM, n = 6, #p<0.05, ##p<0.01, ###p<0.001 white (NaCL-treatment) vs. brite (CL-
treatment), *p<0.05, **p<0.01, ***p<0.001 basal vs. insulin stimulation.  
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Figure 16. Browning induces GLUT-1 expression which only partially explains  elevated glucose  
uptake.  (A) mRNA expression, (B) Western Blot analysis and (C) corresponding imageJ 
quantification (relative to VCP) of GLUT-1 in primary iWAT SVF-derived adipocyte progenitors 
differentiated into white (EtOH-treated) or brite (cPGI2 treated) adipocytes. (D) Representative 
Western Blot and (E) imageJ quantification (relative to VCP) of GLUT-1 from iWAT of mice housed 
at 23 °C and 5 °C respectively for 10 days. (F) mRNA expression and (G) immunohistochemic 
staining of GLUT-1 in iWAT of mice fed LFD upon 10 days of CL or control treatment. (H) 
Representative immunoblot and (I) imageJ quantification (relative to VCP) of GLUT-1 from iWAT of 
STZ-injected upon 10 days of CL or control treatment. (J) 3H-2DOG uptake by primary iWAT SVF-
derived adipocyte progenitors differentiated into white (EtOH-treated) or brite (cPGI2 treated) 
adipocytes, ± GLUT-1 inhibitor STF-31 for the last 2 days and stimulated ± 20 nM Insulin for 20 
minutes. All values are expressed as means ± SEM, n = 6-10 for in vivo experiments and 10–12 
animals for cell isolation, #p<0.05, ##p<0.01, ###p<0.001 white (EtOH treatment in cells, NaCL-
treatment or housing at room temperature in mice) vs. brite (cPGI2 treatment in cells, CL-treatment 
or housing at 5 °C in mice), *p<0.05, **p<0.01, ***p<0.001 basal vs. insulin stimulation, §p<0.05, 
§§p<0.01, §§§p<0.001 vehicle vs STF-31.  
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BROWN ADIPOSE TISSUE IS ONE OF THE CHECKPOINTS FOR THE 
METABOLIC MASTER-REGULATOR TBLR 
Another focus of this project, besides the data presented on the interplay between insulin 
signalling and white adipose tissue browning, was to untangle what specific role the 
metabolic master-regulator Transducin (beta)-like 1 X-linked Receptor 1 (TBL1XR1, or also 
TBLR) plays in brown adipose tissue (BAT) and how this local signal impacts metabolism 
systemically. Based on its known role in regulating liver [140] and general adipose tissue 
[139] we hypothesised in BAT, which has very unique functions in contrast to white adipose 
(WAT) or other tissues, such a regulator would assume distinct tissue-specific roles. To this 
point we not only studied the role of TBLR in mouse BAT under diverse metabolic 
challenges, but also employed in vitro and in vivo methods depleting brown adipocytes from 
TBLR to elucidate its physiological relevance. 
TBLR localises to the nucleus in vitro, but to the cytosol in vivo 
In the initial phase of our investigations we tested different antibodies to assure that 
subsequently retained results would be reliable. We did so by generating nuclear and 
cytosolic lysates of BAT and of differentiated preBAT cells (brown adipocyte progenitors 
immortalized by SV40 T infection [148] , which were used for all in vitro studies unless 
indicated otherwise). When incubating fractionated BAT lysates that were either wildtype or 
deficient of TBLR with the commercial antibodies NB600-270 (Novus), ab24550 (Abcam) or 
with 1:5 diluted antisera produced by immunizing rabbits with TBLR peptide (done by 
Pineda) it became apparent that only one of these was suitable to specifically detect TBLR. 
Antiserum detected a large number of unspecific proteins and ab24550 (Abcam), despite 
detecting only a small number of proteins, was unable to distinguish between control and 
knockout (KO) samples (Figure 17.A). Hence both of these antibodies were excluded from 
former studies. NB600-270 however was able to detect specifically a 50 kDa protein that was 
absent in TBLR KO BAT (Figure 17.A), therefore this protein was assumed to be TBLR and 
this antibody was used in all subsequent experiments. Detecting the cytosolic marker protein 
glycerinaldehyd-3-phosphat-dehydrogenase (GAPDH) and the nuclear marker poly-[ADP-
Ribose]-polymerase 1 (PARP1) confirmed successful fractionation of BAT to nuclear and 
cytosolic lysates, respectively (Figure 17.A). Interestingly, despite being known to be a 
nuclear receptor co-regulator, we detected TBLR at stronger levels in the cytosol than in 
nuclei. There was an approximately 70 kDa band detected in the nuclei that seemed to be 
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present at lower levels in BATKO animals (Figure 17.A). It cannot be excluded that this 
presents a modified nuclear form of TBLR, despite the fact that phosphatase treatment of 
TBLR immunuprecipitated from nuclear and cytosolic extracts of wildtype mice did not affect 
the size of the detected nuclear band (Figure 17.B). Also, CL injection to the animals 2, 4 or 
8 hours before tissue collection did not cause any detectable shuttling or changing in band 
rations (data not shown). 
In vitro however, TBLR localised to the nucleus as expected, the identity of the band being 
confirmed by comparing lysates of control cells to lysates from cells transfected with 
adenovirus expressing short hairpin RNAs (shRNAs) to knock down TBLR (AV_shTblr), its 
sequence homologue and interaction partner Transducin (beta)-like 1 X-linked (TBL1X, or 
also TBL) (AV_shTbl) or both, respectively (Figure 17.C). In cells deficient of TBL, TBLR 
could to some extent also been found in the cytosol (Figure 17.C). Overall we concluded that 
NB600-270 is a suitable antibody for TBLR detection in brown fat and that TBLR localises to 
the nucleus in cells, however to the cytosol in tissue. 
 
 
Figure 17. TBLR1 localises to the cytosol in BAT, but to the nucleus in preBAT cells .  (A) Western 
Blot analyses of cytosolic and nuclear lysates of BAT from  Tblr1fl/flUcp1Cre+ or Tblr1fl/flUcp1Cre- 
mice injected for 5 consecutive days with 2 mg/mouse/day of tamoxifen (BATKO and ctrl) and 
incubated with 1:5 diluted serum of rabbits immunized against TBLR, 1:1000 ab24550 (Abcam), 
1:1000 NB600-270 (Novus) or antibodies against GAPDH or PARP1. (B) Western Blot analyses of 
TBLR (detection AB: NB600-270), immuno-precipitated (precipitation AB: NB600-270) from 40 µg 
nuclear and cytosolic lysates. Precipitate was on-bead treated with 100 units of Lambda Protein 
Phosphatase or control conditions without enzyme. (C) Western Blot analyses of cytosolic and 
nuclear lysates of preBAT cells infected with AV_shTblr, AV_shTbl or both and then differentiated 
for 7 days, incubated with NB600-270 or antibodies against PARP1. 
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Tblr expression in BAT is inducible in vitro 
To understand its role in brown adipose cells or tissues we next asked the question whether 
Tblr is regulated, and if so, by which pathways. We approached this question first by 
bioinformatic data already available. Since more experimental annotation data was available 
for the human sequence of Tblr, we chose to display the human sequence, however the 
identified regulatory regions are conserved in mouse. 
Displaying Tblr in the UCSC genome browser [149] we first identified a 10 kB region 
(chr3:176,911,000-176,921,000) with high GC content, which is often indicative of a promoter 
region since it allows regulation of gene expression via DNA methylation (Hartl, Jones 
(2005). ISBN 0-7637-1511-5) (Figure 18.A, upper panel shows the whole gene sequence, 
the peak is highlighted with a blue box and shown in larger view in the lower panel). We then 
enabled further information on this sequence to be displayed and assuming that DNAse 
sensitive, interspecies conserved regions with active chromatin [150] were important in its 
regulation, we identified one major peak (at the transcription start site) and two minor peaks 
(upstream, intronic) to possess the properties of active chromatin (Figure 18.B, upper panel, 
the three peaks are highlighted with a blue, red and green box, respectively, and shown in 
larger view in the lower panels). The track “Transcription Factor ChIP-seq” (161 factors, from 
ENCODE with Factorbook [151, 152] was activated to display transcription factors (TFs) 
binding this region (darkness of bars corresponds to TF binding signal intensity) (Figure 
18.B).  
The set of transcription factors binding the active regions around the Tblr gene were 
compared to hits predicted by other bioinformatics tools, such as generegulator.com or 
rVISTA (http://rvista.dcode.org). The strongest open chromatin peak is bound by RNA 
polymerase, confirming it to be the transcription start site (Figure 18.A). Overall, growth 
promoting factors were the most prominent binding factors, such as E2F, MAX, MYC and 
AP-1 / AP-2 associated proteins (FOS, JUN, basic leucine zipper transcription factor (BATF)) 
[153], (Figure 18.A). E2F is known to regulate expansion versus differentiation in early 
adipogenesis [154-156], and MYC / FOS / JUN have been suggested to play a role in the 
MAPK pathway [157-159]. However, also RUNX3, a known tumor-suppressor [160], is 
reported to bind to the Tblr promoter region, suggesting the possibility of tissue- or stage-
dependent differences in the role of TBLR for growth and differentiation. 
Further, factors known to regulate early adipogenesis, such as the forkhead box A1 (FOXA1) 
interactor GATA binding protein 3 (GATA3) [161], C/EBPβ and E1A binding protein p300 
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((E)p300) [162] as well as the adipose regulator forkhead box A2 (FOXA2) [163] were 
standing out (Figure 18.A). Finally, a TF who is associated with type II diabetes risk if 
mutated, TCF7L2, strongly bound the Tblr promotor [164] (Figure 18.A).  Overall, based on 
our predictions a metabolic role of TBLR, possibly by equilibrating growth versus 
differentiation, seemed likely. 
 
 
Figure 18. The transcription start site of TBLR is a region of active chromatin regulated by  growth 
and adipogenes is  involved t ranscript ion fac tors .  (figure legend continued on next page) 
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Having characterized the Tblr promoter region we were interested in its relevance in brown 
adipocytes. TBLR shares 90% sequence homology with its homologue TBL [128], and while 
in liver both proteins are required for the transcription of fatty acid oxidation genes [140], in 
white adipose tissue the absence of TBLR alone is sufficient to cause deregulated 
metabolism [139]. To compare their roles in brown adipocytes, the expression levels of Tblr 
and Tbl were compared both in primary iWAT or BAT SVF-derived adipocyte progenitors and 
differentiated white, brite or brown adipocytes (as described above). The data is based on 
microarray analysis with Affymetrix chips and was kindly provided by Alexandros 
Vegiopoulos. Tblr was expressed at lower levels than Tbl both in white and in brown 
adipocyte progenitors, however only Tblr but not Tbl was higher in brown compared to white 
cells, indicating a brown-selective role (Figure 19.A). Further, while both mRNA (Figure 19.B) 
and protein (Figure 19.C) levels of TBLR were slightly but significantly induced during brown 
adipocyte differentiation, and even stronger during white or brite adipocyte differentiation 
(Figure 19.D), Tbl mRNA decreased both in brown and white or brite differentiating 
adipocytes (Figure 19.E, F), resulting in final levels of Tbl not being elevated anymore over 
those of Tblr (Figure 19.G). We hypothesised that the induction of Tblr during differentiation 
might depend on glucocorticoid signalling as a direct result of the dexamethasone (Dex) 
present in the medium in the 24 hours following induction of differentiation, and indeed, 
treatment of mature preBAT adipocytes with Dex lead to elevated Tblr mRNA expression 
(Figure 19.H). However, mice deficient for the glucocorticoid receptor (GR), did not show 
differential levels of Tblr mRNA expression (data not shown). These data show that Tblr, but 
not its homologue Tbl, is induced during adipocyte differentiation and is present in higher 
levels in brown adipocyte progenitors than in white. 
Figure 18. The transcription start site of TBLR is a region of active chromatin regulated by  growth 
and adipogenes is  involved t ranscript ion fac tors .  (figure legend continued from previous page) 
(A) UCSC genome browser view of the human Tblr1x1 gene and regions with high GC content 
(upper panel). The region highest in GC content is highlighted with a blue box and shown in larger 
magnification in the lower panel. (B) UCSC genome browser view of the human Tblr1x1 gene 
aligned with experimental information (upper panel). Shown are sites protected from DNAse digest, 
conserved between species, comprised of active chromatin in terms of histone modification and 
bound by transcription factors. The three most active regions are highlighted with a blue, red and 
green box, respectively and shown in larger magnification in the lower panel, alongside with more 
detailed information about transcription factor binding data for this region. 
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Figure 19. Tblr mRNA expression is induced upon init iat ion of  adipogenic  dif ferent iat ion.  (A) 
Affymetrix expression signal of Tblr and Tbl in iWAT or BAT SVF-derived adipocyte progenitors at 
the time of induction of adipogenic differentiation or (G) at day 8 of adipogenic differentiation. (B) 
Affymetrix expression signal of Tblr during the time of brown adipogenic differentiation. (C) Western 
Blot analyses (upper panel) and imageJ quantification (lower panel) of TBLR during the time of 
brown adipogenic differentiation. (D) Affymetrix expression signal of Tblr in primary iWAT SVF-
derived adipocyte progenitors differentiated into white (EtOH-treated) or brite (cPGI2 treated) 
adipocytes. (E) Affymetrix expression signal of Tbl in primary BAR or (F) iWAT SVF-derived 
adipocyte progenitors differentiated into adipocytes. (H) mRNA expression of Tblr in differentiated 
preBAT adipocytes treated for 3 hours with 5 µM dexamethasone (Dex). All values are expressed 
as means ± SEM, n = 3 technical replicates, *p<0.05, **p<0.01, ***p<0.001 day 0 vs. different 
times (A) or ctrl vs. Dex (E), #p<0.05, ##p<0.01, ###p<0.001 white vs brown 
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Besides factors involved in adipogenic differentiation, also MAPK pathway components are 
predicted regulators of Tblr. Since the activation of brown fat by β-adrenergic stimulation 
leads to PKA-mediated stimulation of the MAPK pathway [88] we hypothesised that in this 
cell type Tblr expression might depend on PKA-MAPK signalling and might be inducible by β-
adrenergic stimuli. While treatment of differentiated preBAT cells with the β-adrenergic 
agonist CL316243 (CL) did induce a time-dependent elevation of Ucp1 mRNA as expected, 
Tblr mRNA was significantly, but only slightly induced (Figure 20.A), which was not visible on 
protein level during the short time period of observation (Figure 20.B). However since this 
weak induction could be consistently observed in our studies with primary BAT-derived 
adipocytes (data not shown), we assumed that the cell culture medium might contain factors 
blocking the induction of Tblr expression through CL. When cultured in serum- and glucose-
free Krebs-Ringer Buffer (KRB), treatment with insulin lowered Tblr expression (Figure 20.C), 
and indeed, when applying CL in KRB instead of medium it did induce Tblr expression in 
differentiated preBAT cells (Figure 20.D). To further prove that this activation is dependent 
on PKA signalling we applied the PKA inhibitor H-89, which efficiently blocked the CL-
induced induction of Tblr (Figure 20.E). 
These data indicate that Tblr expression is induced in the initial phase of adipocyte 
differentiation and is also regulated in mature brown adipocytes. Insulin blunted and β-
adrenergic stimulation-induced Tblr expression, the signal being transmitted via the PKA-
MAPK pathway and potentially being mediated via promoter region binding of transcription 
factors linked to this pathway. 
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Tblr expression in BAT is inducible in vivo 
We then posed the question whether Tblr expression is regulated in vivo, examining brown 
adipose tissue (BAT) gene expression under various conditions. The samples were obtained 
either from previous studies or from studies performed by colleagues (Dasa Medrikova, 
Jessica Fuhrmeister, Alexandros Vegiopoulos) or collaborators (Pavel Flachs, Jan Kopecky). 
Since insulin was shown in vitro to blunt Tblr expression (Figure 20.C), we compared 
expression levels in fasted and refed mice (Figure 21.A) as well as in control and leptin 
receptor knockout (db/db) mice (Figure 21.B), and observed that in states known to induce 
high circulating insulin levels, Tblr expression was reduced. Interestingly, Tblr was up-
regulated in BAT of HFD compared to LFD-fed mice (Figure 21.C). Analogously to our in 
vitro observations, CL stimulation in vivo strongly induced BAT Tblr  expression. In mice 
treated for 10 days with daily injection of CL (Figure 21.D) or exposed to cold for 10 days 
Figure 20. Tblr mRNA expression in adipocytes is induced by β-adrenergic induction of the PKA-
MAPK pathway.  (A) mRNA and (B) protein expression of Tblr and Ucp1 in differentiated preBAT 
adipocytes in medium upon stimulation with 1 µM CL316243 (CL). (C) mRNA expression of Tblr in 
differentiated preBAT adipocytes upon 3 – 4 hours of treatment with 20 nM insulin (ins), (D) 1 µM 
CL or (E) 50 µM H-89, cultured in Krebs-Ringer buffer (KRB) unless stated otherwise. All values 
are expressed as means ± SEM, n = 3 technical replicates, *p<0.05, **p<0.01, ***p<0.001 ctrl vs. 
treatment. 
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(Figure 21.E), Tblr expression was induced compared to animals injected with vehicle or 
housed at room temperature (22 °C), respectively. This was also true comparing cold 
exposed animals to animals housed at thermoneutrality (30 °C) and the regulation was 
shown to peak acutely upon exposure to the cold stimulus to then decline to relatively lower, 
but still elevated levels, and in this way behaved differently from Ucp1, whose levels 
continued to rise for an extended period (Figure 21.F). Analogously for the results shown 
above for adipogenic differentiation, also for acute Tblr induction in mature adipocytes we 
wanted to distinguish between Tblr and its homologue Tbl. We hypothesised that if Tbl is 
able to fully compensate for the function of Tblr in BAT, it should likewise be induced by β-
adrenergic stimulation. However Tbl mRNA expression was only induced to a minor degree 
(Figure 21.F), which was also reflected in vitro (data not shown). Further, Tbl was not 
differentially expressed in BAT upon fasting or in db/db mice or in CL injected mice (data not 
shown). 
 
 
Figure 21 Tblr mRNA expression in BAT is transiently induced by β-adrenergic  s t imuli.  (A) Tblr 
mRNA expression in BAT of animals fasted for 24 hours or refed for 6 hours (n=4), (B) of random 
fed control and db/db animals (n=4), (C) of mice treated for 10 consecutive days with daily i.p. 
injection of or NaCl or 1 mg/kg body weight CL (n=7), (D) housed at room temperature or 4 °C for 
10 days (n=7) or (E) acutely exposed to 4 °C (n=8). All values are expressed as means ± SEM, 
*p<0.05, **p<0.01, ***p<0.001 fasting vs. refeeding (A), ctrl vs. db/db (B), LFD vs. HFD (C), ctrl vs. 
CL (D), 22 °C vs. 4 °C (E) or 30 °C vs. 4 °C (F). 
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Since the induction of Tblr mRNA expression was strongest immediately after stimulation 
(Figure 21.F) we chose to closer examine the exact site of regulation 8 hours following 
injection of CL. At this time Tblr was induced almost as strongly as Ucp1 (Figure 22.A), which 
was not translated into elevated protein levels at this short time period (Figure 22.B). 8 hours 
after injection we dissected BAT and subjected it to collagenase digestion to fractionate it 
into (floating) mature adipocyte fraction (AF) and (pelleting) stromal vascular fraction (SVF), 
containing undifferentiated adipocyte progenitors. We confirmed by qPCR that SVF was 
enriched in the pre-adipocyte marker Cd31 (Figure 22.C), while the AF was enriched in the 
mature adipocyte marker β3-adrenoreceptor (Adrb3) (Figure 22.D). However the difference 
between fractions was only minor and it was found that SVF expressed Ucp1, which was 
further elevated in samples from CL- versus vehicle-treated animals (Figure 22.F). Since 
adipocyte progenitors do not express the β3-adrenoreceptor [78] and thus also do not react 
to CL-stimulation, we conclude that brown adipocytes, being lower in fat content than white 
and thus denser, partly pellet together with the SVF. Because of that no conclusive 
statement can be made about gene expression in pelleted cells, while floating cells still can 
be assumed to comprise the differentiated adipocyte fraction of BAT. We observed that AF 
from 8 hour CL-treated animals expressed strongly elevated mRNA levels of Tblr (Figure 
22.E). Since TBLR was found to localise to the nucleus in vitro but to the cytoplasm in vivo 
(Figure 17.A and B) we were interested whether localisation of TBLR might be affected by 
CL-treatment in vivo. To these regards we injected mice with CL and dissected BAT after 
various timepoints and fractionated the tissue to cytosol and nuclei. We could detect no 
difference in the cytosolic to nuclear ratio of TBLR protein (Figure 22.G). 
Taken together, we show that, in accordance with in vitro findings, in vivo Tblr expression is 
down-regulated in states with high circulating insulin and induced in a transient manner by β-
adrenergic stimulation. This regulation seems to be a feature distinguishing Tblr from Tbl in 
BAT. This induction takes place in the mature adipocyte fraction of BAT and does not trigger 
shuttling of TBLR protein from the cytosol to the nucleus. 
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Tblr1 is involved in the adipogenic program and in mature adipocyte function 
TBLR, as a nuclear receptor co-regulator, can bind to regulatory sequences of genes and 
influence their expression [128, 132]. Having observed that Tblr expression is regulated in 
brown fat upon pro-adipogenic and β3-adrenergic stimulatory conditions we were interested 
to study the gene expression programs controled by TBLR in brown adipocytes. We thus 
performed global analysis of TBLR binding to genomic DNA (chromatin immunoprecipitation 
followed by sequencing, ChIPseq). In order to distinguish between the roles of TBLR during 
the two states in which it was found to be transcriptionally regulated – upon induction of 
adipogenic differentiation or in mature adipocytes – analyses were performed preBAT cells 
harvested at two distinct timepoints, either 24 hours following induction of adipogenic 
differentiation or 7 days later in the fully differentiated state. First we checked the quality of 
the obtained material, i.e. chromatin crosslinked with bound proteins, by ChIP with PPARγ 
Figure 22. Tblr1 is induced by CL in mature adipocytes without inducing cytoplasmatic  to nuc lear 
shut t l ing.  (A) mRNA and (B) protein expression of Tblr and Ucp1 in BAT of mice injected 
intraperitoneally with 1 mg/kg BW CL and sacrificed at the indicated timepoints (n=3). (C) CD31 
and (D) Adrb3 mRNA expression in the adipocyte fraction (AF) or stromal vascular fraction (SVF) 
of BAT of mice AF was separated from SVF by collagenase digest followed by centrifugation, the 
floating fraction being defined as AF, the pelleting cells as SVF (n=5). (E) Tblr and (F) Ucp1 mRNA 
expression in AF or SVF of BAT of mice injected with NaCl or CL 8 hours before sacrifice (n=5). 
(G) Western Blot analyses of cytosolic (C) and nuclear (N) lysates of BAT from mice injected with 
CL and sacrificed at the indicated timepoints (n=3). All values are expressed as means ± SEM, 
*p<0.05, **p<0.01, ***p<0.001 0 hours vs. indicated time (A), NaCl vs. CL (E, F) 
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antibody. From the obtained bound genomic regions we amplified by qPCR positive and 
negative control sequences for PPARγ binding [4]. Indeed, the positive control region (“2 
kB”) was clearly enriched over the negative control regions (“negative”, “1 kB”, “2.8 kB”) 
(Figure 23.A), confirming sufficient material quality. We next performed ChIP with an 
antibody against TBLR and subjected the obtained DNA to sequencing after having 
confirmed by qPCR that TBLR bound to two genomic regions known to be involved in 
adipogenic differentiation, the Pparg2 promoter and caveolin 2 (Cav2) [4] (Figure 23.B). 
ChIPseq and data analyses were performed by our collaborator Anne Loft (Susanne 
Mandrup’s lab, Department of Biochemistry and Molecular Biology, University of Southern 
Denmark). 
 
 
Table 1 TBLR binds to genes assoc iated with adipocyte dif ferent iat ion and funct ion.  
Unbiased ranking by enrichment of all KEGG pathways with significantly enriched TBLR binding 
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In general, more binding events were observed during the initial phase of differentiation than 
in differentiated adipocytes, indicating that coordination of the adipogenic program is one of 
the key functions of TBLR in brown adipocytes. Table 1 lists the results of KEGG pathway 
analyses performed on the set of genes found to be bound by TBLR (ranked by enrichment). 
In general, both during differentiation and in mature adipocytes, TBLR binding occurred 
within gene networks known to regulate growth (cancer) versus differentiation. Those 
pathways are highlighted in red. During differentiation of preBAT cells, TBLRbinding was 
enhanced at gene loci associated with pathways involved in adipocyte differentiation and 
lipid accumulation, such as fatty acid biosynthesis and elongation or adipocytokine and 
insulin signalling (highlighted in grey). In differentiated adipocytes, in addition to pathways 
involved in immunity, TBLR was found to bind to genes involved in mature adipocyte 
function, such as PPAR signalling or adipocytokine and insulin signalling (highlighted in 
grey). 
To combine these data with functionality, i.e. to determine extent and direction of the 
regulation of the identified pathways, we performed global gene expression analyses of 
preBAT cells following adenoviral (AV)-mediated shRNA knockdown of Tblr. Since TBLR 
binding to genomic DNA was found to be more intense during adipogenic differentiation, we 
decided to knock down TBLR prior to induction of adipogenic differentiation, resulting in 
adipocytes that were deficient of TBLR during differentiation. We confirmed that in all the 
samples AV mediated KD of gene expression was strong and specific (Figure 23.C) and thus 
subjected RNA from these cells to microarray analyses. Sample handling and data analyses 
were performed by our collaborator Carsten Sticht (Medical Faculty, University Mannheim). 
Table 2 lists all significantly regulated KEGG pathways in preBAT cells transduced with 
shTblr compared to cells transducted with shCtrl, ranked by enrichment. In general pathways 
found to be regulated, in accordance with data obtained in ChIPseq analyses, were 
pathways associated with the balance between growth and differentiation. There was a shift 
from pro-growth to pro-differentiation in the absence of TBLR, the most strongly de-
repressed pathways being the key metabolic pathways in adipocytes, oxidative 
phosphorylation and the citric acid cycle, while the most strongly depleted pathway involved 
cancer growth. 
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Correlating the knowledge gained about TBLR binding and genes found to be de-regulated in 
TBLR-deficient cells, it was possible to identify some target genes found to be both, strongly 
bound and regulated by TBLR. Interestingly, the most outstanding candidate was Ucp1, 
being both the most strongly bound target gene in differentiated adipocytes and the most 
strongly de-repressed target upon TBLR knockdown. Further genes found to be repressed 
Table 2 TBLR KD leads to reduced growth-promoting signature and de-repress ion of  metabolic  
pathways.  
Unbiased ranking by enrichment of all KEGG pathways significantly regulated by TBLR KD. 
Pathways induced by TBLR (depleted in KD) are indicated in red, pathways repressed by TBLR 
(de-repressed in KD) are highlighted in green. 
Results - Brown Adipose Tissue is one of the checkpoints for the metabolic master-regulator TBLR 
 
 
52 
 
by TBLR in differentiating adipocytes included players of differentiation, such as Ppargc1a or 
SMAD family member 6 (Smad6), proteins involved in fatty acid synthesis, such as acetyl-
coenzyme A carboxylase (Acc) as well as regulators of mitochondrial energy metabolism, 
such as pyruvate dehydrogenase kinase (Pdk4), acetyl-Coenzyme A acyltransferase 2 
(Acaa2), the glycerol transporter aquaporin7 (Aqp7) or the components of the repiratory 
chain, namely subunits of NADH dehydrogenase, cytochrome c oxidase and ATP synthase. 
On the other hand, mitogen-activated protein kinase (MAPK) pathway components such as 
mitogen-activated protein kinase kinase kinase kinase (Map4k), the jun proto-oncogene, dual 
specificity phosphatase 6 (Dusp6) or the TGF-beta activated kinase Tab2 appeared to be 
activated by TBLR binding, since their expression was found to be decreased in KD cells. 
The UCSC genome browser was used to visualize examples of genomic regions bound by 
TBLR. Figure 23 depicts binding to to Ucp1 (Figure 23.D) and Dusp6 (Figure 23.E) as 
compared to a non bound gene (DNA polymerase A1, pola1, (Figure 23.F)). Table 3 
summerizes ChIPseq binding data (Tag counts per gene) correlated with microarray 
expression data (fold change by TBLR KD) to the genes mentioned above, Figure 23.F 
depicting the relative abundance of TBLR regulated genes in preBAT adipocytes. 
Overall global analyses confirmed that Tblr is not only regulated in brown adipocytes, but 
also does participate in key metabolic pathways, mainly during adipogenesis and further in 
mature brown adipocytes. Surprisingly, despite being up-regulated during differentiation, 
TBLR in this phase seems to promote growth and suppress differentiation and development 
of brown mitochondria. In mature adipocytes, despite exhibiting lower overall binding 
behavior and not targeting respiratory chain players anymore, TBLR was found to target 
regulators of mature brown function, such as Ucp1 and signalling proteins, indicating that 
TBLR can play different roles depending on the developmental state of the cells. 
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Figure 23.  ChIPseq analys is  of  global TBLR binding and microarray  analys is  of  global 
geneexpression in the basence of  TBLR reveal i ts  involvement  in adipogenes is  and brown 
adipocyte funct ions.  (figure legend continued on next page) 
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Figure 23.  ChIPseq analys is  of  global TBLR binding and microarray  analys is  of  global 
geneexpression in the basence of  TBLR reveal is t  involvement  in adipogenes is  and brown 
adipocyte funct ions.  (figure legend continued  from previous page) 
 (A) qPCR amplification of genomic DNA pulled down by PPAR-γ antibody or (B) TBLR antibody 
from crosslinked chromatin of preBAT cells at day 1 or day 7 of adipogenic differentiation. Values 
are expressed as % input (chromatin before pulldown), the amplified targets are a general negative 
control sequence (negative), 2 negative control sequences for PPAR-γ binding (1 kB, 2.8 kB) and 
a PPAR- γ binding positive control sequence (2 kB) or positive control sequences frequently 
bound in adipogenic differentiation (Cav2, Pparg2 promoter). [4] (C) Tblr mRNA expression in 
differentiated preBAT cells transduced before the induction of adipogenic differentiation with AV 
expressing shCtrl or shTblr with a multiplicity of infection (MOI) of 50. (D-F) ChIPseq for TBLR 
binding in preBAT cells was performed on day1 and day7 respectively of adipogenic differentiation 
and results were visualised in the UCSC genome browser, comparing sequence abundance upon 
               
                
                 
   
Table 3. TBLR binding represses brown adipocyte metabolic  genes and induces prol i ferat ive 
genes.  
Ranking by fold-regulation of gene expression in TBLR KD. Genes induced by TBLR (depleted in 
KD) are indicated in red, genes repressed by TBLR (de-repressed in KD) are highlighted in green. 
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Tblr1 ablation in vitro can distinguish between role during differentiation and 
role in mature adipocytes 
Having discovered the regulation of Tblr in BAT and its action on gene expression by DNA 
binding, we continued to elucidate which role TBLR-mediated gene regulation would have on 
brown adipocytes. In order to investigate both the role TBLR is expected to play during the 
initial phase of adipogenesis as well as its role in mature adipocytes, we tested knockdown at 
two timepoints: 2 days prior to induction of adipogenic differentiation (“early KD”) and 2 days 
prior to harvest of mature adipocytes (“late KD”), and in both cases the adipocytes were 
harvested on day 7 of adipogenic differentiation. We used the adenoviral vectors described 
above to ablate Tblr/Tbl gene expression and chose to use preBAT cells rather than primary 
BAT SVF-derived adipocyte progenitors for most of the experiments, since we found knock 
down of TBLR expression was more reproducible in this cell line. We found that upon early 
KD, mRNA levels of Tblr and Tbl were still reduced in mature preBAT adipocytes (Figure 
24.A), the effect being much more pronounced at the protein level (Figure 24.B). Upon late 
KD, while mRNA levels were strongly reduced (Figure 24.C), protein levels were diminished 
but there was not complete deletion of TBLR or TBL (Figure 24.D). Likewise, in primary BAT 
SVF-derived adipocytes, early KD reduced protein levels more strongly than late KD (Figure 
24.E). These findings indicate that TBLR protein is very stable, reacting only with some days 
of delay to changes in mRNA levels. There was no apparent difference in cell shape or lipid 
accumulation of mature adipocytes subjected either to early or late KD (Figure 24.F-G), 
likewise the adipogenic markers Ppargc1a and sterol regulatory element-binding protein 1c 
(Srebp1c) were not affected (Figure 24.H-I). In primary BAT SVF-derived adipocytes 
subjected to early or late KD Fabp4 expression was assessed and in concordance with the 
findings showed above were not found to be affected by the treatment (Figure 24.J-K). Also 
largely unchanged HSL and ATGL protein levels (Figure 25. C) indicate that cells 
differentiated into mature adipocytes regardless of TBLR and TBL ablation before 
differentiation. Taken together these results indicate that AV knockdown of TBLR alone or 
together with TBL is specific and does not generally inhibit the adipogenic program, however 
TBLR protein is very stable and not immediately removed from the cells upon transduction. 
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Figure 24. AV mediated KD of Tblr and Tbl is strong and specific without blocking the adipogenic  
program. (A) Tblr mRNA and (B) protein expression of preBAT cells subjected to “early KD”, i.e. 
transduction with a multiplicity of infection (MOI) of 50 of AV expressing shCtrl, shTblr and/or shTbl 
2 days prior to induction of adipogenic differentiation. (C) Tblr mRNA and (D) protein expression of 
preBAT cells subjected to “ late KD”, i.e. transduction with a multiplicity of infection (MOI) of 500 
of AV 2 days prior to harvest of mature adipocytes. (E) TBLR protein expression of primary BAT 
SVF-derived adipocytes subjected to early KD or late KD as described in (A-D). (F) Microscopy of 
mature preBAT adipocytes previously subjected to early or (G) late KD. (H) mRNA expression of 
Pgc1a and Srepb1c in mature preBAT adipocytes previously subjected to early or (I) late KD. (J) 
mRNA expression of Fabp4 in primary BAT SVF-derived adipocytes previously subjected to early 
or (K) late KD. All values are expressed as means ± SEM, n=3 technical replicates for preBAT 
cells or n=8-10 mice for primary cells, *p<0.05, **p<0.01, ***p<0.001 ctrl vs. KD 
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First, we addressed the role of TBLR during adipogenesis and investigated the metabolic 
phenotype of preBAT adipocytes upon early KD. Lipolysis, in terms of free fatty acids and 
glycerol released into the medium in the basal state or upon stimulation with the general β-
adrenergic agonist isoproterenol (Iso), was mainly maintained functional also in TBLR or 
TBLR/TBL-deficient adipocytes (Figure 25. A). There was a trend to lowered lipolysis upon 
KD of both factors, and this effect was reproduced in primary BAT SVF-derived adipocytes, 
however still being marginal (Figure 25. B). In accordance with these findings, the expression 
of the 2 major lipases, HSL and ATGL, as well as phosphorylation of HSL upon Iso 
stimulation, was largely unaffected by TBLR KD alone and slightly decreased by double KD 
(Figure 25. C). The uptake of isotope-labelled non metabolisable glucose analogue 3H-2-
deoxy-D-glucose (3H-2-DOG) was significantly lower in cells lacking TBLR and TBL during 
differentiation, both basally or in the insulin stimulated state (Figure 25. D), which was also 
observed in primary brown adipocytes and was found to depend more on TBL than on TBLR 
(Figure 25. E). In accordance with this, also glucose metabolism in terms of retention of 
metabolisable 14C-D-glucose was lowered particularly in the absence of both factors (Figure 
25. F), and less of this glucose was converted into lipids in the basal state, which could be 
overcome by insulin treatment (Figure 25. G). Further, these cells exhibited de-regulated 
gene expression, as the brown fat markers Ucp1 and Cpt1b were induced upon early KD 
(Figure 25. H), which could be observed also in primary cells and was true both in the basal 
as well as in the β-adrenergic stimulated state (Figure 25. I). Taken together, early KD of 
both TBLR and TBL leads to less active adipocytes with a lower lipid from glucose production 
rate and a deregulated profile of brown fat marker genes. 
Analogously, preBAT adipocytes subjected to late KD were assessed for their metabolic 
phenotype. In these cells, in which TBLR and TBL were present during differentiation but 
depleted in mature cells, albeit only partially, due to technical limitations (Figure 24.D), 
lipolysis was unaffected (Figure 26.A), although double KD tended to decrease lipase protein 
levels (Figure 26.B) similar to what was observed upon early KD. 3H-2-DOG uptake (Figure 
26.C), retention of 14C-D-glucose (Figure 26.D) and subsequent conversion to lipids (Figure 
26.E) were unaffected by the viral treatment, regardless of the presence of insulin. Different 
from cells deficient of TBLR and TBL during differentiation, ablation in mature cells 
decreased rather than increased Ucp1 mRNA expression (Figure 26.F). Overall, partial 
depletion of TBLR and TBL from mature adipocytes decreased their expression of 
thermogenic genes but allowed them to maintain their metabolic competence. 
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Figure 25. Early KD of TBLR and TBL leads to less active adipocytes  with de-regulated brown 
gene expression prof i le.  preBAT cells were subjected to early KD of TBLR alone or TBLR and TBL 
together by transduction with a MOI of 50 of adenovirus 2 days prior to induction of adipogenic 
differentiation. Cells were then differentiated to mature adipocytes until day 7 and used for assays. 
For primary SVF-derived adipocyte progenitors, a MOI of 10 was used. (A) Release of free fatty 
acids (FAA) as indicator of triglyceride hydrolysis in preBAT adipocytes or (B) primary brown 
adipocytes 3 hours after treatment with 1 µM isoproterenol (Iso) or vehicle. (C) Western Blot 
analyses of lipase expression and phosphorylation in preBAT adipocytes upon 15 minutes 
treatment with 1 µM Iso or vehicle. (D) 3H-2-DOG incorporation to preBAT adipocytes or (E) 
primary brown adipocytes in the basal or 20 nM insulin stimulated (ins) state during the course of 
20 minutes. (F) 14C-D-glucose accumulation and (G) conversion to lipids in preBAT adipocytes in 
the basal or 20 nM ins stimulated state during the course of 20 minutes. (H) mRNA expression of 
Ucp1 and Cpt1b in preBAT adipocytes and (I) Ucp1 mRNA expression in primary adipocytes 
stimulated for 3 hours with 1 µM NE or vehicle. All values are expressed as means ± SEM, n = 3 
technical replicates for preBAT cells, n= 8 mice for primary cells, *p<0.05, **p<0.01, ***p<0.001 ctrl 
vs. KD. 
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To further understand the metabolic status of adipocytes deficient of TBLR or TBL we 
performed extracellular flow bioanalysis on a Seahorse XF96 analyser. By this method, living 
cells can be automatically treated with diverse substances and their reaction in terms of 
oxygen consumption and glycolytic activity can be observed in real time. 
In the experiments shown above, early KD affected both glucose metabolism and lipogenesis 
stronger than late KD and Ucp1 expression was regulated in the opposite direction in these 
two settings (Figure 25.F-H and Figure 26.D-F). Extracellular flow bioanalysis, however, 
showed very similar effects in both cases. The absence of TBLR and TBL in adipocytes lead 
to them being less metabolically active, exhibiting both a lower oxygen consumption rate 
Figure 26. Late KD of TBLR and TBL leads to adipocytes with lower Ucp1 and normal metablic  
competence.  preBAT cells were  differentiated to mature adipocyte and subjected to late KD of 
TBLR alone or TBLR and TBL together by transduction with a MOI of 500 of adenovirus 2 days 
prior to assays. (A) Release of free fatty acids (FAA) as indicator of triglyceride hydrolysis in 
preBAT adipocytes 3 hours after treatment with 1 µM isoproterenol (Iso) or vehicle. (B) Western 
Blot analyses of lipase expression and phosphorylation in preBAT adipocytes upon 15 minutes 
treatment with 1 µM Iso or vehicle. (C) 3H-2-DOG incorporation to preBAT adipocytes in the basal 
or 20 nM insulin stimulated state during the course of 20 minutes. (F) 14C-D-glucose accumulation 
and (G) conversion to lipids in preBAT adipocytes in the basal or 20 nM insulin stimulated state 
during the course of 20 minutes. (H) mRNA expression of Ucp1 and Cpt1b in preBAT adipocytes 
stimulated for 3 hours with 1 µM NE or vehicle. All values are expressed as means ± SEM, n = 3 
technical replicates, *p<0.05, **p<0.01, ***p<0.001 ctrl vs. KD. 
Results - Brown Adipose Tissue is one of the checkpoints for the metabolic master-regulator TBLR 
 
 
60 
 
(OCR) (Figure 27.A) and glycolytic activity, assessed in terms of extracellular acidification 
rate (ECAR) (Figure 27.B). The same observation was true in primary cells (Figure 27.C). 
Consequently, there was no shift from oxidative phosphorylation to glycolysis, regardless 
whether glucose was present in the medium (Figure 27.D). 
Since we showed that KD of TBLR alone or together with TBL compromises basal glucose 
uptake, which can be rescued by the addition of insulin (Figure 25.F,G), we were interested 
in the glycolytic capacity of these metabolically less active adipocytes. Thus, glucose and 
insulin were added, subsequently, to the cells. Addition of glucose could not rescue the 
defect in basal glycolysis in either early KD (Figure 27.E) or late KD (Figure 27.F) cells. In 
fact, the relative response in terms of delta AUC was even lower in cells deficient for TBLR or 
TBL (statistical AUC analysis was performed using the seahorse software) (data not shown). 
The addition of insulin, however, could rescue the defect and bring the ECAR of cells 
subjected to early or late KD back to the level of control cells (Figure 27.E-F).  
Since the mitochondrial uncoupling protein Ucp1 was not only identified as a target of TBLR 
by ChIPseq analysis (Figure 23.D), but also was found to be dysregulated upon early or late 
KD of TBLR alone or TBLR/TBL, we speculated that deficient cells might exhibit altered 
uncoupling. We assayed the performance of the mitochondrial respiration of these cells by 
treating them with different compounds, observing the effect on oxygen consumption (OCR). 
Addition of the ATP synthase inhibitor oligomycine lowered OCR and the degree of this 
reduction reflects respiration caused by ATP production (coupled respiration), while all 
oxygen still consumed is caused by proton leak. We found that preBAT cells subjected to late 
KD reduced their OCR, and the remaining respiration (proton leak) was still lower in KD cells, 
demonstrating that they are not more uncoupled (Figure 27.G). Still, subtracting OCR of 
oligomycin-treated cells from their basal OCR (reflecting the rate of ATP production) revealed 
that also this rate was significantly lower in KD cells (Figure 27.H). 
In the normal brown adipocyte setting, uncoupling mainly takes place via fatty acid-mediated 
UCP-1 activation [4, 95]. We thus speculated that by applying Iso, which is thought to allow 
fatty acid-mediated uncoupling via UCP-1 by inducing lipolysis [101], we would be able to 
assay lipolysis and fatty acid-dependent brown adipocyte respiration. Indeed, Iso could 
induce uncoupling of respiration in the absence, but not in the presence of the fatty acid 
scavenger BSA, indicative of the dependence of the respiration-stimulatory effect of Iso on 
free fatty acids (Figure 27.I) [165]. In preBAT adipocytes subjected to late KD, Iso could not 
fully rescue the defect in respiration (Figure 27.J). Anaologously, in primary adipocytes 
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deficient of TBLR, TBL or both, NE failed to fully rescue respiration (Figure 27.K). However, 
addition of the ion carrier carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP), 
that uncouples respiration from ATP production by dissipating the H+ gradient over the 
mitochondrial membrane, even lead to higher maximal thermogenic capacity (that is, OCR 
induction over baseline respiration) in knockdown preBAT or primary adipocytes (Figure 
27.L-M). 
Taken together, these data demonstrate that in the absence of TBLR/TBL adipocytes are 
less metabolically active, and both their coupled and uncoupled respiration rates are lower. 
Both insulin and chemical uncoupling via FCCP rescued the effect, in accordance with the 
observation that Ucp1 and respiratory chain elements are expressed more abundantly upon 
TBLR KD (Figure 23.G, Table 3), while fatty acid dependent respiration was still deficient. 
Consequently, we wanted to know whether the knockdown adipocytes were capable of 
normal β-oxidation. 
We found that the direct addition of fatty acids in the form of BSA-conjugated palmitate, but 
not of BSA alone, did enhance respiration over baseline in preBAT cells subjected to early 
KD (Figure 27.N) or late KD (Figure 27.O). However, cells lacking TBLR alone or TBLR/TBL 
during differentiation, responded less to the substrate stimulus (Figure 27.N), which to a 
lesser degree was also true for cells in which knockdown was achieved after differentiation 
(Figure 27.O). To assess to which degree this induction is dependent on a defect in β-
oxidation (rather than on, for example, less fatty acid-induced uncoupling [99, 100, 166] due 
to less available substrate), an inhibitor of mitochondrial fatty acid-import, Etomoxir, was 
applied and the decrease in OCR was calculated. There was a trend for β-oxidation to be 
lower in cells deficient of TBLR alone or TBLR/TBL (Figure 27.P). 
Overall, our in vitro findings demonstrate that adipocytes need TBLR and TBL to be present, 
mainly during differentiation but to a lower degree also in the differentiated state, in order to 
act as fully metabolically competent adipocytes. In the absence of the factors, adipocytes 
exhibit lower metabolic rates, such as glycolysis, glucose uptake, respiration and lipogenesis, 
unless stimulated. However, mitochondrial function per see seemes to be intact, since 
stimulators of nutrient uptake (insulin) or chemical uncouplers (FCCP) rescued these defects. 
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Figure 27. TBLR and TBL deficient adipocytes are less metabolically act ive in the unst imulated  
s tate.  (figure legend continued on next page) 
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Figure 27. TBLR and TBL deficient adipocytes are less metabolically act ive in the unst imulated  
s tate.  (figure legend continued from previous page) 
preBAT cells or primary brown SVF dedived adipocytes were subjected to early or late KD and 
analysed on a Seahrose extracellular flux analyser. (A) preBAT adipocyte oxygen consumption 
rate (OCR) as indicator for oxidative phosphorylation or (B) extracellular acidification rate (ECAR) 
as indicator for glycolytic activity, both displayed relative to shCtrl transducted cells. (C) OCR and 
ECAR in primary brown SVF dedived adipocytes. (D) AUC over 30 minutes of OCR versus ECAR 
of preBAT adipocytes assayed with or without glucose in the medium. (E) ECAR of early KD and 
(F) late KD preBAT adipocytes subjected to a glycolysis stress assay, subsequently adding 10 mM 
glucose, 20 nM insulin and 100 mM 2-DOG. (G) Proton leak in early and late KD preBAT cells, 
defined as AUC over 30 minutes of OCR upon treatment with 2 µM oligomycine, displayed relative 
to shCtrl transducted cells. (H) ATP production in early and late KD preBAT cells, defined as the 
difference in average AUC over 30 minutes of cells before (“basal”) and after (“coupled”) 
treatment with 2 µM oligomycine, displayed relative to shCtrl transducted cells. (I) Changes in OCR 
relative to baseline in control preBAT cells treated with 1 µM isoproterenol (Iso) in the presence or 
absence of 0.1 % bovine serum albumin (BSA). (J) OCR of late KD preBAT adipocytes and (K) 
early KD primary brown adipocytes subjected to a mitochondrial stress assay, subsequently adding 
2 µM oligomycine, 1 µM isoproterenol or 1 µM norepinephrine (NE) and 1 µM each of rotenone and 
antimycin A. (L) Changes in OCR relative to baseline in late KD preBAT adipocytes and (M) early 
KD primary brown adipocytes, subsequently adding 2 µM oligomycine, 0.5 µM FCCP and 1 µM 
each of rotenone and antimycin A. (N) OCR of early KD and (O) late KD preBAT adipocytes 
subjected to a fatty acid oxidation assay, subsequently adding 200 µM palmitate-BSA conjugate or 
BSA alone and 1 mM etomoxir. (P) β-oxidation in early and late KD preBAT cells, defined as the 
difference in average AUC over 40 minutes of cells in the presence of 200 µM palmitate-BSA 
conjugate before and after treatment with 1 mM etomoxir, displayed relative to shCtrl transducted 
cells. Statistical ANOVA analysis was performed using the Seahorse analysis software based on 
the AUC of OCR or ECAR over all measurements performed at the respective condition. n = 4-32 
wells per condition, *p<0.05, **p<0.01, ***p<0.001 ctrl vs. KD. 
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BAT-specific TBLR ablation in vivo is strong and specific 
With the data above we have established that TBLR is regulated specifically under conditions 
that activate brown adipose tissue, that in brown adipocytes it regulates gene expression 
programs connected to adipogenesis and mature adipocyte function and that its ablation in 
vitro during or after adipogenic differentiation, especially when eliminating also its homologue 
TBL, leads to metabolically impaired adipocytes. We hypothesised that TBLR, being a 
metabolic master regulator with known functions in liver and adipose tissue, can exert its 
actions in a tissue-specific way and that thus brown adipose tissue-specific knockout of 
TBLR will impact the whole organism. To address this hypothesis we crossbred Tblr floxed 
mice [139] with mice expressing tamoxifen-inducible Cre recombinase under the control of 
the Ucp1 promoter [167]. By this method we obtained Tblr1fl/flUcp1Cre+ and Tblrfl/flUcp1Cre- 
mice, the former of which become knockout for the Tblr gene in all Ucp1 expressing cells 
upon tamoxifen injection (“BATKO” mice). 
Female BATKO mice showed strongly decreased Tblr mRNA levels in BAT while other 
tissues such as inguinal or abdominal white adipose tissue (iWAT, aWAT), skeletal muscle 
(gastrocnemius, GC) or liver expressed normal Tblr levels (Figure 28.A). The same was true 
in male animals (data not shown). The knockout was stable also upon up to 3 week long 
exposure to thermoneutrality (30 °C) or cold (4 °C) at both the level of mRNA (Figure 28.B) 
and protein (Figure 28.C). Since in this animal model only Ucp1-expressing cells are targeted 
by the knockout and BAT is comprised of both UCP-1+ adipocytes and UCP-1- stromal 
vascular cells, it was not surprising that TBLR was still to some degree detectable in BAT 
lysates. Further, TBLR knockout was conserved at the level of mRNA (Figure 28.D) and 
protein (Figure 28.E) even following 2 months of high fat diet feeding. Finally we tested 
whether this genetic mouse model technically allows the induction of knockout in brite 
adipocytes. To show this we injected Tblr1fl/flUcp1Cre+ and Tblrfl/flUcp1Cre- mice with 
tamoxifen to render them BATKO and control mice, respectively. Following a three week 
adaptation phase, we acclimatised them to 4 °C for 3 weeks and then divided them into 3 
groups. While cre- control animals and one cre+ BATKO group were injected with another 
dose of tamoxifen, the other group of cre+ BATKO mice received only vehicle. Interestingly, 
while both BATKO groups maintained strong Tblr knockout in BAT, the group re-injected with 
tamoxifen after cold-induced recruitment of UCP-1+adipocytes in WAT exhibited reduced Tblr 
levels in WAT (Figure 28.F). We hereby showed that this is a strong, stable and specific 
genetic mouse model for inducible BAT- (and brite-) specific knockout of TBLR. 
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TBLR ablation in vivo hardly affects BAT gene expression 
Analogous to our in vitro studies we were interested in the impact of TBLR deletion on BAT 
gene expression. We first analysed the expression of selected individual targets and then 
performed microarray analysis on RNA obtained from BAT that was control or knockout, 
respectively, for TBLR. We analysed BAT of animals housed at room temperature or 
exposed to 4 °C for 2 days. The expression of Ucp1, the main player in brown adipose tissue 
thermogenic function, was not differentially regulated in BATKO mice, despite the fact that it 
was identified as the most strongly bound target in mature preBAT adipocytes and to be 
dysregulated upon in vitro KD of TBLR (Figure 29.A and B). Neither did KO of TBLR lead to 
Figure 28. Tamoxifen induced TBLR knockout in BATKO mice is strong, stable and spec if ic .  (A) 
Tblr mRNA levels in BAT, aWAT, iWAT, GC and liver of female BATKO and cre- control mice (n=3-
4). (B) Tblr mRNA and (C) protein levels in BAT of BATKO and control mice housed for 3 weeks at 
30 °C, 22 °C or 4 °C (n=3-10). (D) Tblr mRNA and (E) protein levels in BAT of BATKO and 
control mice fed a HFD or LFD for 2 months at 22 °C (n=6-7). (F) Tblr mRNA levels in BAT, iWAT 
and aWAT of BATKO and cre- control mice all injected with tamoxifen, then exposed to 4 °C for 3 
weeks, then injected again with either tamoxifen or sunflower oil as vehicle. All values are 
expressed as means ± SEM, *p<0.05, **p<0.01, ***p<0.001 ctrl vs. BATKO, #p<0.05, ##p<0.01, 
###p<0.001 LFD vs. HFD 
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compensatory up-regulation of Tbl (Figure 29.C). Differently from in vitro results, where 
TBLR ablation before induction of differentiation enhanced expression of mitochondrial 
respiratory chain components, upon in vivo knock out of TBLR in mature adipocytes we 
found a modest tendency for mitochondrial markers and the β3-adrenergic receptor to be 
reduced (Cox7a1, Cox8b, succinate dehydrogenase complex subunit B and C (Sdhb, Sdhc), 
ATP synthase subunit O (Atp5o) and Adrb3), although the differences were not statistically 
significant (Figure 29.D). Analysis of global gene expression in BAT revealed that BATKO 
mice showed a very similar profile to control mice both at room temperature (Figure 29.E) 
and at 4 °C (data not shown). 
 
 
KEGG pathway analyses did not give overlapping results between BAT of mice housed at 22 
°C or 4 °C, and in general yielded low enrichment scores (Table 4), the highest enriched 
pathway scoring ± 0.7, as compared to ± 2.5 in the in vitro study shown in Table 2. This 
further indicates that there was little specific influence of TBLR deletion in mature brown 
adipocyte or BAT global gene expression programs. 
Figure 29. TBLR deficient BAT shows only marginally affected gene express ion pat terns .  Gene 
expression was analysed in BAT of female BATKO and cre- control mice. (A) Ucp1 mRNA and (B) 
protein levels. (C) mRNA levels of Tbl and (D) mitochondrial and adipocyte markers. (E) Heatmap 
showing differential mRNA expression between BAT of BATKO and cre- ctrl mice housed at 22 
°C. Higher and lower expression is displayed in red and blue, respectively. All values are 
expressed as means ± SEM, n = 5-10, *p<0.05, **p<0.01, ***p<0.001 ctrl vs. BATKO. 
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Of all significantly regulated genes, neither of them was changed by more than 70 % (at 4 
°C) or 30 % (at room temperature), respectively, and a higher number of genes was up- 
rather than down-regulated upon TBLR knockout in both settings, indicating that in BAT 
TBLR acts more often as a co-repressor than as a co-activator. For analysis, only genes 
expressed differentially by at least 10% and with a p-value smaller than 0.05 were 
considered. The complete list of genes matching these criteria is shown below (Table 5).  
At 22 °C, the most strongly reduced gene in TBLR-deficient BAT was elongation of long-
chain fatty acids family member 6 (Elovl6). Further, the highly expressed adipokine 
complement factor D (Cfd, also known ad adipsin), which is known to be regulated in obesity 
and to stimulate glucose transport and fatty acid re-esterification [168], was found to be 
Table 4. Regulation of KEGG pathways by TBLR knockout is weak and not reproducible in different 
temperature set t ings .  
KEGG pathways significantly regulated by TBLR KO ranked by enrichment. 
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expressed at lower levels in TBLR deficient BAT. This gene is reported to inhibit lipolysis, as 
is another target found to be down-regulated, Apolipoprotein C3 (Apoc3), which is an 
inhibitor of LPL [169]. Also the glucose transporter Slc2a12 (solute carrier family 2 member 
12) was down-regulated in TBLR-deficient BAT.  
There was no clear redundance or common pattern of changes in BAT gene regulation in 
response to TBLR KO comparing samples from animals housed at 4 °C or at 22 °C, 
respectively. Interestingly, many muscle associated genes were de-repressed. In the set of 
genes decreased in expression in TBLR-deficient BAT, the LDL receptor (Ldlr) stood out. 
 
  
Overall, in terms of gene expression, TBLR-deficient BAT largely resembled wildtype, with 
muscule-like signatures being enriched in the cold, while KO at room temperature resulted in 
a reduction of genes associated with lipogenesis-induction and lipolysis-suppression. 
Table 5.  TBLR def ic ient  BAT shows only  marginal changes in gene express ion.  
Ranking by fold-regulation of gene expression in TBLR KO. Genes induced by TBLR (depleted in 
KO) are indicated in red, genes repressed by TBLR (de-repressed in KD) are highlighted in green. 
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TBLR ablation does not affect adiposity in HFD feeding 
Since Rohm et al found that adipose-specific deletion of TBLR induces overweight [139] we 
were interested whether selective brown fat-specific knockout would show the same 
phenotype. However, BATKO mice did not gain more weight on HFD or LFD (Figure 30.A) 
and their food intake was not changed (Figure 30.B). Since with conventional methods only 
LFD intake can be quantified reliably (whereas the lipid-rich HFD crumbles too much for 
weighing), we made use of Phenomaster cages (TSE Systems), that, among other 
parameters, are able to track food intake. We found that the feeding behaviour of BATKO 
and control mice was equal at all light cycle phases during normal chow diet feeding as well 
as HFD re-feeding after an overnight fast (Figure 30.C) (average of light and dark phase 
shown). In accordance with body weight, magnetic resonance analysis of body composition 
proved that fat and lean mass did not differ between genotypes (Figure 30.D-E). After 6 
weeks of HFD feeding, weight loss and re-gain during fasting and re-feeding respectively 
was determined, and also in this regard BATKO and control mice were found to be equal 
(Figure 30.F). In line with these findings, the weight of individual organs was not significantly 
affected at 22 °C, however WAT depots tended to be smaller (Figure 30.G). Since brown fat 
weight was found to be slightly reduced upon KO of TBLR in individual cohorts, while it was 
not affected in biological replicates in the same settings, all available data was compared. 
Overall, there was no significant difference in BAT weight at any housing temperature (Figure 
30.H). Since it is known that TBLR-deficient white adipocytes accumulate more lipids due to 
a defect in lipolysis [139], we hypothesised that despite unaltered adiposity in brown fat-
specific TBLR deficiency, the lipid content of BAT might be different between genotypes, 
however we found also BAT triglycerides not to be affected by TBLR knockout at any 
temperature (Figure 30.I). 
Overall BATKO mice were not more obese than controls, and the same observations made 
on female mice were found in male BATKO and control animals (data not shown). Thus 
BATKO mice do not reproduce the previously described phenotype of whole fat-specific 
ATKO mice [139]. 
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Figure 30. The adiposity of BATKO mice does not  dif fer f rom controls .  (A) Body weight and (B) 
food intake of BATKO and control mice fed a high fat diet (HFD) or low fat diet (LFD) for 14 weeks 
(n=4-7). (C) Food intake of BATKO and control mice housed at 30 °C in phenomaster cages and 
presented, subsequently, with normal chow, no food, or HFD (as indicated) (n=9-10). (D-E) ECHO-
MRI body composition analysis of BATKO ant control mice fed a HFD or LFD, fat mass (D) and 
lean mass (E) were determined every 4 weeks (n=4-7). (F) Changes in body weight of the mice 
shown in (A), (B) and (D) upon 16 hours fasting and 6 hours of refeeding of the respective diet. (G) 
Organ weights of BATKO and control mice housed at 22 °C (n=3-4). (H) BAT weight of BATKO 
and control mice housed at the indicated temperatures (n=17-33). (I) Triglyceride content in BAT of 
BATKO and control mice housed at the indicated temperatures (n=3-10). All values are expressed 
as means ± SEM, n = 4-10, *p<0.05, **p<0.01, ***p<0.001 ctrl vs. BATKO, #p<0.05, ##p<0.01, 
###p<0.001 LFD vs. HFD 
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Absence of TBLR in BAT does not affect systemic glucose handling 
Since in vitro data indicated that brown adipocytes deficient in TBLR exhibit reduced glucose 
metabolism (Figure 25.D-F), that Tblr expression is repressed by insulin (Figure 20.C) and 
since ChIPseq analysis in preBAT cells indicated that components of the insulin signalling 
pathway were regulated by TBLR (Table 1), we hypothesised, that despite their unaltered 
adiposity, BATKO mice might exhibit differential glucose handling properties. However 
determination of random fed blood glucose of mice housed at different temperatures (Figure 
31.A) as well as in fasted or refed state at room temperature (Figure 31.B) illustrated that 
systemic blood glucose was independent from the presence of TBLR in BAT. BATKO and 
control mice fed on a HFD or LFD were subjected to monthly glucose tolerance tests (GTTs). 
Neither blood glucose levels (Figure 31.C) nor corresponding serum insulin levels (Figure 
31.D) were found to be different between genotypes for the first 8 weeks of feeding the 
respective diet. After 12 weeks of HFD feeding, when mice started to exhibit signs of the 
onset of insulin resistance such as elevated serum insulin levels compared to LFD-fed 
animals (Figure 31.D, right panel), HFD-fed BATKO mice tended to clear less glucose from 
the blood (Figure 31.C, right panel). We hypothesised that TBLR-deficient BAT, analogously 
to in vitro findings, would take up less glucose. To address this question, we housed mice at 
22 °C or at 4 °C for 3 weeks in order to compare BAT in different levels of activation. The 
uptake rate of intraperitoneally injected 3H-2DOG tracer into WAT, BAT, heart or brain of 
BATKO or control mice was determined (Figure 31.E), and the relevance to systemic glucose 
clearance was estimated by expressing tissue contribution as the product of the uptake rate 
and the respective tissue weight as described in the first section (Figure 31.F). While BATKO 
mice tended to deposit more glucose to the heart and less to brain, adipose tissues behaved 
equally in both genotypes. There was a tendency for BAT to take up less glucose in the cold, 
however technical variation in these experimental settings is high and thus more data would 
be required to confirm this observation. Overall, depletion of TBLR from mature, UCP-1-
expressing brown adipocytes in vivo did not lead to an impairment of glucose uptake, 
consistent with observations in cells in which TBLR was absent during adipogenic 
differentiation (Figure 25.D-F), indicating that the role of TBLR in the regulation of glucose 
metabolism of brown adipocytes is probably more pronounced during the course of 
adipogenesis. Further, in vivo other factors such as the presence of TBL might compensate 
the deficiency of TBLR. 
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Figure 31. Absence of TBLR in BAT does not affect systemic  glucose handling.  (A) Random fed 
blood glucose levels of mice housed at the indicated temperatures (n=3-10) or (B) random fed, 16 
hour fasted or 6 hour refed blood glucose levels of BATKO and control mice fed a HFD or LFD for 
12 weeks (n=4-7). (C) Blood glucose and (D) serum insulin levels of 6 hour fasted BATKO or 
control mice fed a HFD or LFD for 4 weeks, 8 weeks or 12 weeks, respectively, upon i.p. injection 
of 1 g/kg body weight glucose (n=4-7). (E) 3H-2DOG uptake rate into aWAT, BAT, heart and brain 
of mice housed at 22 °C or 4 °C for 3 weeks (n=3-4). (F) Total 3H-2DOG uptake by each tissue 
of the mice shown in (E), calculated from the 3H-2DOG uptake rate and from the weight of each 
tissue. All values are expressed as means ± SEM, *p<0.05, **p<0.01, ***p<0.001 ctrl vs. BATKO, 
#p<0.05, ##p<0.01, ###p<0.001 LFD vs. HFD (A-D) or 4 °C vs. 22 °C (E-F) 
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TBLR-deficient BAT is capable of normal lipolysis 
Albeit previous studies on the effect of TBLR KO in whole adipose tissue [139] suggested 
impaired lipolytic capacity of TBLR-deficient adipose tissue, in vitro studies of specifically 
brown adipocytes suggested that lipolysis is largely unaffected by the deletion of TBLR 
(Figure 25.A-C). We wanted to exclude the possibility that in vitro knockdown was simply not 
strong enough to mediate effects as observed in vivo previously, so BAT from BATKO and 
control mice was dissected and subjected to a lipolysis assay. Although the efficient deletion 
of Tblr expression could be confirmed (Figure 32.A), neither lipolysis (Figure 32.B) nor 
glucose metabolism (Figure 32.C) or lipogenesis (Figure 32.D) were found to be different in 
BAT from BATKO mice. In line with these findings, the analysis of protein levels in BAT of 
BATKO and control mice revealed that BATKO mice at 30 °C tended to express reduced 
levels of HSL (Figure 32.E). However, in mice housed in the cold or at thermoneutrality, 
neither PKA signalling nor HSL phosphorylation were affected by the knockout of TBLR, 
indicating that activation of lipolysis is not impaired in BATKO mice (Figure 32. E). 
 
 
Figure 32. TBLR deficient BAT shows normal l ipolys is .  (A-D) BAT of BATKO or control mice was 
dissected and subjected to lipolysis or lipogenesis assays. (n=5-7) (A) Tblr mRNA levels, (B) 
release of free fatty acids (FAA) as indicator of triglyceride hydrolysis 3 hours after treatment with 1 
µM isoproterenol (Iso) or vehicle, (C) 14C-D-glucose accumulation and (D) conversion to lipids in 
the basal or 20 nM insulin (ins) stimulated state during the course of 20 minutes. (E) Western Blot 
analysis of BAT of BATKO and control mice housed at 4 °C or 30 °C (n=6-10). All values are 
expressed as means ± SEM, *p<0.05, **p<0.01, ***p<0.001 ctrl vs. BATKO. 
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Similar to the previously shown findings that a defect in glucose uptake following TBLR KD in 
vitro did not translate to a glucose-metabolism defect in BATKO mice in vivo, we show that 
the same is the case for TBLR-mediated regulation of lipolysis. Thus, TBLR-mediated 
regulation of lipid and glucose handling in brown fat is probably indirect by affecting basal 
metabolic settings as a result of dysregulated gene programs during adipogenesis. 
Acute stimulation reveals a defect in maximal capacity of TBLR KO BAT 
We so far have established by in vitro experiments that TBLR deficiency has more severe 
adverse effects on adipocytes when manifested already during adipogenesis (Figure 17 
compared to Figure 18), and accordingly in vivo did not observe differential lipolysis or 
glucose metabolism in BATKO mice (in which TBLR is absent only from mature, UCP-1 
expressing adipocytes). However TBLR was found to be required also in mature adipocytes, 
since knockdown both before and after differentiation into mature adipocytes similarly 
compromised metabolism (Figure 27). Thus we hypothesised that in BATKO mice, the 
respiratory capacity of BAT in response to β3-adrenergic stimulation would be compromised. 
We made use of phenomaster cages in which not only the ambient temperature can be 
regulated, but also a multitude of metabolic parameters are assessed, such as oxygen (O2) 
consumption and carbon dioxide (CO2) production and the resulting respiratory exchange 
ratio (RER), or movement and conversely the resting metabolic rate (RMR) of non-moving 
animals. The RER is an indicator of fuel use, where pure carbohydrate consumption leads to 
a ratio of volume of consumed oxygen (VO2) to volume of produced carbon dioxide (VCO2) of 
nearly 1, whereas pure lipid oxidation results in an RER of 0.7; RMR is the oxygen 
consumption corrected for consumption caused by physical activity and thus represents 
movement-independent metabolism, including thermogenesis. Observing BATKO and 
control mice subjected to a subsequent change of ambient temperature from 30 °C to 22 °C 
and then to 4 °C, we found that neither VO2 (Figure 33.A) nor VCO2 (data not shown) and 
thus neither RER was affected by the KO of TBLR in BAT (Figure 33.B). Further, physical 
activity did not differ between genotypes (data not shown), thus RMR was equal between 
BATKO and control mice (Figure 33.C). Also assessing these parameters separately for the 
active dark or the inactive light phase did not reveal differences between genotypes (data not 
shown). 
In order to assess the ability of the mice to defend their body temperature in various ambient 
temperatures, they were implanted with subcutaneous transponder thermometers prior to 
phenotyping. While at thermoneutrality body temperature was 0.5 °C higher in BATKO 
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animals, putting the mice to 4 °C lead to a drop in body temperature of 2 °C in both groups, 
equalizing the difference (Figure 33.D). Also upon prolonged adaptation to 4 °C, body 
temperature was maintained at 35° in both groups, with no difference between BATKO and 
control animals (Figure 33.E). 
Since it is believed that not only temperature but also dietary challenges can induce 
thermogenesis [104, 170, 171], a study was performed to observe the acute metabolic 
response to fasting, refeeding and subsequently feeding of HFD. The measurements were 
done at thermoneutrality, thus allowing us to determine thermogenesis independently of 
requirements for thermoregulation. The phenomaster cages were able to detect the general 
consequences of these dietary cues, body weight dropped during fasting, was re-gained in 
refeeding and started to rise continuously immediately upon changing the diet from chow to 
HFD, however there was no difference between BATKO and control mice (Figure 33.F). Fuel 
use was adapted to the feeding situation as expected. The RER was around 0.9 on chow 
diet, dropped to 0.8 during the fasting-induced switch from the use of carbohydrate to lipid 
stores, rose to almost 1 upon re-feeding (where lipid reserves are replenished and 
carbohydrates are oxidised) and dropped as low as 0.8 when feeding a HFD, indicating that 
the high fat content of the diet forces a switch to higher lipid oxidation. However, BATKO 
mice and controls adapted their metabolism to the corresponding situation in the same way, 
indicating that TBLR is dispensable for these functions (Figure 33.G). VO2 and RMR were 
found to rise in response to HFD, indicating diet-induced thermogenesis (Figure 33.H). RMR 
on HFD tended to be lower in BATKO animals, implying that the diet-induced induction of 
thermogenesis depends on the action of TBLR in mature BAT, however this difference was 
not significant. 
Overall, BATKO mice were able to adapt as well as their wildtype counterparts to 
thermogenic challenges caused by ambient temperature or diet. 
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Since we observed earlier that cold exposure leads to an acute but transient induction of Tblr 
expression (Figure 21.F), we hypothesised that the role of TBLR in the thermogenic 
response in mature adipocytes might only serve a very acute purpose, and that subsequent 
recruitment of factors and mechanisms might allow for compensation of TBLR knockout over 
time. Based on these observations we decided to assess the acute maximal BAT capacity by 
Figure 33. In both BATKO and control mice, metabolism adapts to changes in temperature and 
diet .  (A-D) BATKO and control mice were implanted with subcutaneous transponder thermometers 
and housed individually in phenomaster cages where the ambient temperature was set to be 30 
°C for 3 days, 22 °C for other 3 days and finally 4 °C for 10 days (n=6-7). (A) Oxygen 
consumption (VO2), (B) respiratory exchange ratio (RER) of VO2/VCO2, (C) resting metabolic rate 
(RMR) and (D) body temperature in BATKO and control animals at the indicated temperatures. (E) 
Body temperature in BATKO and control mice subjected to prolonged cold exposure (n=4-7). (F-H) 
BATKO and control mice housed individually in phenomaster cages at 30 °C were fed a chow diet 
for 6 days, fasted for 16 hours, then re-fed with chow for 2 days and subsequently fed a HFD for 
the rest of the duration of the experiment (n=9-10). (F) Body weight, (G) RER, (H) VO2 and (I) RMR 
in BATKO and control mice being fed the indicated diets. All values are expressed as means ± 
SEM, *p<0.05, **p<0.01, ***p<0.001 ctrl vs. BATKO 
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injecting the animals with the β3-adrenergic agonist CL and determining the immediate 
oxygen consumption-response. Since this agent also reduced physical activity, we corrected 
the data for movement, resulting in VO2 caused by BAT activity. Strikingly, we found that 
BATKO mice housed at thermoneutrality exhibited a blunted maximal BAT capacity, being 15 
% lower compared to controls (Figure34.A). Subsequent acclimatisation of the same animals 
to 4 °C and repetition of the measurement after 1 week (Figure34.B) and 3 weeks 
(Figure34.C) respectively of cold adaptation (always measuring at 30 °C though, to inactivate 
the sympathic tone), revealed that although the general the capacity of cold-adapted BAT to 
react to acute stimuli was increased, BATKO mice always demonstrated a dampened 
oxygen consumption-response compared to controls (Figure34.D). These findings 
demonstrate that mature BAT is dependent on TBLR to acutely respond to thermogenic 
stimuli, but that its role is transient and that compensatory mechanisms can be activated. 
 
 
Figure 34. TBLR is required for immediate reaction of BAT to thermogenic  s t imuli.  BATKO and 
control mice were acclimatised to 30 °C, injected intraperitoneally with 1 mg/kg body weight CL 
and respiration at 30 °C was assessed in phenomaster cages. Subsequently, the animals were 
transferred to 4 °C for another 3 weeks, the measurement being repeated 2 more times at 30 °C 
(n=10). Correction for physical activity was performed. (A) VO2 at 30 °C, (B) after 1 week and (C) 
3 weeks of housing at 4°C. (D) Average VO2 per condition at the indicated times and 
temperatures. All values are expressed as means ± SEM, *p<0.05, **p<0.01, ***p<0.001 ctrl vs. 
BATKO (comparing the avereage rate per condition). 
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BATKO mice have reduced serum VLDL at different temperatures 
Interestingly, despite unaltered adiposity, glucose handling and BAT lipolysis in BATKO 
mice, we found that serum triglyceride (TG) levels in these animals were lower, not only at 4 
°C where BAT is highly active, but also at room temperature (22 °C) and thermoneutrality (30 
°C) (Figure 35.A). This was specific for TGs, while there was no difference in serum levels of 
free fatty acids (Figure 35.B) or cholesterol (Figure 35.C). Also when challenging fasted mice 
with oral administration of a defined dose of olive oil (oral lipid tolerance test, OLTT), serum 
TG levels were maintained at lower levels in BATKO mice compared to controls (Figure 
35D). Fast‐protein liquid chromatography (FPLC) analysis revealed that in the serum of mice 
housed at 4 °C (Figure 35.E) or 30 °C (Figure 35.F) the fraction corresponding to very low 
density lipoprotein (VLDL) was reduced in TG (AUC of protein signal during FPLC, being 50 
% reduced at 4 °C and 20 % reduced at 30 °C), with cholesterol levels not greatly being 
affected (2 % more signal in BATKO at both temperatures) (Figure 35.G-H). 
This phenotype is very interesting, since BATKO mice exhibit diminished thermogenesis 
upon acute activation and thus are expected to oxidize less rather than more nutrients. 
However we cannot outrule that vice versa the altered lipid profile is the primary defect in 
BATKO mice that in turn leads to comprised thermogenic flexibility in situations with 
increased fuel demand. 
To address the question of how BAT-specific knockout of TBLR can affect systemic serum 
VLDL levels despite not being metabolically more or less active in terms of glucose uptake 
(Figure 31.E-F), lipolysis or lipogenesis (Figure 32.B-E), we hypothesised that BAT, being 
known to have the potential to function as an endocrine organ [172, 173], might signal to 
other organs, thus affecting systemic lipid handling. We thus individually dissected the routes 
in which lipids systemically are distributed and used. Hypothetically, lower serum lipid levels 
can be the result of a multitude of different settings. The amount of TGs being taken up into 
the system via feeding might be lowered by hypophagia [174] or increased loss of energy to 
feces [175, 176]. Alternatively, hepatic output of VLDL or on the other hand lipid clearance 
from the blood might be disturbed [177-179].  
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Figure 35. BATKO mice have lower serum VLDL levels .  Serum levels of BATKO and control mice 
housed at the indicated temperatures of (A) triglycerides (TGs), (B) free fatty acids or (C) 
cholesterol (n=3-10). (D) Oral lipid tolerance test (OLTT) in BATKO and control mice housed at 22 
°C. Mice were fasted over night and an oral dose of 100 µl olive oil was gavaged, followed by blood 
sampling every 90 minutes and serum triglyceride determination (n=7-8). (E-H) Fast‐protein liquid 
chromatography (FPLC) was performed from pooled serum of BATKO or control mice housed at 4 
°C or 30 °C, pooling the serum of 6 mice per group and eluting 1 fraction of 0.5ml per minute. 
UV absorption signal was used to determine location and intensity of lipoprotein peaks and 
subsequently triglyceride and cholesterol concentration of the individual fractions were determined. 
(E-F) Triglyceride levels of BATKO and control mice housed at 4 °C (E) and 30 °C (F) 
respectively and corresponding protein intensity for VLDL peaks; and (G-H) cholesterol levels of 
BATKO and control mice housed at 4 °C (G) and 30 °C (H) respectively and corresponding 
protein intensity for HDL peaks. Values for (A-D) are expressed as means ± SEM, n = 3-10, 
*p<0.05, **p<0.01, ***p<0.001 ctrl vs. BATKO 
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Food intake as assessed by weighing of food (Figure 30.B) had shown not to be affected by 
BAT-specific KO of TBLR, however we made use of the ability of phenomaster cages to 
more closely observe the behaviour of individual mice in response to acute metabolic 
challenges. We made the observation that the increase in food intake induced in mice by 
lowering the ambient temperature to 4 °C was blunted in BATKO mice (Figure36.A). This 
difference in feeding behaviour was found to disappear quickly when raising the temperature 
back to 30 °C (Figure36.B) or allowing the animals to acclimatise to 4 °C for 3 weeks before 
determining their food intake (Figure36.C). In accordance with that, food intake during re-
feeding after over-night fasting was lowered in BATKO mice but then normalized quickly 
(Figure36.D). While these findings may partially explain altered serum lipid profiles in mice 
shortly after being challenged with cold stress, it is likely that also other factors contribute 
and thus allow the phenotype to be conserved in different temperature settings. We next 
determined fecal energy content and could prove that BATKO mice did not differ in terms of 
energy absorption from food (Figure 36.E).  
We next turned our attention to the liver, being active in lipogenesis and being the 
responsible organ for VLDL output [180]. We could not detect increased phosphorylation of 
Acetyl-CoA carboxylase (ACC) as an indicator of lowered liponeogenesis (Figure 36.F). 
Likewise, at room temperature liver mRNA expressions of genes involved in lioponeogenesis 
and lipid homeostasis, like sterol regulatory element-binding protein (Srebp1c), stearoyl-CoA 
desaturase-1 (Scd1), sirtuin-1 (Sirt1) and angiopoietin-like 3 (Angptl3), were mainly 
unaffected by BAT-specific TBLR deficiency, even if, interestingly, there was a trend for 
angiopoietin-like 4 (Angptl4) to be up-regulated in BATKO livers. (Figure 36.G). As a final 
proof to outrule decreased hepatic VLDL production as the cause of the lowered plasma TG 
levels observed in BATKO mice we subjected animals housed at room temperature to a 
hepatic output assay. Mice were fasted for 16 hours to eliminate intestinal lipid absorption 
and chylomicron production, thus TGs accumulating in the serum can be attributed to hepatic 
production. To outrule plasma lipolytic activity and subsequent lipid clearance to tissues, 
tyloxapol was administered intravenously, allowing the observation of serum TG-
accumulation. As expected, BATKO and control mice did not differ in terms of hepatic output 
(Figure 36.H). 
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Figure 36. While hypophagic in acute cold stress, BATKO mice show no dif ference in fecal i lpid 
excretion or hepatic product ion.  (A) Food intake of BATKO and control mice housed individually in 
phenomaster cages where the ambient temperature was set to be 30 °C for 3 days, 22 °C for 3 
days and 4 °C for 10 days (n=6-7) or (B) 22 °C for 6 days, 4 °C for 7 days and 30 °C for 7 
days (n=3-4) or (C) were cold acclimatised for 3 weeks before measuring food intake for another 2 
weeks (n=4-7). (D) Food intake of BATKO and control mice housed individually in phenomaster 
cages at 30 °C, fasted for 16 hours, then re-fed with chow (n=9-10). (E) Fecal energy content in 
BATKO and control mice housed at room temperature was assessed by bomb calorimetry  and 
total fecal energy content was calculated based on the fecal mass produced over the course of 24 
hours (n=7). 
(figure legend continued on next page) 
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Since lipids were not lost to feces and were neither differentially produced by the liver, we 
assumed that the observed difference in serum TG levels in BATKO mice is caused by 
dysregulated clearance of TGs to peripheral tissues. We speculated that since, based on the 
respiration measurements shown above, enhanced thermogenic oxidation in BAT is unlikely 
to account for lowered serum TG levels, that the observed enhanced TG clearance in 
BATKO mice might rather be mediated by an endocrine BAT factor acting on peripheral 
tissues. Meta-analysis of all available data on tissue weights of BATKO and control mice at 
different housing temperatures was performed, compiling relative organ weights between 
genotypes across several independent studies. Interestingly we could reveal that WAT tends 
to be heavier in BATKO mice, which reached significance at 4 °C and 22 °C (Figure 37.A, 4 
°C, Figure 37.B, 22 °C, Figure 37.C, 30 °C). In line with these findings, WAT, but not BAT or 
liver tended to exhibit higher TG concentrations in BATKO mice housed at 22 °C (Figure 
37.D, BAT, Figure 37.E, WAT, Figure 37.F, liver). 
To address the question, if and how BATKO mice differ from controls in regard to their TG 
clearance, we performed an oral lipid tolerance test (OLTT). Gavaging fasted animals 
housed at 22 °C with a defined volume of olive oil traced with 3H-triolein allowed us to assess 
tracer accumulation in tissues after a defined period of time. First, accumulation of the 
administered tracer in the blood was followed over the time of the experiment, as well as the 
total TG levels. We found that while the absorption of 3H-triolein was comparable between 
groups, even tending to be higher in BATKO compared to control mice (Figure37.G), total 
serum TG levels did not rise as drastically (Figure 37.H), indicative of higher clearance in the 
knockout animals. When measuring tracer accumulation in diverse tissues, we found that in 
general, BAT showed the highest TG uptake rate of all assayed tissues, followed by liver and 
then WAT and muscle. While BAT and liver TG uptake rates did not differ between 
genotypes, we could observe that in BATKO mice white adipose tissue had an 80 % 
Figure 36. While hypophagic in acute cold stress, BATKO mice show no dif ference in fecal i lpid 
excret ion or hepat ic  product ion.  (figure legend continued from previous page) 
(F) ACC protein expression and phosphorylation in the liver of BATKO and control mice housed at 
the indicated temperatures (n=3-10). (G) mRNA expression of Srebp1c, Scd1, Sirt1, Angptl3 and 
Angptl4 in the liver of BATKO and control mice housed at 22 °C (n=3-4). (H) Hepatic output of 
VLDL in BATKO and control mice fasted for 16 hours and i.v. injected with 500 mg/kg tyloxapol, 
determining serum triglyceride levels every 30 minutes (n = 7). All values are expressed as means 
± SEM, *p<0.05, **p<0.01, ***p<0.001 ctrl vs. BATKO (comparing the avereage rate per 
condition). 
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elevated TG uptake rate, and also the heart of these animals cleared TGs at a 30 % higher 
rate (Figure 37.I). In order to estimate the physiological relevance of these observations, we 
calculated total TG uptake by each tissue by factoring the respective depot size into their 
uptake rates (Figure 37.J). While it becomes evident that white adipose tissue in general is 
only a side player in lipid clearance compared to liver and BAT, it is still reasonable to 
assume that the enhanced deposit of TG into WAT of BATKO mice contributes to their lower 
serum TG levels. 
 
 
Figure 37. BATKO mice clear more triglycerides from their blood, which accumulate in WAT. (A-C) 
Meta-analysis of organ (BAT, iWAT, aWAT, liver, GC) and body weights across all performed 
experiments, calculating the ratio of BATKO over cre- for all parameters and compiling data of mice 
housed at equal temperatures and diets for comparable time periods (n=17-33). Shown are mice 
housed at (A) 4 °C, (B) 22 °C or (C) 30 °C. (D-F) Triglyceride (TG) content of (D) BAT, (E) 
WAT or (F) liver of BATKO or control animals at the indicated temperatures (n=3-10). (G-J) Oral 
lipid tolerance test. BATKO and control mice housed at 22 °C were fasted for 16 hours and orally 
gavaged with 100 µl olive oil traced with 10 µCi/mouse 9,10-3H(N)-triolein. Serum was collected 
every hour and the mice were sacrificed 3 hours after tracer administration (n=8). (G) 3H(N)-triolein 
accumulation and (H) total TG concentration in the serum. (I) TG accumulation rate in BAT, iWAT, 
aWAT, GC, heart and liver. (J) Whole body accumulation was calculated multiplying each tissue’s 
accumulation rate with its respective weight. All values are expressed as means ± SEM, n = 6-10, 
*p<0.05, **p<0.01, ***p<0.001 ctrl vs. BATKO 
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Overall, we could observe that BATKO mice, albeit being genetically modified only in their 
brown adipose tissue, exhibit a systemic phenotype in the form of lowered serum VLDL 
levels, which is indicative of a signalling function of BAT to peripheral tissues. General 
energy loss to feces, or altered liver metabolism, were outruled as causative contributors to 
the phenotype. We did however observe that BATKO mice were hypophagic during acute 
cold stress and that they deposit more TGs to WAT compared to control animals, both of 
which presumably leads to loss of lipids from the circulation. 
TBLR-deficient BAT differentially expresses secreted proteins 
Having shown that TBLR-deficient BAT can cause systemic effects in mice we aimed to 
identify candidate proteins differentially secreted from BAT in the absence of TBLR. Among 
the targets most strongly regulated in BAT genome-wide expression analysis (see Table 5.), 
the regulation of Ldlr and Apoc3 in BATKO mice stood out, both being known to regulate lipid 
clearance, the former enhancing it by mediating LDL internalization [181, 182], the latter 
dampening it by inhibiting lipoprotein lipase (LPL) [169]. Further, angiopoietin-like 3 
(Angptl3), another inhibitor if LPL [183, 184], was found to be significantly down-regulated in 
KO BAT (albeit only to a small degree, thus not showing up in Table 5.). Further, ChIPseq 
data from preBAT cells as described earlier suggested TBLR binding to the Lpl gene as well 
as to several members of the angiopoietin-like family, such as angiopoietin-like 4 (Angptl4) 
(Figure38.A-B), a known inhibitor of LPL [185-187]. We thus investigated the expression of 
some of these secreted factors and found that while Angptl4 expression was not differentially 
regulated in BAT of BATKO mice, Angptl3 expression was strongly reduced in TBLR-
deficient BAT (Figure38.C). Interestingly, also other tissues, such as iWAT, aWAT and liver 
of BATKO mice at 4 °C expressed lower Angptl3 levels (Figure38.D), indicating that Angptl3 
may not be a direct TBLR target in BAT but rather be affected downstream of TBLR 
regulated factors secreted by BAT. Other BAT secreted factors with known metabolic roles 
are, for example, fibroblast growth factor 21 (Fgf21) [188], Leptin [189, 190] or neuregulin 4 
(Nrg4) [172], thus we profiled their expression. While there was no differential Nrg4 or Leptin 
expression in BAT of BATKO mice, there were lower levels of Fgf21 at 4 °C, a state in which 
BAT mRNA expression is known to be induced and is supposedly mediating thermogenic 
response [191] (Figure38.E-F). Analyses of serum revealed that lowered Angptl3 expression 
was, at least in the cold, also reflected in the serum of BATKO mice, there was only a non-
significant trend for serum FGF21 levels to be lower in the serum of BATKO mice at any 
housing temperature (Figure38.G). 
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Overall these data indicate that, directly or indirectly, TBLR ablation in BAT leads to 
systemically lower Angptl3 expression, which we hypothesise may contribute to de-inhibition 
of LPL and subsequently to enhanced lipid import from the serum to WAT. 
 
 
Figure 38. TBLR deficient BAT differentially expresses secreted proteins .  (A-B) ChIPseq for TBLR 
binding in preBAT cells was performed on day1 and day7 respectively of adipogenic differentiation 
and results were visualised in the UCSC genome browser, comparing sequence abundance upon 
TBLR-pulldown to chromatin input Control. (A) Ldl (A) and Angptl4 (B) binding are shown, blue 
boxes highlighting TBLR hotspots. (C) Angptl3 and Angptl4 mRNA expression in BAT of BATKO 
and control mice housed at the indicated temperatures (n=6-10).  
(figure legend continued on next page) 
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iWAT browning and TBL potentially compensate for TBLO KO 
In the study presented here we show that TBLR, being a transcriptional regulator known to 
be implicated in liver and white adipose tissue metabolism, not only needs to be present for 
proper differentiation of brown adipocytes, but also integrates non-thermogenic as well as 
acutely thermogenic rules in mature BAT. However, considering the striking phenotype of 
TBLR deficiency in WAT [139], BATKO mice were remarkably capable of adapting their 
metabolism regardless of the presence of TBLR, unless acutely challenged. 
In vivo complex interlocked networks guarantee backup mechanisms in the case of defects 
in individual players of a regulatory network, thus it is challenging to experimentally 
demonstrate the specific role of individual players by depleting them. One of these backup 
mechanisms, in the case of brown fat, is the ability of white adipose tissue to adapt brown 
adipocyte features in order to back up the defect in BAT function [192]. We thus 
hypothesised that in BATKO mice one of the factors compensating for the absence of TBLR 
in BAT, particularly in the presence of thermogenic stimuli, might be white adipose tissue 
browning. At room temperature, iWAT of BATKO mice (albeit itself expressing normal levels 
of Tblr) demonstrated slightly elevated expression of brown marker genes (Figure39.A). Also 
at 4 °C, where iWAT browning is part of the normal cold adaptation process, iWAT of BATKO 
mice on top of that expressed higher levels of Ucp1 (Figure39.B), even if morphology of 
BATKO iWAT largely resembled that of control animals (Figure39.C). Overall these findings 
indicate indicate that iWAT browning is part of the compensatory mechanism rescuing 
BATKO mice from the absence of TBLR. 
Figure 38. TBLR deficient BAT differentially expresses secreted proteins .  (figure legend continued 
from previous page) 
(D) Angptl3 mRNA expression in BAT, aWAT or liver of BATKO and control mice housed at 4 °C 
(n=4-7). (E) Fgf21, Leptin and Nrg4 mRNA expression in BAT of BATKO and control mice housed 
at 4 °C (n=6-7) or (F) 22 °C (n=5). (G) Cirulating FGF21 and (H) ANGPTL3 levels in serum of 
mice housed at the indicated temperatures were determined via enzyme-linked immunosorbent 
assay (ELISA) (n=4-10). All values are expressed as means ± SEM, n = 4-10, *p<0.05, **p<0.01, 
***p<0.001 ctrl vs. BATKO 
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However the most likely factor capable of compensation for the deletion of TBLR is its 
homologue TBL. Analogously to in vitro studies, in which double knock down of TBLR 
together with TBL exacerbated the observed phenotype (Figures 17-19), we expect the 
ablation of TBL in BATKO mice to allow the observation of a more pronounced phenotype. 
To address this problem we designed a BAT-specific adeno-associated viral (AAV) vector 
expressing a microRNA targeting Tbl, aiming to achieve Tbl knockdown in vivo upon 
intravenous injection of the virus. To achieve expression of the miR-Tbl specifically in BAT, it 
was necessary to set it under the control of the BAT specific Ucp1 promoter. However the 
Ucp1 promoter region in its original form is too long to allow packaging of the final construct 
to a double stranded AAV. Thus a shortened version was generated by amplifying the two 
minimal elements identified as to being crucial for the promoter’s function (“220bp element” 
and “cre4pro element”) by Kozak et al [193], with their kind permission to use the constructs 
described in this publication and with the primers listed in Table 9. The described elements 
were inserted into the pGL3-Basic Vector (Figure 40). 
Figure 39. iWAT of BATKO mice shows compensatory browning.  (A) mRNA expression of Tblr and 
of the brown marker genes Ucp1, Cidea, Pgc-1α and Cox8b in iWAT of BATKO and control mice 
housed at 22 °C (n=3-4). (B) mRNA expression of Tblr and Ucp1 in iWAT or (C) hematoxylin and 
eosin staining of iWAT slices of BATKO and control mice housed at 4 °C for 3 weeks (n=10). All 
values are expressed as means ± SEM, *p<0.05, **p<0.01, ***p<0.001 ctrl vs. BATKO 
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Functionality and specificity of the mini-promoter was confirmed by luciferase assays 
performed by Eva Gröter, showing that it is responsive to rosiglitazone or forskolin in a brown 
adipocyte-specific way as compared to in non-adipocyte cells (data not shown). Thus, the 
Ucp1 mini-promoter was amplified and subcloned to a double stranded AAV construct 
expressing a microRNA targeting Tbl, replacing the present LP-1 promoter (pdsAAV-LP1-
GFPmut-miR-Tbl1).  
Since systemic application of AAV is expected to lead to large amounts of the virus being 
deposited to the liver, it is possible that even with a tissue-specific promoter some leaking of 
the Tbl microRNA expression might affect expression of liver Tbl. Therefore, a target site for 
the liver-specific miR-122 was inserted, resulting in an AAV construct that, when expressed 
in an off target manner in hepatocytes, would be degraded (pdsAAV-GFPmut-miR122site-
miR-Tbl1) (Figure 41, Figure 42). Analogously, vectors expressing miR-NC or miR-Tblr1 
were produced. 
Figure 40. The Ucp1 mini promoter was generated by insertion of 2 c rucial elements  to a pGL3-
Bas ic  Vector.  From the template vector pGL3_3.1kbUcp1p (citation), the desired sequences were 
amplified using PCR primers adding the restriction sites necessary for subsequent addition to a 
luciferase reporter vector. 
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Figure 42.  Final construc t  pdsAAV-
GFPmut-miR122s ite-miR-Tbl1. An 
illustration of the he final construct 
cloned as described above was created 
using the Genious software. 
 
 
 
 
 
Figure 41. The Ucp1 mini promoter and a miR-122 binding s ite were inserted to an AAV miR-Tbl 
expression vector. Using the available double stranded AAV vector expressing miR-Tbl1 (pdsAAV-
LP1-GFPmit-miR-Tbl1), a BAT specific version was created by replacing the present LP1 promoter 
with the newly generated Ucp1 mini promoter and by inserting a target site for miR-122 mediated 
degradation of the expressed product in the liver. 
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DISCUSSION 
The presented work is casting light on mechanisms controlling the regulation of browning of 
white adipose tissue as well as on the function of classical brown adipose tissue. Uncoupling 
of the respiratory chain may emerge as a promising strategy to treat obesity [194]. While 
potent chemical activators are available, their use or application is limited by toxicity [195], 
thus understanding the physiological regulatory mechanisms controlling BAT recruitment and 
activation is crucial for safe therapy.  
The first part of this thesis elucidates the interplay between insulin signaling and the 
recruitment of brite adipocytes in white depots. While it was known before that obesity 
correlates with reduced brite capacity [196, 197], it was not clear whether this correlation is 
based on a causative connection. We published our findings on this topic, outlining two 
hypotheses on how insulin signalling and brite capacity might be co-dependant [198]. On the 
one hand it is known that insulin is crucial for general adipogenic development [199], raising 
the possibility that the recruitment of brite cells might depend on functional insulin signalling 
and that upon the onset of insulin resistance in obesity this in turn leads to a lesser degree of 
browning of WAT. Adressing the problem from the opposite angle, our alternative hypothesis 
on the correlation of obesity and lower BAT activity is that lower brite recruitment establishes 
before the onset of obesity, eventually causing weight gain by lowering insulin tolerance. It is 
known that BAT has the potential to systemically clear glucose, thereby improving insulin 
sensitivity in humans [42, 43], however if brite cells and tissues per se are more responsive 
to insulin remained unressolved. 
Surprisingly, we discovered that β3-adrenergic stimulation was able to fully recover brite 
activation, allowing mice either deficient of insulin or insulin resistant to normally induce the 
browning program in WAT. These findings are in line with a recent study on classical BAT 
that demonstrated that insulin/IGF-1 signalling are dispensable for activation of the BAT 
thermogenic program [143]. 
When tackling insulin sensitivity in the brite recruited state, we postulated that previous 
studies neglected to distinguish between systemic and cell- or tissue-specific insulin 
sensitivity. We show that brite cells exhibit strongly elevated basal glucose uptake, 
irregardless of the presence of insulin. Further, stimulating either brite cells or brite recruited 
mice with insulin does result in higher glucose uptake to cells and clearance from the system 
than in the white state, however the relative response of the system compared to the non 
insulin-stimulated state is unchanged. Thus, it is the presence of brite tissue, not its 
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sensitivity to insulin, that is promoting the beneficial effects on glucose homeostasis 
described in previous studies. Higher presence of brite WAT translates to higher target tissue 
abundance for insulin. However, while in terms of the whole organism thus the brite state 
allows for increased glucose clearance upon insulin stimulation and can be described as 
more insulin sensitive, this is not based on cell-specific sensitivity. 
The mechanism allowing brite cells taking up elevated amounts of glucose independently 
from insulin may in part be due to the expression of the insulin-independent glucose 
transporter GLUT-1, which we, for the first time, reported to be markedly increased upon 
browning. This is in line with the fact that while GLUT-1 is known to only play a minor role in 
WAT [200], but is expressed in high abundance in BAT [201]. What still remains to be 
understood is the upstream regulatory cascade leading to induction of GLUT-1 in brown and 
brite adipocytes. Partially this may be mediated by FGF-21, which is elevated two-fold in brite 
compared to white adipocytes (data not shown) and is known to elevate GLUT-1 expression 
[202]. However, we showed that high fat diet fed mice, which are reported to be FGF-21 
resistant [202], are able to upregulate GLUT-1 in response to browning, thus additional 
mechanisms may contribute to this effect. Also, GLUT-1 induction does not seem to be the 
only mechanism aumenting glucose uptake in brite adipocytes, since we show that browning 
can overcome the reduction in glucose uptake observed upon specific GLUT-1 inhibition. 
Overall, we showed that the brite state did prove beneficial for systemic glucose homeostasis 
and could circumvent insulin resistance. This was due to the fact that regardless of functional 
insulin signalling, brite recruitment could take place. Further, brite cells and tissues had the 
capacity for higher glucose uptake, likely through a multilayer network involving elevated 
expression of the insulin-independent glucose transporter GLUT-1. Thus, even in the insulin 
resistant state, recruitment of brite adipose tissue promises to counteract hyperglycemia in 
diabetic patients. 
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The second part of this thesis was investigating the regulation and role in brown adipose 
tissue of the transcriptional co-regulator TBLR, which acts together with its homologue TBL 
in multi-protein complexes regulating global gene expression. TBLR is well described in 
different disease settings like mental disabilities [133-135] or cancer, where depending on 
tissue type it can act as pro-tumorigenic [137] or anti-tumorigenic [136]. Our group identified 
the role of TBL and TBLR as metabolic players, preventing hepatosteatosis and 
hypertriglyceridemia in the liver by promoting fatty acid oxidation [132], and preventing 
obesity by regulating lipolysis in WAT [139]. 
Using brown adipocyte cell lines as well as brown fat-specific TBLR knockout mice, 
numerous findings have been presented here casting light on TBLR-dependent brown 
adipose mechanisms. This study focussed mainly on TBLR rather than TBL for the following 
reasons: (1) in WAT, TBLR alone was sufficient to mediate effects on lipolysis independent 
of TBL [139], (2) we found Tblr to be regulated stronger than Tbl in response to the signal 
that activates BAT, β-adrenergic stimulation, and (3) while for the in vivo deletion of Tblr we 
had a mouse model available, Tbl, located on the X chromosome, could currently not be 
deleted in mice. However it should be kept in mind that the actions of TBLR and TBL are 
likely interdependent, since it is known that these factors often have additive effects and 
manipulating one of them can, by disrupting their interaction, impacts the actions of the other 
[132]. 
 
The data presented make it clear that when describing the role of genetic regulators in 
adipose tissue, it has to be distinguished between the phase of adipogenesis where cells 
shift from growth to differentiation, and the specific metabolic function of mature, 
differentiated cells. 
We show that upon induction of adipogenic differentiation, the expression of Tblr was up-
regulated, while that of Tbl was reduced. Since in silico analyses identified hotspots in the 
Tblr promoter that in human are reported to be bound by factors involved in adipogenesis, 
such as C/EBPβ , (E)p300, FOXA1, FOXA2 or GATA3, it can be assumed that the observed 
regulation of Tblr is part of the physiological adipogenic program. The same can be assumed 
for the observed regulation of Tbl, which similary in humans is targeted by C/EBPβ and 
PPARα (data is publically available on https://genome.ucsc.edu). The possibility remains that 
the observed regulation was an artefact of cell culture, since we showed that one of the 
agents used to induce differentiation, dexamethasone, was able to directly induce Tblr 
expression in already differentiated adipocytes. 
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Still, we demonstrated that TBLR is an active player in adipogenesis, which was not only 
regulated transcriptionally, but also targeted genes involved in the differentiation of 
adipocytes by direct DNA binding. Interestingly we observed that immediately upon induction 
of differentiation, pathways over-abundantly targeted by TBLR binding were found to be both, 
pathways regulating cancer and growth and pathways regulating metabolic functions such as 
adipocytokine and insulin signalling and lipogenesis. TBLR can, depending on interaction 
partners and targets, act either by mediating gene suppression [130] or activation [132]. Thus 
the observation that its targets are involved in opposing pathways indicates that TBLR 
containing complexes have the potential to serve as a common platform for the cell to switch 
between pro- and anti-proliferative pathways. 
Surprisingly, despite being up-regulated during differentiation, we did not observe a general 
impairment of adipogenesis upon TBLR depletion in terms of morphology or general 
adipocyte marker gene expression. Further, by linking binding data obtained by ChIPseq to 
global gene expression analyses, we showed that brown adipocyte-specific gene sets, 
specifically components of the mitochondrial respiration chain and the key BAT gene Ucp1, 
were repressed by Tblr during differentiation. Considering that we showed Tblr expression to 
be elevated more strongly during white than during brown adipogenesis it is possible that 
Tblr promotes white rather than brown adipogenesis. This inference is supported by the fact 
that it targets and represses Ppargc1a and Ppargc1b, which cause a switch from white to 
brown adipogenesis [127]. 
Interestingly, two of the most strongly bound targets of TBLR were found to be Tblr itself and 
Tbl (data not shown), which might indicate that upon initial induction there is a feedback loop 
bringing Tblr expression back down to normal levels. However TBLR is unlikely the only 
causative factor for the observed down-regulation of Tbl during adipogenesis, since we never 
observed strong Tbl up-regulation in TBLR-deficient cells (data not shown). 
 
Despite expressing higher levels of Ucp1 and mitochondrial markers, brown adipocytes 
lacking TBLR during their differentiation did not exhibit an elevated oxygen consumption rate. 
On the contrary, basal respiration as well as glycolytic rate were found to be reduced in this 
setting. However, treatment with the chemical uncoupler FCCP not only rescued the 
phenotype, but allowed even higher respiration than in control cells, which was to be 
expected considering the higher content of mitochondrial genes. Since we also observed 
impaired import of glucose in adipocytes lacking TBLR during differentiation, it is conceivable 
that the lowered metabolic rates in knockdown cells depend on limited substrate availability, 
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which is an assumption strengthened by the observation that insulin treatment was able to 
rescue the defect. Further, there was no shift between respiration and glycolysis, as would 
be expected if one of those pathways was selectively affected by the absence of TBLR. And 
finally, norepinephrine treatment, known to stimulate UCP-1-mediated uncoupling via 
generating fatty acids as substrate and activators [82, 99], was not able to cause higher 
respiration in knockdown cells, despite higher Ucp1 expression, further indicating that these 
cells lack available substrate. 
It has to be considered, that lower glucose import to adipocytes, which also translated to 
lower lipid generation, was only clearly pronounced if both TBLR and TBL were ablated at 
the same time. Still, in both settings, respiration and glycolysis were impaired. Therefore, it is 
likely that other factors contribute to decreased basal metabolism despite higher 
mitochondrial capacity. 
The presented data clearly establish a role of TBLR during adipogenesis. We propose the 
following model, as outlined in Figure 43. Tblr expression is induced by adipogenic 
activators. TBLR as part of the NCoR complex, targets either pro- or anti-proliferative 
pathways, depending on the nuclear environment such as available binding partners. In an 
adipogenic setting it targets pathways involved in the regulation of white versus brown 
differentiation, lipid and glucose handling, facilitating cells to mature to functional adipocytes. 
 
 
The actions of TBLR, once mature brown adipocytes have formed, seem to have less 
impact. Overall we observed lower TBLR to DNA binding frequency in fully differentiated 
brown adipocytes compared to differentiating cells. This correlated with the observation that 
Figure 43.TBLR serves as a common platform to balance pro- and anti-proliferative cues. (A) TBLR 
expression is under the control of growth promoting cues (E2F, MAX, MYC, FOS, JUN), but also 
adipogenic cues (C/EBPβ, (E)p300, FOXA1, FOXA2 or GATA3). (B) Binding partners and 
mediated response of TBLR in the co-regulator complex depend on the environment (pro-growth or 
pro-adipogenic setting). 
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knockdown of TBLR in mature cells did not reproduce the defects in glucose import or basal 
lipolysis found in cells lacking TBLR during differentiation. This may be partly attributed to 
technical limitations, since due to high protein stability of TBLR, its levels remain stable for 
days after administration of shTblr expressing AV, hence knockdown in mature adipocytes 
was weaker compared to earlier KD (Figure 24.B and D). Still, in vivo results were in 
accordance with in vitro findings, global gene expression analysis in TBLR-deficient BAT 
revealed that there was hardly any alteration in expression patterns. Interestingly, despite 
being the most strongly bound gene in mature adipocyte cells, and to having been shown to 
being the most strongly de-repressed gene upon TBLR depletion during brown adipocyte 
differentiation, Ucp1 was not found to be repressed by TBLR in mature brown adipocytes. On 
the contrary, in cell culture, upon double knockdown of Tblr and Tbl, Ucp1 expression was 
even decreased. 
Mature adipocytes differ from pre-adipocytes as they switch from β1- to β3-adrenergic 
receptor (β1/3-AR) expression [85]. Downstream of the β3-AR, the MAPK pathway mediates 
the thermogenic response in acute cold stimulation [78]. TBLR, whose promoter is predicted 
to be targeted by components that are under the control of the MAPK pathway, such as 
MYC, FOS and JUN [157-159], was found to also target the MAPK signalling pathway by 
binding to its components, when performing ChIPseq analysis of mature brown adipocytes. It 
can thus be assumed that the role of TBLR differs from its actions during differentiation once 
this signalling pathway regulating the key brown adipogenic function of thermogenesis is 
established. In line with our expectations that in mature BAT TBLR would be involved in the 
regulation of the thermogenic program, Tblr expression was found to be strongly induced 
both in cell culture and in vivo upon treatment with β3-adrenergic agonists. This induction 
was much stronger in the mature adipocyte fraction compared to the undifferentiated stromal 
vascular fraction of BAT, and was dependent on cAMP signalling, since applying a PKA 
inhibitor blunted the response. Further, insulin signalling also regulated Tblr expression, as 
treatment of mature adipocytes with insulin or re-feeding in fasted mice decreased Tblr 
expression. In HFD-fed mice, which are known to be insulin resistant [147], Tblr levels in 
BAT were elevated. It is not clear by which mechanism insulin affects Tblr levels. Since 
insulin is known to disrupt β3- adrenergic signals to PKA [203], its inhibition of Tblr 
expression might be indirect, via blocking the MAPK pathway dependant induction described 
above. 
It is known that ablation of TBLR from all adipose tissues impairs lipolysis and causes 
obesity [139]. However the brown fat-specific TBLR deficiency of BATKO mice did not result 
in the same phenotype. Neither in adipocytes in which TBLR was knocked down after 
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differentiation into mature cells, nor in BAT explants from BATKO mice, we observed 
comprised fatty acid release or lipase phosphorylation. Further, BATKO animals did not differ 
from controls in terms of body weight, body composition, glucose tolerance or glucose 
clearance to tissues. 
We thus postulate that TBLR in BAT, being shown to be under the control of brown fat-
specific signalling cascades, fulfils divergent roles than that in white adipose tissues. 
The absence of long term effects and the transiency of Tblr induction upon β3-adrenergic 
stimulation prompted us to hypothesise that a role of TBLR in BAT lies in the mediation of the 
acute thermogenic response. In fact, while in both cold and warm settings BATKO mice 
showed normal respiration and body temperature, challenging mice acclimatised to 
thermoneutrality with an acute β3-adrenergic stimulus [204] revealed a defect in maximal 
thermogenic capacity in BATKO mice. This confirmes TBLR is an indispensable player in 
mediating acute thermogenic activation in response to β3-adrenergic stimulation. The 
mechanisms that are responsible for the ability of BAT to compensate for the absence of 
TBLR upon prolonged cold exposure are not yet clear. It can be speculated, based on the 
fact that TBLR in mature brown adipocytes was shown to bind to components of the MAPK 
pathway, that TBLR deficiency in BAT results in dysbalanced levels of players of this 
pathway, hampering its ability to mediate the acute β3-adrenergic response. This hypothesis 
is outlined in Figure 44. 
 
 
Figure 44. TBLR balances players  required for the acute ac t ivat ion of  BAT. TBLR binds and 
regulates players of the MAPK pathway, the canonical route of acute activation of BAT. This may 
explain why TBLR deletion hampers the ability of BAT to react to acute β3-adrenergic stimulation. 
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Unexpectedly, we found that despite robust compensation for the knockout of TBLR in BAT 
in most settings, BATKO mice maintained lower serum TG levels, not only in the cold, but 
also at room temperature and at thermoneutrality. Since KO BAT was found to have either 
impaired or unaltered metabolic capacity, this phenotype cannot be explained by altered BAT 
lipid oxidation. Since lipid uptake into BAT was not increased, nor did lipid content or 
histology indicate elevated uptake into BAT, it becomes evident that the TGs must be lost via 
a different route. The emerging understanding that BAT has the capacity to act as an 
endocrine organ [172, 173] lead us to the assumption that the KO of TBLR in BAT disrupts 
signalling to other organs, which in turn induces the observed decrease in serum TG levels. 
Since FPLC analyses revealed that the depleted triglycerides correspond to the VLDL 
fraction, we initially assumed that hepatic VLDL output might be decreased in BATKO mice. 
The liver is a known target of BAT endocrine signals [172] and the responsible organ for 
VLDL production [205]. However we did neither observe differential VLDL output in BATKO 
mice nor lipid accumulation in the liver of KO animals as would be expected in the case of 
diminished TG excretion [206]. Further, there was no differential loss of energy to feces and 
feeding behaviour was largely normal. Curiously, BATKO mice tended to be hypophagic 
during the initial phase of cold challenge, however since they quickly recovered, this 
behaviour is unlikely to explain the markedly lower serum TG levels observed at different 
housing temperatures. 
We observed however, that WAT of BATKO mice tended to be heavier and have higher lipid 
content compared to control animals. Indeed, the uptake of labelled triglycerides to white 
adipose tissue was found to be slightly but significantly elevated in BATKO mice. 
Lipid uptake to adipose tissue is mainly mediated by LPL [207], which leads to VLDL 
clearance from the serum [208]. Thus, if there is a factor secreted by BAT increasing TG 
deposit to other tissues, we hypothesised this would be a factor influencing LPL activity. We 
found TBLR-deficient BAT to express lower levels of Fgf21 at 4 °C, a secreted hormone 
mediating glucose and lipid metabolism and being under thermogenic control in BAT [191]. 
However levels of circulating FGF-21 were not altered in BATKO mice compared to controls. 
While we thus exclude FGF-21 to being the responsible hormone for the observed systemic 
effects, it is still very well possible that FGF-21 regulation in TBLR-deficient BAT might 
contribute to the metabolic capacity of BATKO mice. Recent reviews suggest that FGF-21 
also acts in an autocrine manner [209], and by targeting factors like PGC-1α [210] might 
influence BAT function independent from circulating protein levels. 
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ChIPseq analysis suggested that in brown adipocytes, besides Lpl, Angptl4, a known 
secreted inhibitor of LPL [211], was targeted by TBLR. Angptl4 expression was not found to 
be different in BATKO mice, however, strikingly, the expression of a related LPL inhibitor, 
Angptl3 [211], was reduced not only in BAT, but also in WAT, muscle and to some extent in 
liver, both in the cold or at thermoneutrality. Even circulating ANGPTL-3 levels were found to 
be reduced at 4 °C. Since it is known that Angptl3 KO leads to lower serum TG levels [183], 
its downregulation in BATKO mice might partly be responsible for the lower TG levels 
observed, potentially by inhibiting WAT associated LPL. However it is not clear whether LPL 
de-inhibition can by itself suffices to explain the reduced serum TG levels, since studies on 
adipose-specific knockout of LPL or studies tracing TG uptake showed that it is rather BAT 
than WAT being responsible for TG clearance from the serum [111, 212]. We did however 
not observe increased lipid uptake or accumulation in BAT. 
While ANGPTL-3 may not be the only responsible mediator of the observed systemic 
response, it is still noteworthy that BAT-specific knockout of TBLR induced robust systemic 
changes in gene expression. Angptl3 expression is known to be suppressed by insulin and 
leptin [213], however BATKO mice did not express higher levels of leptin and also serum 
insulin levels were never found to be altered (Figure 31.D). We hypothesise, since Angptl3 is 
reported to being regulated by hormones such as thyroid hormone [214] or ligands of the 
liver X rexeptor (LXR) [215, 216], that BATKO mice differently secrete hormones that in turn 
alter gene expression and lipid handling in peripheral tissues. The classical hormone known 
to be secreted by BAT is thyroid hormone (triiodothyronine, T3) [173, 217, 218], so we 
hypothesise that TBLR in mature BAT regulates the expression of hormones that act on 
peripheral tissues, altering their capacity for lipid clearance. (Figure 45). This hypothesis 
remains to be experimentally tested. 
We can only speculate on the necessity of BAT to up- or down-regulate peripheral lipid 
clearance. We suggest that BAT, being an organ known to clear circulating lipid levels [111, 
219], may depend on sufficient TG supply when challenged with acute cold exposure. This 
might be an additional or even alternative explanation for our findings that BATKO mice 
exhibit a defect in the acute induction of the thermogenic response, potentially just lacking 
fuel, before compensatory mechanisms such as WAT lipolysis [96-98] are triggered. 
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As a side-note it is worthy to mention that the estrogen antagonist tamoxifen, the drug we 
used in this model to induce TBLR knockout, was shown to modulate serum lipid levels in 
human. Some reports found a decrease in VLDL [220], others an increase [221]. While the 
inducible Cre-lox system uses a mutated form of the ER to control Cre recombinase 
expression, thus excluding its activation by endogenous estrogen, tamoxifen-induced toxicity 
and side-effects are still possible [222]. In our model cre- control animals were treated with 
the same dose of tamoxifen to account for unspecific side effects. However, the TBL/TBLR 
co-regulator complex is reported to regulate, among others, the actions of the estrogen 
receptor (ER) [3]. Thus, some possibility remains that upon the onset of TBLR deficiency, 
ER-mediated signals caused by tamoxifen are processed differently, potentially altering 
metabolism. Whether this would have to be considered a side-effect of tamoxifen or rather a 
phenotype of TBLR deficiency can be debated. 
Figure 45. TBLR KO in BAT changes systemic gene expression and l ipid clearance.  BATKO mice 
are hypotriglyceridemic and express lower levels of Angptl3 in WAT and muscle. This may lead to 
LPL de-inhibition and enhanced lipid deposit to peripheral tissues. 
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A last consideration has to be made to conclude our findings, and also generally when 
working with tissue-specific knockout models, namely the validity of promoter-usage in 
knockout models. This study uses the Ucp1 promoter to control the expression of the Cre 
recombinase, triggering TBLR KO supposedly only in fully differentiated brown adipocytes. 
However, Ucp1 expression is activated already during the process of adipogenic 
differentiation. In cell culture, we found Ucp1 mRNA to be undetectable in pre-adipocytes, 
however as early as 1 day after induction of differentiation, mRNA levels increase gradually, 
reaching 300-fold higher Ucp1 mRNA levels 1 week later (data not shown). It is thus possible 
that when treating mice with tamoxifen, a part of the SVF pool is targeted together with the 
mature adipocyte fraction. Still, having chosen an inducible knockout model, we limit this 
possibility compared to constitutive models, in which the Cre recombinase is not only 
activated upon stimulation, but can mediate knockout whenever its promoter is activated. 
The presented study could not reproduce some findings showed previously on constitutive 
TBLR knockout under the control of the promoter of aP-2 (adipocyte protein 2, also known as 
fatty acid binding protein 4, FABP4) [139]. While the main reason for this discrepancy seems 
to be differential action of TBLR in white versus brown adipose tissue as outlined above, it 
still needs to be considered that the models differ in terms of what cells are targeted and 
when. Constitutive KO driven by the Fabp4 promoter leads to TBLR deletion in cells as soon 
as Fabp4 starts to be expressed during adipogenesis. This is rather early, and there are 
even subpopulations of pre-adipocytes expressing aP-2 [223]. On the other hand tamoxifen-
induced KO driven by the Ucp1 promoter allows adipocytes to differentiate fully before the 
deletion is triggered. Thus, the reason that the study on whole fat-specific TBLR KO 
observed a markedly stronger phenotype may be partly attributed to the fact that TBLR 
knockout is, at least partially, present during differentiation of adipocytes, which also in brown 
adipocytes would be expected to cause more severe effects, based on the data presented 
above. Further, the Fabp4 promoter, while widely used for adipocyte-specific KO models, it 
was recently shown that it may be of limited use for this purpose, since it also drives gene 
expression in other tissues, such as the developing central nervous system [224]. 
A further advantage of using inducible KO systems in particular when utilizing the Ucp1 
promoter is that this way not only brown but also brite adipocytes can be targeted. We 
showed that while tamoxifen administration did not induce KO in white adipose tissue, 
administration of a second dose after cold administration did reduce TBLR levels by 30% 
(Figure 28.F), which is less than in brown and probably reflects the fraction of browned 
adipocytes now having activated the Ucp1 promoter. Thus, this mouse model is an 
interesting tool for studies on white adipose tissue browning. 
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CONCLUSION AND OUTLOOK 
The study presented here helps to understand tissue and stage dependence and specificity 
of general regulatory machineries of gene transcription networks, using the transcriptional 
co-regulator TBLR as an example. It became clear that the master-regulator TBLR, for which 
a role in the regulation of lipid and white fat metabolism recently was established, serves as 
a common platform to mediate very distinct responses, probably depending on its 
environment and interaction partners. During adipogenesis, TBLR regulates the players of 
this cascade, helping cells to differentiate into adipocytes fully competent of substrate import 
and usage, and supposedly suppressing brown in favour of white fate determination. In 
differentiated adipocytes we showed TBLR to mediate brown fat-specific roles, not only being 
regulated by the same cues that activate the MAPK signalling cascade, but also targeting the 
same signalling pathway. Its depletion specifically in BAT leads to animals not fully flexible 
when challenged with acute β3-adrenergic stress. Finally, our findings that the absence of 
TBLR in BAT leads to changes in gene expression in other tissues and to 
hypotriglyceridemia make it probable that one of the BAT functions dependent on TBLR 
regulation is the endocrine secretion of hormones. 
It will be extremely interesting to understand the route by which TBLR in BAT affects 
peripheral tissues. This involves, firstly, the BAT inherent mechanism of TBLR leading to the 
observed effects. Since we hypothesised that TBLR can act as a common platform with 
different actions depending on its interaction partners, these partners will need to be 
characterised. A possible approach would be co-immunoprecipitation of TBLR in order to 
detect its associated proteins, potentially in different settings, stages of differentiation or 
tissues.  
Further, levels of BAT secreted hormones such as T3 might cast light on the players 
mediating the described systemic effect on circulating lipid levels. It is however not certain 
that the unknown secreted factor is already well characterised, thus this approach bears the 
risk of remaining in the dark. Comparative secretome analyses, while not trivial, might be a 
more sensitive and, importantly, an unbiased method to identify differentially secreted 
proteins from TBLR-deficient compared to control BAT. Further, the actual events in target 
tissues remain unclear. Different analyses promise help elucidate if and how WAT, muscle, 
liver or other tissues are affected by the ablation of TBLR in BAT, whether it be via global 
gene or protein expression analyses or by determination of the activity of key metabolic 
enzymes. A promising candidate enzyme, based on the data presented here, would be LPL, 
which is inhibited by ANGPTL-3 and thus may exhibit higher activity in the periphery. 
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Finally, since TBLR and TBL are described as functionally redundant [128], it would be very 
interesting to see if presented findings are true in the setting of both TBL and TBLR ablation. 
We generated an AAV vector expressing an shRNA targeting Tbl under the control of a 
truncated form of the Ucp1 promoter. Since we also inserted a liver-specific micro-RNA 
target site to the expression product of this vector, it is expected that it will prove as a useful 
tool to mediate brown fat-specific gene knock down upon systemic administration, without 
leakage to the liver. 
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METHODS 
Molecular and Biochemical Methods 
Determination of Nucleic Acid Concentration 
DNA or RNA concentration was determined subjecting 1.2 µl of nucleic acid to a NanoDrop 
ND-1000 Spectrophotometer (Peqlab Biotechnology) and measuring absorbance at 260 nM. 
RNA Isolation and Quantitative RT-PCR 
Cells and tissues were harvested in QIAzol (QIAGEN), tissues were additionally lysed in a 
tissuelyser (QIAGEN). RNA was isolated using the RNeasy Micro- and -Mini Kit (QIAGEN) 
for cells and tissues, respectively, performing on-column DNAse digest. 100 to 1000 ng RNA 
were reverse transcribed with the SuperScript II Kit (Invitrogen) and Oligo(dT) primers 
(Fermentas), then cDNA was diluted to a final concentration of 1 ng input RNA per µl cDNA 
and 5 µl were used for RT-PCR. Detection of gene expression was performed using the 
Taqman system with Taqman Gene Expression Master Mix and specific Gene Expression 
Assays and an ABI StepOnePlus sequence detector (Applied Biosystems). mRNA levels 
relative to TBP expression were calculated by the delta Ct method. 
Microarray Analysis 
Lin−Sca1+ adipocyte progenitor cells were isolated and cultured to confluency as described 
below. Then adipogenic differentiation with 1 µM carbaprostacyclin (cPGI2) (Biozol) or 
ethanol was induced with or without the presence of 1 µg/ml insulin (Sigma). After 24 h cells 
were harvested, RNA was isolated as described and subjected to gene expression analysis 
using mouse430.2 arrays (Affymetrix), the group size was 3 arrays per condition. cDNA was 
synthesized and hybridized according to the manufacturer’s recommendations. Annotation of 
the arrays was performed with a CustomCDF (Version 14) with Entrez based gene 
definitions. The Raw fluorescence intensity values were normalized by quantile 
normalization. Differential gene expression was analysed based on loglinear mixed model 
ANOVA [29], [30] with a commercial software package (SAS JMP7 Genomics, version 4) 
(SAS Institute, Cary, NC, USA). Significance was assumed based on a false positive rate of 
p = 0.05 with FDR correction. 
Chromatin Immunoprecipitation DNA-Sequencing 
preBAT cells were differentiated into mature adipocytes in 15 cm dishes (Falcon). Medium 
was replaced with phosphate buffered saline (PBS) (Life Technologies) containing 2mM 
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disuccinimidyl glutarate (DSG crosslinker) (Proteochem) and 0.4% DMSO and cells were 
incubated for 45 minutes at RT. Then cells were crosslinked for 10 minutes at RT with PBS 
containing 1 % formaldehyde (Baker), subsequently glycine (Sigma) was added to a final 
concentration of 0.125 M. After 2 PBS washes, cells were harvested in Chip Lysis Buffer 
(20mM Tris (Sigma), 0.15 M sodium chloride (NaCl) (Sigma), 1 mM 
ethylenediaminetetraacetic acid (EDTA) (Sigma), 0.1 % Sodium dodecyl sulfate (SDS) 
(Sigma), 1 % Triton-X100 (Applichem), pH 8). The chromatin was subjected to 16 on/off 
cycles of sonication (30 seconds, maximal intensity) with a Bioruptor (Diagenode) followed 
by 10 minutes centrufugation at 13,000 rpm and 4 °C. Aliquots of the supernatant were used 
for chromatin immunoprecipitation or stored for subsequent input control. Up to 1.5 ml 
Chromatin was diluted 3-fold in Chip Lysis Buffer and antibody (anti-PPARg H100 (sc-7196, 
Santa Cruz) or anti-TBL1XR1 (NB600-270, Novus)) and bovine serum albumin (BSA) 
(Sigma) were added to a final concentration of 6.7 µg/ml and 1 µg/µl, respectively. After 3 
hours of rotation at 4 °C, 1/3 volume of 1:5 diluted protein A/G agarose beads (sc-2003) (pre-
blocked with 1 µg/µl BSA for 2 hours) were added and the samples were being rotated over 
night at 4 °C. 
Then the beads were washed twice with Wash Buffer 1 (20mM Tris, 0.15 M NaCl, 1 mM 
EDTA, 0.1 % SDS, 1 % Triton-X100, 0.1 % sodium deoxycholate (NaDOC) (Sigma), pH 8), 
once with Wash Buffer 2 (20mM Tris, 0. 5 M NaCl, 1 mM EDTA, 0.1 % SDS, 1 % Triton-
X100, 0.1 % NaDOC, pH 8), once with Wash Buffer 3 (20mM Tris, 1 mM EDTA, 0.5 % 
NaDOC, 0.5 % NP-40 (Sigma), 0.25 M lithium chloride (LiCl) (Roth), pH 8) and twice with 
Wash Buffer 4 (20mM Tris, 1 mM EDTA, pH 8), each washing step consisting of 5 minutes of 
rotation at 4 °C and 5 minutes of centrifugation at 2,700 rpm and 4 °C. One original 
chromatin volume of Elution Buffer (1% SDS, 0.1 M sodium hydrogen carbonate (NaHCO3) 
(AppliChem)) was added to the beads and chromatin was eluted rotating 20 minutes at RT. 
After centrifugations, supernatants and input controls were de-crosslinked by adding NaCl to 
a final concentration of 200mM and incubating for 4 hours at 65 °C. 
Bound DNA was recovered by phenol chloroform extraction, mixing it with 1 volume of 
phenol chloroform isoamylalcohol (PCI) (Roth), incubating for 5 minutes followed by 5 
minutes of centrifugation at 13,000 rpm and RT, collecting the upper liquid phase, mixing it 
with 1 volume of chloroform (VWR) and incubating and spinning like previously. DNA was 
precipitated from the liquid phase by adding 80 µg/ml glycogen, 0.3 M sodium acetate 
(NaAc) (Applichem) and 2.5 volumes of ethanol followed by 1 hour incubation at -20 °C. 
Samples were centrifuged for 25 minutes at 13,000 rpm and 4 °C, washed with 70% ethanol, 
dried and dissolved in water. 
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DNA concentration was determined using the Qubit dsDNA HS Assay Kit (Life Technoligies). 
For determination of binding to individual targets, DNA was diluted 10-fold and used for 
quantitative real time PCR as described above. ChIP sequencing and data analysis were 
performed by Anne Loft et al as described in their prior publications [225]. Binding was 
visualized using the UCSC genome browser. 
RNA-Sequencing 
preBAT cells were cultured and differentiated as described below. 2 to 3 days before RNA 
harvest, cells were transducted with adenovirus expressing short hairpin RNAs against 
TBLR1 or TBL1 as described below, using a MOI of 10 for adipocyte progenitors and a MOI 
of 100 for adipocytes. Cells were harvested on day1 and day7, respectively, of adipogenic 
differentiation and RNA was isolated as described above. RNA sequencing and data analysis 
were performed by Anne Loft et al as described in their prior publications. 
Cloning 
Restriction digest 
Plasmid DNA restriction was performed for 4-6 hours at 37 °C using 20-50 U of restriction 
enzyme and corresponding buffer (used enzymes are listed in Table 13). When performing 
single enzyme digest, 10 U Calf Intestinal Phosphatase (CIP, New England Biolabs) was 
added. Subsequently, the DNA was supplemented with loading dye (final concentration of 
1.7 mM EDTA, 11.7 % glycerol, trace amounts of Orange G (Sigma)), subjected to 
gelelectrophoresis on 1% agarose (Applichem) / TBE gels (10 mM Tris, 0.1 mM EDTA, 9 mM 
boric acid (Sigma), pH 8) containing 1µg/ml ethidiumbromide (EtBr, Roth), bands of the 
appropriate size were identified using a Gel Imager (Intas) and UV light (254 nM), cut and 
DNA was purified from gel pieces with the Qiaquick Gel Extraction Kit (Qiagen). 
Insert generation 
Insert DNA was generated either by annealing artificial oligonucleotides (denaturated at 95 
°C followed by slow cooling to RT, sequences listed in Table 7), or by restriction digest from 
existing constructs as described above, or by Polymerase Chain Reaction (PCR) for 35 
cycles (10 seconds denaturation at 98 °C, 30 seconds annealing and elongation at 72 °C) 
using a PTC-200 thermocycler (Biozyme), Phusion High-Fidelity DNA-Polymerase and 
according buffer (Thermo Scientific), dNTPs (Life Technologies) and 5µM of primers listed in 
Table 9, followed by purification of the DNA using the QIAquick PCR Purification Kit 
(Qiagen). 
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Ligation 
100 ng plasmid DNA were ligated with either double stranded insert DNA generated by PCR 
or restriction digest (at a molar ratio of 1/3 mols of plasmid DNA) or with 10 - 100 picomoles 
of annealed artificial oligonucleotide, using T4 Ligase (New England Biolabs) and 
corresponding buffers for 2 hours at RT followed by o.n. incubation at 4 °C. 
Transformation 
25 µl One Shot TOP10 Chemically Competent E. coli (Life Technologies) were 
supplemented with 2.5 µl of ligation reaction, incubated for 30 minutes at 4 °C, heat shocked 
for 30 sec at 42 °C, supplemented with 250 µl S.O.C. medium (Life Technologies), incubated 
for 60 minutes at 37 °C, shaking, and plated to LB agar plates (Roth) and 50 mg/L ampicillin 
(Sigma). Following o.n. incubation at 37 °C, colonies were picked and cultured in 4 mL LB 
medium + 50 mg/L ampicillin, shaking o.n. 
Plasmid purification 
Plasmid DNA was isolated using the QIAprep Plasmid Miniprep Kit (Qaigen) and 10µl of 100 
ng/µl DNA were supplemented with 5µl of 5 µM sequencing primers listed in Table 8 
(sequencing was performed by LGC genomics and results were analysed using the CLC 
sequence viewer 7 or the genious software). 
Cloning strategy 
The “220bp element” and “cre4pro element” described by Kozak et al [193] were inserted 
into the pGL3-Basic Vector (Promega) using SacI and XhoI for the 220bp element and 
BamHI and HindIII for the cre4pro enhancer element (whereby the BamHI site attached to 
the cre4pro element is compatible with the BglII site in the pGL3-Basic Vector). The Ucp1 
mini-promoter was amplified and subcloned to the pdsAAV-LP1-GFPmut-miR-Tbl1 construct 
(based on [226], using MluI and PstI, replacing the LP1 promoter. Subsequently, 
ologonucleotides containing 3 repeats of a binding site for the liver-specific miR-122 were 
annealed as described above and inserted to the AAV construct using ApaI and AgeI. This 
resulted in the construct pdsAAV-GFPmut-miR122site-miR-Tbl1. Analogously, vectors 
expressing miR-NC or miR-Tblr1 were produced. 
Luciferase assays 
For luciferase assays, cells were transfected with luciferase reporter plasmids (firefly 
luciferase pGL3 construct plus 1/20 amount renilla luciferase pRL-TATA-luc) as described 
below. 30 hours after transfection, cells were stimulated for 16 hours with 10µM Forskolin 
(Forsk), 2.5µM Rosiglitazone (Rosi) or 1µM Norepinephrine (NE). Cell lysis and 
determination of luciferase activity were performed using the Dual-Luciferase Reporter Assay 
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System (Promega), a Mithras Microplate Reader (Berthold) and the MicroWin software 
(Siemens), following the manufacturer’s instructions. 
Protein Analysis 
Generation of total protein lysates 
Cells were harvested in protein extraction buffer (PEB) consisting of 25 mM Tris-HCl (pH 
7.4), 100 mM NaCl, 1 mM EDTA, 0.5% Triton-X100, 0.5% NP-40, 1x protease inhibitor 
cocktail (PIC) (Sigma), 1x phosphatase inhibitor cocktail (Sigma), 0.5 mM sodium 
orthovanadate (Na3VO4) (Sigma), 10 mM sodium fluoride (NaF) (Sigma) and 10 mM glycerol-
2-phosphate (G2P) (Sigma). Nuclear and cytosolic extracts were generated using the NE-
PER Nuclear and Cytoplasmic Extraction Kit (Thermo Scientific). 
Tissue protein lysates were generated by homogenising pre-pulverized tissue in a tissuelyser 
with protein lysis buffer, rotation for 1 hour at 4 °C and subsequent centrifugation for 10 
minutes at 4 °C and 13,000 rpm and harvest of the supernatants.  
Separation of nuclear and cytosolic protein extracts 
Nuclear and cytosolic extracts were generated by sacrificing female C57Bl6 mice up to 8 
hours after injection of 1 mg/kg bodyweight of CL316243 (CL) (Tocris Bioscience) and 
dissecting brown adipose tissue (BAT) as described below. 1ml of Tissue Fractionation 
Buffer A (50 mM Tris, 250 mM sucrose (Sigma), 10mM potassium chloride (KCl) (Roth), 1 
mM EDTA, 10 mM NaF, 2 mM Na3VO4 , 1 mM dithiothreitol (DTT) (Roth), 1 x PIC, pH 7.2) 
was added and whole tissue biopsies were homogenized by subjecting them to 15 strokes in 
a dounce homogenizer. After 30 minutes of rotation at 4 °C, lysates were centrifuged for 10 
minutes at 3,200 rpm and 30 °C, supernatants were defined as cytosolic extracts. Pelles 
were lysed in 500 µl of Tissue Fractionation Buffer B (50 mM Tris, 25% glycerol (Sigma), 420 
mM NaCl, 1.5 mM MgCl2 (Sigma), 10 mM NaF, 1 mM DTT, 1 x PIC, 0.1% SDS, 1% NP-40, 
pH 7.2), rotated 30 minutes at 4 °C, centrifuged for 30 minutes at 10,000 rpm and 
supernatants were defined as nuclear extracts. 
Separation of stromal vascular and adipocyte fraction for protein extracts 
Stromal vascular fraction (SVF) and adipocyte fraction (AF) of BAT were generated by 
sacrificing female C57Bl6 mice up to 8 hours after injection of 1 mg/kg bodyweight of CL and 
dissecting BAT as described below. The tissue was subjected to collagenase digest and 
centrifugation as described below. 500 µl of the floating adipocytes were referred to as AF, 
mixed with 1 ml Qiazol and frozen. The cell pellet was referred to as SVF, resuspended in 1 
ml Qiazol and frozen. RNA was extracted and analysed as described above. 
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Western Blot 
Protein concentration was quantified using the BCA Protein Assay (Thermo Scientific) or the 
2D-Quant kit (GE Healthcare) and 20-50 µg of protein were loaded to 12% SDS-
polyacrylamide gels (collection gel consisting of 5% acrylamide/bisacrylamide 37.5:1 (Roth), 
125mM Tris, 0.1% SDS, 0.1% ammonium persulfate (APS) (Roth), 0.1% N,N,N',N'-
tetramethylethane-1,2-diamine (TEMED) (Roth), pH 6.8; and separation gel consisting of 
collection gel consisting of 12% acrylamide/bisacrylamide 37.5:1, 375mM Tris, 0.1% SDS, 
0.1% APS, 0.04% TEMED, pH 8.8). Separation was performed at 80 – 120 volts in Running 
Buffer (200mM glycine, 25mM Tris, 0.1% SDS). Subsequently, separated proteins were 
blotted to nitrocellulose membranes (GE Healthcare) for 90 minutes at 80 volts in Transfert 
Buffer (150mM glycine, 20mM Tris, 20% methanol), blocked for 1 hour at RT with 5% milk 
(Gerbu) in tris buffered saline with tween (TBS-T) (50 mM Tris, 150 mM NaCl, 0.1% Tween 
20 (Sigma), pH 7.6) and incubated over night at 4 °C with 1:1000 diluted primary antibodies 
in 5% milk / TBS-T. For the detection of phospho-proteins, BSA (Biomol) was used instead of 
milk. Blots were washed 3 x 10 minutes in TBS-T, incubated for 1 hour at RT with 1:5000 
secondary antibody in 5% milk / TBS-T, washed 3 x 10 minutes in TBS-T and protein bands 
were detected using the ECL Western Blotting Substrate (Thermo Scientific) and a 
ChemiDoc XRS Blot imager (Biorad). Band identity was confirmed by comparing to 
PageRuler Prestained Protein Ladder (Thermo Scientific). The antibodies used for Western 
Blot are listed in Table 12. Quantification was performed using the Image Lab software. 
Phosphatase digest of protein lysates 
40µl of cytosolic or nuclear protein lysates were diluted to equal volumes, incubated over 
night with 1:500 antibody against TBLR (NB600-270, Novus) and protein A/G agarose beads 
(sc-2003), washed 3 times with TBS-T and treated with 100 units of Lambda Protein 
Phosphatase (Lambda PP, New England Biolabs) according to the manufacturer’s 
instructions. Control samples were treated with the same buffers and temperatures without 
the enzyme present. 
Immunohistochemistry 
Tissues were subjected to 24 h fixation in 4% paraformaldehyde (Histofix) (Roth), washed for 
2 h in running tap water and stored in 70% ethanol for up to several weeks until paraffine-
embedding, then tissues were sliced and dried. For staining, slices were stepwise de-
paraffinated by incubating them for 5 minutes in xylene (Merck), 100% ethanol, 96% ethanol, 
90% ethanol, 80% ethanol, 70% ethanol, H2O and PBS. For antigen retrieval, slides were 
boiled in 10 mM citrate buffer (10 mM sodium citrate (Sigma), 0.05% Tween 20, pH 6.0), 
blocked for 1 h with 1% BSA (Biomol) and stained with 1:50 anti-UCP-1 (ab23841, Abcam) 
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antibody over night at 4 °C. After 3 x 10 minutes washing in PBS, 1 hour incubation at RT 
with secondary antibody (172–1019, BioRad) and another 3 x 10 minutes of washing with 
PBS, slides were subjected to 3,3′-diaminobenzidine (DAB) (Sigma) staining and 
hematoxylin (Sigma) – eosin (Roth) counterstaining. After re-hydration (2 minutes incubation 
in the ethanol solutions previously used, increasing concentration) slides were mounted with 
Eukitt quick-hardening mounting medium (Sigma) and examined by light microscopy (Zeiss). 
Quanification of Mouse Serum Metabolites 
Serum insulin, FGF21 and ANGPTL3 were quantified using a mouse insulin ELISA (Alpco), 
mouse FGF21 ELISA (R&D) and mouse ANGPTL3 ELISA (R&D), respectively, following the 
manufacturer’s instructions. Serum lipids were quantified using commercial kits for the 
detection of non-esterified fatty acids (NEFAs) (WAKO), glycerol and triglycerides (TGs) 
(Sigma) and cholesterol (Randox). For all measurements, 4 µl of serum were measured in 
duplicates. 
Cholorimetric absorption was measured with the Mithras Microplate Reader (Berthold) and 
analysed using the MicroWin software. 
Quantification of Tissue Triglyceride Levels 
10 – 20 mg tissue powder were homogenised using a tissuelyser and 1 ml of 2:1 
chloroform:methanol (Sigma). Samples were rotated for 20 minutes at RT and centrifuged for 
10 minutes at 4,000 rpm and RT. The aqueous phase was mixed with 1 volume 0.9% NaCl 
and centrifuged for 5 minutes at 2,000 rpm. 100 µl of the lower organic phase were mixed 
with 10 µl of 1:1 Chloroform:Triton-X100, dried o.n. under the fumehood and dissolved in 50 
µl H2O. TG content was measured as described above and normalized to material weight. 
Fast‐protein liquid chromatography 
Serum from a specified number of mice per experimental group was pooled and subjected to 
fast‐protein liquid chromatography (FPLC). 0.3 ml of pooled plasma were loaded onto a 
Superose 6B 10/300 column (GE Healthcare) and eluted with a constant flow of PBS. 1 
fraction per minute (corresponding to a volume of 0.5 ml) was collected and TG and 
cholesterol content were determined as described above. Values were calculated as μg of 
triglyceride or cholesterol per ml. 
Bomb calorimetry of feces 
Feces of mice individually housed on chow diet and at room temperature were collected over 
the period of 24 hours. A defined aliquot was subjected to lyophilization and subsequent 
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bomb calorimetry using a calorimeter (IKA). The determined energy content in Joules per dry 
weight, the water content based on weight pre and post lyophilization and the total fecal 
mass during 24 hours were used to calculate the total fecal output per mouse. 
Cell Biology 
Cell Cultivation 
Eucaryotic cells were cultivated under sterile conditions at 37 °C, 5 % CO2 and 95 % 
humidity. Media and supplements were purchased from Life Technologies (Invitrogen) and 
DMEM with 4.5 g/l glucose was used unless stated otherwise. 
1 ml frozen cell aliquots containing 10% DMSO and stored in liquid nitrogen (N2) were 
thawed at 37 °C, washed in 9 ml of the respective medium, centrifuged for 3 minutes at 
3,000 rpm and RT and distributed to a 15 cm dish in 20 ml medium. 24 hours later medium 
was exchanged to new medium, cells were cultivated to 80 % confluency and propagated by 
3 minutes incubation at 37 °C with 3 ml trypsin (Life Technologies), washing with 9 ml 
medium, centrifugation for 3 minutes at 3,000 rpm and RT and redistribution to 15 cm dishes 
in 1:10 to 1:80 dilutions. 
Human embryonic kidney cells (HEK293 [227]) were cultivated in DMEM + 10% fetal calf 
serum (FCS) + 100 U/ml (1%) penicillin / streptomycine (P/S). When using HEK293A, 
containing sequences necessary to faciliate adenovirus production, 1% non-essential-amino-
acids (NAA) were added. Immortalized hibernoma cells (HIB1B [228]) and 3T3-L1 
preadipocyte cells [229] were cultivated in DMEM + 10% FCS + 1%P/S. Brown adipocyte 
progenitors immortalized by SV40 T infection (PreBAT cells, [148]) were cultivated to 
confluency in maturation medium (DMEM, 20% FBS, 1% P/S, 20 nM insulin (Sigma) and 
1nM 3,3′,5-Triiodo-L-thyronine sodium salt (T3) (Sigma)). Primary adipocyte progenitors 
were cultivated to confluency in laminin (Santa Cruz) coated cell culture plates in DMEM, 
10% FBS, 1% P/S), and 10 ng/ml murine basic fibroblast growth factor (bFGF) (R&D 
Systems). 
In vitro differentiation 
In 3T3-L1 cells, differentiation was induced by exchanging the medium to induction medium 
(DMEM, 10% FBS, 1% P/S, 172 nM insulin, 0.25 µM dexamethasone (Dex) (Sigma), 0.5 mM 
3-isobutyl-1-methylxanthin (IBMX) (Sigma), 0.125mM indometacine (Sigma), 250 µM L-
ascorbat (Sigma), 17 µM pantothenat (Sigma), 1 µM D-biotin (Sigma)). 2 days later fresh 
induction medium was applied, another 2 days later medium was replaced by induction 
medium without Dex and IBMX, another 2 days later by normal culture medium. Cells were 
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harvested on day 8. In preBAT cells, differentiation was induced by exchanging the medium 
to induction medium (DMEM, 20% FBS, 1% P/S, 5 µM Dex, 0.5 mM IBMX, 0.125mM 
indometacine, 20 nM insulin and 1nM T3). After 24 hours the medium was replaced with 
maturation medium and after day 3 of differentiation medium was exchanged daily. Cells 
were harvested on day 7. In primary adipocyte progenitors differentiation was induced by 
exchanging the medium to DMEM, 10% FBS, 1% P/S, 500 nM Dex, 172 nM insulin and 3 nM 
T3 (“day 0”). To induce brite differentiation 1 µM cPGI2 or ethanol as vehicle control was 
added during the duration of the differentiation process as described previously [230]. After 2 
days the medium was replaced by DMEM, 5% FBS, 172 nM, 3 nM T3 and 1 µM cPGI2 or 
ethanol. The medium was exchanged every day. Cells were harvested on day 8. 
Cell stimulation for mRNA expression analysis 
For the study of effects on mRNA expression, the respective cells were treated for 3 hours 
with 1 µM CL, 1 µM NE, 100 nM insulin, 10 µM GW7647 (Ppar-α agonist), 1 µM GW501516 
(Ppar-βδ agonist), 2.5 µM Rosi (Ppar-γ agonist) or 5 µM Dex. For co-application of the PKA 
inhibitor H-89 (Calbiochem), cells were washed with PBS, pre-incubated for 1 hour without 
stimuli and with or without 50 µM H-89, and subsequently incubated for 3 hours with or 
without CL and H-89. For harvest, cells were washed with PBS, homogenised in 1 ml Trizol, 
and mRNA was prepared as described above. 
Progenitor Isolation and Cell Culture 
All antibodies were obtained from eBioscience. Primary SVF-derived Lin−Sca1+ adipocyte 
progenitor cells [144] were isolated from inguinal white adipose tissue of male C57Bl6 mice 
(Charles River) at age 6–8 weeks. Progenitor isolation has been approved by the DKFZ 
ethical committee (DKFZ252) and was performed previously in our lab [139]. Tissues were 
minced, digested with 1.5 mg/ml collagenase type II (Sigma) in DMEM (4.5 g/l glucose) 
supplemented with 0.5% BSA (Sigma), 15 mM HEPES (Life Technologies), 3.2 mM CaCl2, 
10% FBS and 0.05 mg/ml DNase I (Roche) for 30 to 50 minutes shaking at 37 °C. The cell 
suspension was strained through a 300 µM nylon mesh (Neolab), collected by centrifugation 
at 900 rpm for 10 minutes, washed in BSA-buffer (1x PBS supplemented with 0.5% BSA and 
1 mM EDTA) and strained again through a 70 µM cell strainer (BD biosciences). 
Subsequently cells were incubated on ice for 10 minutes with anti-CD16/32, then for 30 
minutes additionally with Lin (anti-CD31-biotin, anti-CD45-biotin and anti-Ter119-biotin), 
washed twice with BSA buffer and incubated on ice for 15 minutes with streptavidin 
microbeads (Miltenyi Biotech). After washing with BSA-buffer, cells were separated using MS 
columns and the Octo MACS Separator Starter Kit (Miltenyi Biotech), collecting the Lin− cell 
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fraction by pelleting the cells of the flow through at 900 rpm for 10 minutes. Those cells were 
incubated on ice for 15 minutes with anti-Sca1 microbeads (Miltenyi Biotech). Then cells 
were subjected to the separation columns again, discarding the flow through and eluting the 
Lin−Sca1+ fraction by removal of the magnet. Cells were counted, seeded at 104 cells/well 
and cultivated as described above. 
Transfection 
Transfection of plasmid DNA 
Depending on the cell line, different transfection reagents and protocols were applied. 
Generally, cells were cultured as described below and 16,000 cells / well were seeded to 48-
well-plates in normal culture medium. 24 hours after seeding, cells were transfected after 
allowing plasmid DNA and transfection reagents to form complexes for 15 minutes at room 
temperature. 24 hours post transfection, medium was exchanged to fresh medium. 
For HIB1B cells, 4.5 µl/µg DNA of Attractene (Qiagen) were applied together with 150 ng 
vector DNA (plus 7 ng renilla luciferase ctrl vector in luciferase assays) per well. Culture 
medium of cells was replaced with 1/2 volume of fresh medium, then 1/2 volume of DNA + 
Attractene were added.  
For Hepa-1-6 cells, 2 µl/µg DNA of Lipofectamine 2000 (Life Technologies) were applied 
together with 200 ng vector DNA (plus 10 ng ctrl vector in luciferase assays) per well. Culture 
medium of cells was replaced with 9/10 volume of fresh medium, then 1/10 volume of DNA + 
Lipofectamine were added. 
For HEK293A cells, Polyethylenimin (PEI) (Sigma) at 1/6 final volume of medium on the cells 
was applied together with 250 ng vector DNA (plus 12.5 ng ctrl vector in luciferase assays) 
per well. Culture medium of cells was replaced with 1/2 volume of fresh medium, then 1/2 
volume of DNA + Lipofectamine were added. 
Transfection of siRNA 
Primary iWAT SVF-derived Lin−Sca1+ adipocyte progenitor cells were isolated and plated as 
described above and transfected with 50 nM siRNA 2 days prior to induction of 
differentiation, using Mm_Slc2a1_5 FlexiTube siRNA or Allstars Negative Control siRNA 
(Qiagen). Nucleic acids were pre-incubated with DharmaFECT 1 siRNA Transfection 
Reagent (Dharmacon) for 20 minutes before adding them to the cells. 
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Adenoviral Transduction 
The adenoviral (AV) constructs used in this study were already present in the lab and were 
generated based on the BLOCKiT Adenoviral RNAi Expression System (Life Technologies) 
and expressed shRNAs against murine Tblr1, Tbl1 or scrambled control shRNA. 
Virus production 
For virus production, the helper cell line HEK293A, expressing the viral antigens E1 and E3 
necessary for production of viral particles, was utilised. Per construct 20 confluent 15 cm 
dishes were transduced with 1 µl/dish adenovirus. Once ~ 80% of cells detached, they were 
harvested by rinsing and centrifugation for 10 minutes at 2,000rpm in a Super T21 centrifuge 
(Heraeus). The cell pellet was re-suspended in 20 ml PBS-TOSH (30.8 mM NaCl, 120.7 mM 
KCl, 8.1 mM sodium hydrogen phosphate (Na2HPO4) (Neolab), 1.46 mM potassium 
dihydrogen phosphate (KH2PO4) (Roth), 10 mM MgCl2, pH 7.2) and frozen in liquid nitrogen 
(N2). 
CsCl fractionation 
After subjecting the crude lysate to 3 freeze / thaw cycles and 5 minutes centrifugation at 
2,000 rpm in a Biofuge Prime (Heraeus), a cesium chloride (CsCl) (Roth) gradient was 
performed to purify virus particles. The CsCl solutions contained 10 mM HEPES and were 
adjusted to a pH of 7.2. First, a gradient was poured consisting of 9 ml of 4 M CsCl solution, 
topped by 9 ml of 2.2 M CsCl solution. The virus lysate was administered on top and 
ultracentrifugation was carried out for 2 hours at 24,000 rpm and 4 °C. The virus band was 
extracted using a syringe, mixed with 1 volume of a saturated CsCl solution and placed on 
the bottom of a centrifuge tube. Then a gradient was created by adding first 1/2 volume of a 
4 M CsCl solution and then 1/2 volume of a 2.2 M CsCl solution on top. Ultracentrifugation 
was carried out for 3 hours at 35,000 rpm and 4 °C. The virus band was extracted with a 
syringe and sealed in a dialysis tube (Roth). O.n. dialysis was carried out in dialysis buffer (1 
x PBS, 10% glycerol, pH 7.2) before adding 10% glycerol and storing the virus at -80 °C. 
Virus titer determination using the Tissue Culture Infectious Dose 50 (TCID50) method 
To assess the titer of the virus in terms of plaque forming units (pfu) per ml, HEK293A cells 
were seeded at a density of 104 cells / well to a 96 well plate. 2 hours after seeding, an equal 
volume of virus solution of decreasing concentration was added, infecting 10 wells per 
dilution up to a 10-12 dilution of original the virus solution. After 12 days of incubation at 37 °C, 
plaques were counted using the following formula: 
 
titer =  pfu/ml 
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Transduction [231] 
For adenoviral transduction cells were incubated for 24 hours in antibiotic free medium. Then 
adenovirus was added in 1/4 of culture media volume at a multiplicity of infection (MOI) of 10 
(for adipocyte progenitors, applied 2 days prior to induction of adipogenic differentiation) to 
100 (for adipocytes, applied on day 5 of adipogenic differentiation) in DMEM containing 0.5 
µg/ml poly-L-lysine (Sigma). After 90 minutes incubation, DMEM supplemented with FCS 
and P/S was added, reaching a final concentration of 10% and 1%, respectively. 
GLUT-1 Inhibition 
Primary iWAT SVF-derived Lin−Sca1+ adipocyte progenitor cells were isolated and plated 
and differentiated as described above. For the last 2 days the glucose transporter inhibitor III 
STF-31 (Calbiochem) was added to the medium at a concentration of 1 µM according to 
previous reports [232]. 
Lipolysis Assay 
Differentiated adipocytes prior transduced with adenoviral knockdown constructs as 
described above were washed with PBS and incubated for 2 hours at 37 °C with Krebs 
Ringer Buffer (KRB) (115 mM NaCl, 5.9 mM KCl,1.2 mM MgCl2, 1.2 mM sodium dihydrogen 
phosphate (NaH2PO4) (Applichem), 1.2 mM sodium sulfate (Na2SO4) (Applichem), 2.5 mM 
CaCl2, 25 mM NaHCO3, pH 7.4). Subsequently, cells were incubated for 3 hours with 
stimulation medium (KRB containing 5mM glucose (Applichem), 5% BSA (fatty acid free, 
Sigma), 25 mM HEPES) with or without 1 µM of isoproterenol (Iso). Supernatants were 
harvested and NEFA and glycerol levels were determined as described above. Results were 
normalized to protein content by harvesting the cells in Tx protein lysis buffer (150mM NaCl, 
0.05% Triton-X100, 10mM Tris, pH 8) and performing a BCA assay according to the 
manufacturer’s instruction. 
Lipogenesis Assay 
In differentiated adipocytes prior transduced with adenoviral knockdown constructs as 
described above, 24 h before the assay the medium was replaced with low glucose DMEM 
(1 g/l glucose) supplemented with 0.5% BSA. Then, cells were washed with KRB and 
incubated for 2 hours at 37 °C with stimulation medium (KRB containing 5mM glucose 
(Applichem), 0.5% BSA, 20 mM HEPES, 1 µCi/ml glucose D-[14C(U)] (Perkin Elmer)) with or 
without 20 nM of insulin. Cells were lysed in 0.5 M sodium hydroxide (NaOH) (Sigma). 
Protein concentration was determined using the BCA assay. 1/3 volume of cell lysate was 
used for scintillation counting to determine glucose metabolisation, 1/2 volume was used for 
lipid extraction to determine lipogenesis in terms of 14C incorporation to lipids. For this, 1.3 
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volumes of 3:1 chloroform:methanol were added, samples were mixed, incubated for 2 
minutes at room temperature and centrifuged for 2 minutes at 13,000 rpm. Equal volumes of 
the lower lipid phase were transferred to scintillation tubes (VWR) and organic solvent was 
evaporated over night. Scintillation counting was performed by adding 4 ml of Rotiscint 
scintillation liquid (Roth) and counts per minute (CPM) were measured on a liquid scintillation 
counter (Tri-Carb® 2100TR or 2900TR) (Perkin Elmer). Relative glucose metabolisation and 
lipogenesis were calculated compared no samples without insulin. 
In Vitro Glucose Uptake Assay 
In differentiated adipocytes prior transduced with adenoviral knockdown constructs as 
described above, 24 h before the assay the medium was replaced with low glucose DMEM 
(1 g/l glucose) supplemented with 0.5% BSA ± cPGI2 and ± STF-31. Cells were incubated 
for 1 hour at 37 °C with basal medium (KRB containing 5mM glucose, 0.1% BSA, 10 mM 
HEPES, 8mM mannitol (Sigma), 2 mM pyruvate (Life Technologies), 1 mM NAA) and then 
stimulated with stimulation medium (glucose free basal medium spiked with 1mM 2-Deoxy-D-
glucose (2DOG) (Sigma), 0.3 µCi/ml 3H-Deoxy-D-glucose, 2-[1,2-3H (N)] (3H-2DOG) (Perkin 
Elmer) and 0.2 µCi/ml 14C-Mannitol, D-[1-14C] (Perkin Elmer)) with or without insulin (20 nM if 
not stated otherwise) or 25 µM cytochalasin B (Sigma). After 20 minutes at 37 °C the 
reaction was stopped by adding ice cold basal medium supplemented with 25 mM glucose 
followed by a PBS wash. Cells were lysed in protein extraction buffer using a tissue lyser. 
Protein concentration was determined using the BCA assay and glucose uptake by 
measuring scintillation counting of a defined volume as described above. Since dual counting 
was performed, disintegrations per minute (DPM) rather than CPM were determined in order 
to minimize overlap of spectra. 
Calculation of Glucose uptake 
To calculate glucose uptake, 3H counts were measured for glucose and 14C counts for 
mannitol. By comparison to counts measured in a defined volume of original stimulation 
medium, the volume of medium taken up can be calculated and thereby the known amount 
of non-radioactive glucose present in this volume. To refine the data, counts were corrected 
for unspecific extracellular volume remaining on the cells after washing. This was done 
considering 14C counts, since mannitol is not taken up by the cells. Finally, values were 
normalized to protein content per well and duration of the assay to result in the glucose 
uptake rate. 
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Seahorse Metabolic Flux Analysis 
Using a Seahorse XF96 extracellular flow bioanalyser (Seahorse Biosciences), living cells 
were monitored in real time for their respiration (in terms of oxygen consumption rate, OCR) 
and glycolysis (in terms of extracellular acidification rate, ECAR) in response to various 
stimuli. 
preBAT cells were differentiated in 15 cm dishes and transduced with adenovirus to knock 
down Tblr1 alone or together with Tbl in adipocyte progenitors or adipocytes as described 
above. On day 7 of differentiation, 16 hours prior to measurement, adipocytes were 
trypsinized, counted and seeded to XF96 polystyrene (PS) cell culture microplates at a 
density of 70,000 living cells per well. Primary BAT SVF-derived Lin−Sca1+ adipocyte 
progenitor cells were isolated and plated as described above directly in laminin coated XF96 
PS microplates. 2 days prior to induction of adipogenic differentiation, they were transduced 
with adenovirus as described above and subsequently differentiated until day 7, when the 
measurement was performed. 
Following the manufacturer’s instructions, cells were washed and pre-incubated with 
unbuffered (sodium bicarbonate free) minimal DMEM supplemented with 2 mM L-glutamine 
(Life Technologies) carefully adjusted to pH 7.4. For measuring respiration, medium was 
further supplemented with 1 mM pyruvate and 5 mM glucose. For fatty acid challenge, 
instead of DMEM low buffered KRB (110 mM NaCl, 4.7 mM KCl, 2 mM MgSO4, 1.2 mM 
Na2HPO4, pH 7.4) was used, supplemented with 2.5 mM glucose and 0.5 mM L-carnitine 
(Sigma). Cells were stimulated with chemicals provided by the commercially available XF 
Cell Mito Stress Test Kit and XF Glycolysis Stress Test Kit (Seahorse Bioscience): 2 µM 
oligomycine, 0.5 µM carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP), 1 µM 
rotenone, 1 µM antimycin A, 10 mM glucose or 100 mM 2DOG. Further, cells were 
stimulated with chemicals available in the lab, such as 10 µM isoproterenol, 1 µM NE, 20 nM 
insulin. For fatty acid challenge, a conjugate solution of 170 µM BSA and 1 mM sodium 
palmitate (Sigma) was generated by heating palmitate dissolved in a 150 mMNaCl solution to 
70 °C, adding it to 1 volume of a 37 °C 340 µM BSA solution, stirring for 1 hour and adjusting 
the pH to 7.4. Cells were stimulated with BSA alone or with 200 µM palmitate, followed by 
blocking of FA oxidation with 1 mM (+)-Etomoxir sodium salt hydrate (Etomoxir) [233] 
(Sigma). 
For quantification of cell density for normalization of data, cells were fixed for 1 hour at -20 °C 
in 100 µl 95% ethanol and 5% acetic acid (Sigma) and subsequently washed with water and 
stained for 30 minutes with 50µl of a 0.4% solution of sulforhodamine B (Sigma) in 1% acetic 
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acid. Following 4 washing steps with 1% acetic acid, the stain was eluted by shaking for 10 
minutes in 100 µl 10 mM Tris pH 10, measured with the Mithras Microplate Reader (Berthold) 
at 540 nm and analysed using the MicroWin software. 
For data analysis and calculation of statistics for areas under the curve (AUCs), the 
Seahorse XF 96software was used. 
Animals 
For the studies on insulin and brightening, male C57Bl6 mice were purchased from Charles 
River Laboratories (CRL) at age 6–8 weeks, while for the project focusing on the role of 
TBLR1 female mice were used (see genetic models below). 129S6/SvEvTac mice were 
purchased from Taconic. Organs and serum were collected, washed in PBS, snap-frozen in 
liquid nitrogen and stored at −80 °C. Intra-abdominal visceral white adipose tissue (aWAT) 
was dissected from the abdominal cavity, inguinal WAT (iWAT) (equivalent to subcutaneous 
WAT) was dissected from the layer under the skin and outside of the abdominal cavity at the 
hips. Brown adipose tissue (BAT) was dissected from the interscapular region. All lymph 
nodes, as well as adjacent WAT in BAT, were removed prior to further processing. Blood 
serum was obtained by centrifuging blood for 30 minutes at 4 °C and 5,000 rpm. 
Obesity Models 
For the ablation of pancreatic β-cells 13-week old mice were i.p.-injected daily with 60 µg/g 
body weight streptozotocin (STZ) (Axxora) or 0.05 M sodium citrate as vehicle control for 6 
consecutive days. Random fed and 16 h fasted blood glucose levels were determined 3 
weeks later using an automatic glucose monitor (Accu-Chek Performa, Roche) and 
compared to random fed blood glucose levels before the STZ injections to verify the diabetic 
state. For diet studies 8-week old mice were fed with low fat diet (LFD) (10% calories from 
fat) or high fat diet (HFD) (60% calories from fat) (Research Diets) for 12 weeks. Total body 
fat mass was determined by magnetic resonance imaging on an EchoMRI-100 quantitative 
NMR body composition analyser (Echo Medical Systems). 
Genetic Models 
As a model for whole fat knockout of TBLR1 on a C57Bl6 background, the adipose tissue 
knockout (“ATKO”) mice generated and described by Rohm et al [139] were used. 
For brown fat-specific knockout of TBLR1, mice homozygous for floxed allele 5 of the Tblr1 
gene were used, as generated by TaconicArtemis (Cologne, Germany) and described by 
Rohm et al [139]. These mice were bred with mice heterozygously expressing a tamoxifen-
inducible variant of the Cre recombinase under the control of the Ucp1 promotor, as 
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generated and described by Rosenwald et al [167], resulting in Tblr1fl/flUcp1Cre+ and 
Tblr1fl/flUcp1Cre- mice, the former of which, upon tamoxifen injection, become knockout for 
the Tblr gene in all UCP-1 expressing cells (“BATKO” mice). 
Tamoxifen injections 
5 week old Tblr1fl/flUcp1Cre+ and Tblr1fl/flUcp1Cre- mice were intraperitoneally (i.p.) injected 
with 2 mg/mouse/day of tamoxifen (Sigma), dissolved in 5/6 volume sunflower oil (Sigma) 
and 1/6 volume ethanol (EtOH), twice daily for 5 consecutive days. Mice were used only 3 
weeks after the last injection to minimize unspecific side effects of tamoxifen. 
CL316243 injections 
For acute β-adrenergic stimulation, animals were i.p.-injected with 1 mg/kg body weight CL. 
For chronic injections to induce browning, this procedure was repeated once daily for 10 
consecutive days. 
Osmotic Pumps 
For chronic β-adrenergic stimulation to induce browning of white adipose tissue, CL in 0.9% 
NaCl or vehicle was administered at continuous rates at a dose of 1 µg/g body weight/day by 
subcutaneous implantation of an osmotic pump (ALZET model 1002). After 10 days mice 
were sacrificed. 
Glucose Tolerance Test 
BATKO and control mice were fasted for 6 hours and basal blood glucose was recorded 
using an automatic glucose monitor as described above. Then they were i.p.-injected with 1 
g/kg body weight glucose and blood glucose levels were determined 20 minutes, 60 minutes 
and 120 minutes after injection. 
ITT and in Vivo Glucose Uptake Assay 
8-week old male C57Bl6 mice were implanted with osmotic pumps containing CL or vehicle 
and body fat mass was determined by magnetic resonance imaging as described above. 10 
days later, on the day of the experiment, the initial blood glucose value was determined, then 
animals were i.p.-injected with 240 µCi/kg body weight 3H-2DOG (Perkin Elmer) and with 0.5 
U/kg body weight huminsulin 100 (Lilly) or vehicle, all in 0.1 mM 2DOG. Every 15 min, blood 
glucose was determined and 25 µl of blood were collected. After 45 minutes the animals 
were sacrificed and organs and serum were collected, washed in PBS, snap-frozen in liquid 
nitrogen and stored at −80 °C. For analysis tissue weights were recorded and tissue was 
homogenised with a Mikro-Dismembrator S (Sartorius) in 1 ml tissue lysis buffer consisting of 
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50 mM Tris, 1 mM EDTA, 10 mM NaF, 2 mM NOV, 1 mM DTT, 150 mM NaCl and 1% NP-40 
(Sigma), pH 7.5. Lysates were centrifuged at 6,500 rpm for 20 minutes at 4 °C and part of 
this supernatant (S1) was supplemented with 1/4 volume of 0.3 M barium hydroxide solution 
(Ba(OH)2) (Sigma) and 1/4 volume of 0.3 M zinc sulfate solution (ZnSO2) (Sigma) to 
derivatize and precipitate phosphorylated 3H-2DOG. Following a centrifugation 6,500 rpm for 
20 minutes at 4 °C this supernatant (S2) was saved for determination of not taken up 
(underivatised) tracer. S1 and S2 were subjected to scintillation counting as described 
above. Also blood was supplemented with 0.3 M Ba(OH)2 and 0.3 M ZnSO4, centrifuged and 
the supernatant was used for scintillation counting. For standard activity measurement to 
normalize the data the injected insulin/3H-2DOG/2DOG solution was used. 
Calculation of glucose uptake 
Calculations were adapted from known publications [234-236]. For tracer activity in blood an 
AUC over the course of the 45 minutes duration of the experiment was calculated from 
background and volume corrected cpm. These calculations are illustrated in Figure 44. It was 
assumed that from t0 (time of injection) to t15 (first measurement point) blood concentration of 
tracer is increasing (Figure 44.A and B), and subsequently linearly decreasing (Figure 44.C 
and D). Values retrieved from tissue samples were corrected for background measurement, 
tissue weight and dilution and then further corrected for tissue perfusion by subtracting the 
volume of non-phosphorylated and thus not taken up tracer (calculated from S2) from tracer 
volume in tissue (calculated from S1). Together with the activity measured in blood and the 
mean blood glucose values that were determined during the experiment the glucose uptake 
into the various tissues could be determined. 
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Oral Lipid Tolerance and Trioleate Uptake Test 
The method and calculations were adapted from known publications [111]. BATKO and 
control mice were fasted for 16 hours. A 50 µl blood sample was collected prior to assay, 
then animals were gavaged with 100 µl olive oil (Sigma) and further blood samples were 
collected after 1.5 hours, 3 hours and 4.5 hours. The blood samples were centrifuged for 5 
minutes at 5,000 rpm and serum was subjected to triglyceride measurement as described 
above. For Trioleate Uptake Test, the oil was traced with 10 µCi/mouse triolein [9,10-3H(N)] 
Figure 44. The area under the curve of blood glucose during the experiment was 
approximated. (A) Blood glucose upon injection was assumed to start decreasing after an 
initial rise. (B) During the period of increase, AUC was approximated by assuming half the 
measured activity at t15 over the time of 15 minutes. (C) AUC between two timepoints was 
approximated by multiplying the counts of the later time point with the passed time and 
adding half the measured difference of the two time points over the passed time. (D) Total 
AUC was assumed as the sum of individual AUCs. 
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(Hartmann) and further blood samples were collected after 1 hour, 2 hours and at the end of 
the assay. Animals were sacrificed after 3 hours and blood and organs were collected (iWAT, 
aWAT, BAT, liver, gastrocnemius skeletal muscle (GC), heart, intestine). For BAT, liver, ~ 
100 mg of tissue was weighed and homogenized in 1 ml Solvable (Perkin Elmer) using a 
tissue lyser. For the other organs, whole samples were homogenized in 1 ml Solvable. 400 µl 
of homogenates, 5 µl of serum and 50 µl of original traced olive oil were subjected to 
scintillation counting as described above. 
Calculation of triolein uptake 
Counts (cpm) of tissues were corrected for background measurement, tissue weight and 
dilution. Based on the specific activity measured in an aliquot of the traced olive oil that was 
administered to the mice (cpm/mol of triolein), as well as the assay duration, the tissue 
uptake rate (µmol/g tissue/hr) could be determined. Taking into account the original tissue 
weight, the contribution of each tissue to whole body triolein uptake could be determined. 
Hepatic output assay 
An hepatic output assay was performed based on established protocols [237]. BATKO and 
control mice were housed 22 °C and fasted for 16 hours to eliminate intestinal lipid 
absorption and chylomicron production. To block plasma lipolytic activity and subsequent 
lipid clearance to tissues, 500 mg/kg BW Tyloxapol (Sigma) as a 10 % w/v solution in sterile 
0.9 % NaCl was administered intravenously. 50 µl blood sample was drawn before injection 
and every 30 minutes after injection, after 2 hours the animals were sacrificed. The blood 
samples were centrifuged for 5 minutes at 5,000 rpm and serum was subjected to triglyceride 
measurement as described above. 
Metabolic Phenotyping in the TSE System 
BATKO and control mice were housed at 4 °C, 22 °C or 30 °C in PhenoMaster cages (TSE 
Systems) on a 12 h light-dark cycle for up to 3 weeks. For the measurement of acute 
changes in VO2 in response to CL injection, mini chambers were used to minimize movement 
and accelerate rate at which data points can be recorded. 
Detection of body temperature 
For non-invasive measurement of body temperature, mice were implanted with IPTT-300 
transponder thermometers (BioMedic Data Systems), allowing wireless signal detection 
using the DAS-7006/7s handheld reader system for wireless temperature detection 
(BioMedic Data Systems). 
Methods 
 
 
122 
 
Calorimetry and assessment of further metabolic parameters 
For indirect calorimetry PhenoMaster cages were used. Oxygen consumption (VO2), carbon 
dioxide consumption (VCO2), physical activity, feeding, drinking and body weight were 
recorded. Respiratory exchange ratio (RER) resulted from VO2 and VCO2 and expresses an 
indicator of fuel use (values are expected to be between 0.7 at pure lipid use and 1 at pure 
carbohydrate use). The resting metabolic rate (RMR) is metabolism corrected for VO2 
caused by activity and was calculated as previously described [238]. 
Adipose Tissue Explants 
For in vitro culture of adipose tissue, BAT from female C57Bl6 mice was dissected as 
previously described and cut to 12 equally sized pieces per animal. For technical replicates 
of each condition, a tissue piece of a different mouse was used. 1 piece per well was 
weighed and transferred to 24 well plates and assays were performed analogously to cell 
assays in terms of buffer composition, incubation times and supernatant collection. In 
radioactive assays, tissue pieces were homogenized in protein extraction buffer with a tissue 
lyser and specific volumes were used for scintillation counting as described above. 
Ethics Statement 
All animal handling procedures were performed in accordance with the European Union 
directives and the German animal welfare act and have been approved by local authorities 
(Regierungspräsidium Karlsruhe, Az. 35-9185.81/G-82/12). 
Adipocyte progenitor isolation has been approved by the DKFZ ethical committee 
(DKFZ252). 
Statistical Analysis 
The results are shown as means ± standard error of the mean (SEM). Statistical analysis 
was performed by two-tailed student’s t test, For RT-PCR data this was calculated on log10-
transformed data, significance was assumed at p<0.05. For pairwise multiple comparison 
procedures an ANOVA analysis based on the Student-Newman-Keuls Method was 
performed. 
Material 
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MATERIAL 
Buffers 
 
Buffer  name Compos it ion 
Citrate Buffer (Histology) 10 mM sodium citrate, 0.05% Tween 20, pH 6.0 
Dialysis Buffer (adenovirus production) 1 x PBS, 10% glycerol, pH to 7.2 
DNA Loading Dye 6x 10 mM EDTA, 70 % glycerol, trace amounts of Orange G 
Elution Buffer (ChIP) 1% SDS, 0.1 M NaHCO3 
Krebs-Ringer Buffer (KRB) 115 mM NaCl, 5.9 mM KCl,1.2 mM MgCl2, 1.2 mM NaH2PO4, 1.2 mM 
Na2SO4, 2.5 mM CaCl2, 25 mM NaHCO3, pH 7.4 
low buffered KRB (Seahorse) 110 mM NaCl, 4.7 mM KCl, 2 mM MgSO4, 1.2 mM Na2HPO4, pH 7.4 
Lysis Buffer (ChIP) 20mM Tris, 0.15 M NaCl, 1 mM EDTA, 0.1 % SDS, 1 % Triton-X100, pH 8 
PBS-TOSH (adenovirus production) 30.8 mM NaCl, 120.7 mM KCl, 8.1 mM Na2HPO4, 1.46 mM KH2PO4, 10 mM 
MgCl2, pH 7.2 
Protein Extraction Buffer (PEB) 25 mM Tris-HCl, 100 mM NaCl, 1 mM EDTA, 0.5% Triton-X100, 0.5% NP-40, 
1x PIC, 1x phosphatase inhibitor cocktail, 0.5 mM Na3VO4, 10 mM NaF, 10 
mM G2P, pH 7.4 
Running Buffer (Western Blotting) 200mM glycine, 25mM Tris, 0.1% SDS 
SDS sample buffer 5x 250 mM Tris, 10% SDS, 50% glycerol, 0.5 mM DTT, 0.01% bromphenol blue, 
pH 6.8 
T issue Fractionation Buffer A 50 mM Tris, 250 mM sucrose, 10mM, 1 mM EDTA, 10 mM NaF, 2 mM 
Na3VO4 , 1 mM DTT, 1 x PIC, pH 7.2 
T issue Fractionation Buffer B 50 mM Tris, 25% glycerol, 420 mM NaCl, 1.5 mM MgCl2, 10 mM NaF, 1 mM 
DTT, 1 x PIC, 0.1% SDS, 1% NP-40, pH 7.2 
T issue Lysis Buffer (Glucose Uptake 
Assay) 
50 mM Tris, 1 mM EDTA, 10 mM NaF, 2 mM Na3VO4, 1 mM DTT, 150 mM 
NaCl, 1% NP40, pH 7.5 
Transfert Buffer (Western Blotting) 150mM glycine, 20mM Tris, 20% methanol 
Tr is Buffered Saline with Tween-20 (TBS-
T)  
50 mM Tris, 150 mM NaCl, 0.1% Tween 20, pH 7.6 
Tr is-Borate-EDTA Buffer (TBE) 10 mM Tris, 0.1 mM EDTA, 9 mM boric acid, pH 8 
Tx  Protein Lysis Buffer 150mM NaCl, 0.05% Triton-X100, 10mM Tris, pH 8 
Wash Buffer 1 (ChIP) 20mM Tris, 0.15 M NaCl, 1 mM EDTA, 0.1 % SDS, 1 % Triton-X100, 0.1 % 
NaDOC, pH 8 
Wash Buffer 2 (ChIP) 20mM Tris, 0. 5 M NaCl, 1 mM EDTA, 0.1 % SDS, 1 % Triton-X100, 0.1 % 
NaDOC, pH 8 
Wash Buffer 3 (ChIP) 20mM Tris, 1 mM EDTA, 0.5 % NaDOC, 0.5 % NP-40 (Sigma), 0.25 M LiCl, 
pH 8 
Wash Buffer 4 (ChIP) 20mM Tris, 1 mM EDTA, pH 8 
 
 
Table 6.  Buf fers   
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Oligonucleotides 
Oligonucleotides for annealing of double stranded insert 
Overlapping oligonucleotides containing 3 repeats of the miR-122 target sequence 
(underlined) as according to www.mirbase.org were designed to create overlaps matching 
the ApaI and AgeI restriction sites present in the vector (bold). 
 
Des igned pr imer  sequence Desc r iption 
5’CCAAACACCATTGTCACACTCCAGTATACACAAACACCATTGTCACACTCCAGATA
TCACAAACACCATTGTCACACTCCA 
miR-122 Target Site, fwd 
5’CCGGTGGAGTGTGACAATGGTGTTTGTGATATCTGGAGTGTGACAATGGTGTTTG
TGTATACTGGAGTGTGACAATGGTGTTTGGGGCC 
miR-122 Target Site, rev 
Oligonucleotidess for sequencing 
To confirm successful cloning of the Ucp1 mini promoter in the pGL3 vector, the commercial 
primer GL3 (LGC standards) was used, while to confirm subcloning to pdsAAV vector, 
sequencing primers were designed (“Ucp1mini subcloning”). Further, sequencing primers 
were designed to confirm the identity of expressed miRNA (“miR-ID”) or the successful 
insertion of the miR-122 target site (miR-122 insertion).  
 
Des igned pr imer  sequence Desc r iption 
5’TTTGTATTCAGCCCATATCG GL3 
5’ATGATTGACATGCTAGTTTTACGA Ucp1mini subcloning, fwd 
5’ TCGGCATGGACGAGCTGTACAAGT Ucp1mini subcloning, rev 
5’TCCACTTTGCCTTTCTCTCC miR-122 site insertion, fwd 
5’CGTTGTGGCTGTTGTAGTTG miR-122 site insertion, rev 
5’ACTTCAAGATCCGCCACAAC miR-ID, fwd 
5’CCTCAGATCAATTCCCGCCT miR-ID, rev 
Oligonucleotides for PCR in cloning 
To amplify the two key elements for the generation of the Ucp1 mini promoter, PCR primers 
were used to amplify the “220 bp element”, adding restriction sites for SacI and XhoI 
(underlined) and the “Cre4pro enhancer element”, adding restriction sites for BamHI and 
HindIII (underlined) as described by Kozak et al [193]. Subsequently, the Ucp1 mini promoter 
was amplified for subcloning to the pdsAAV vector using PCR primers adding restriction sites 
for MluI and PstI (underlined). 
Table 8.  Oligonuc leot ides  for sequenc ing 
Table 7.  Oligonuc leot ides  for annealing of  double s t randed insert   
Material 
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Des igned pr imer  sequence Desc r iption 
5’GGGGAGCTCCTCTACAGCGTCACAGAGG 220 bp, fwd + SacI 
5’GGGCTCGAGAGTCTGAGGAAAGGGTTGA 220 bp, rev + XhoI 
5’GGGGATCCGAGTGACGCGCGGCTGGG Cre4, fwd + BamHI 
5’GGGAAGCTTGGGCTAGGTAGTGCCAG Cre4, rev + HindIII 
5’GGGACGCGTGGTACCGAGCTCCT Ucp1mini, fwd + MluI 
5’GGGCTGCAGAAGCTTGGGCTAGG Ucp1mini, rev + PstI 
Oligonucleotides for quantitative real-time PCR 
For positive and negative control PCRs to assess ChIP material quality, primers designed 
and ordered via Eurofins MWG Operon were used. 
 
Des igned pr imer  sequence Desc r iption 
5’CTCAGAAAAGGCAGGGAA  Cav2, fwd (adipogenesis positive control 2) 
5’CCCAGTCATGACAACACC Cav2, rev (adipogenesis positive control 2) 
5’TGGTAGCCTCAGGAGCTTGC General ChIP negative control, fwd 
5’ATCCAAGATGGGACCAAGCTG General ChIP negative control, fwd 
5’GTGAATGTGTGGGTCACTGG Pparg2 promoter -300 bp, fwd (adipogenesis positive control 1) 
5’TAATGCTGTCTGCTGCTTTGG Pparg2 promoter -300 bp, rev (adipogenesis positive control 1) 
5’AGCAAACCCGTCTGACACAAGC Taldo+1kB, fwd (PPAR-γ binding negative control 1) 
5’TGGAGCATGTTTTTCCAGCATCCA Taldo+1kB, fwd (PPAR-γ binding negative control 2) 
5’GCCGGTAAACTCTGCACTACACACA Taldo+1kB, rev (PPAR-γ binding negative control 1) 
5’CCCTATAAAAGCCGATGTGCAGTCA Taldo+1kB, rev (PPAR-γ binding negative control 2) 
5’ATACACCCTTTGCCCCGTTT Taldo+2kB, fwd (PPAR-γ binding positive control) 
5’ GTGGCTCGTTCTGCTGTCTT Taldo+2kB, rev (PPAR-γ binding positive control) 
For gene expression analysis, either TaqMan probes or primers designed and ordered via 
Eurofins MWG Operon were used. 
Des igned mouse pr imer  sequence Desc r iption 
5‘AAAGCCAAGAAGTCGGTGGAC Cebpa_for 
5‘CGAGTACCGGGTACGGCGGGAAC Cebpa_probe 
5‘CTTTATCTCGGCTCTTGCGC Cebpa_rev 
5‘AATATGTCTACCTCCGAAGCAGGA Cpt1b_for 
5‘CAACTATTATGCCATGGATTTTGTGCTTATTAAGA Cpt1b_probe 
5‘CGTGAACGGCATTGCCTAG Cpt1b_rev 
5‘GATGGCACGCAGCCCTAT Ppargc1a_for 
5‘CATTGTTCGATGTGTCGCCTTCTTGCT Ppargc1a_probe 
5‘CTCGACACGGAGAGTTAAAGGAA Ppargc1a_rev 
5’GGAGCCATGGATTGCACATT Srebp1c_for 
5’CAGCTCATCAACAACCAAGACAGTGACTTCC Srebp1c_probe 
5’CCTGTCTCACCCCCAGCATA Srebp1c_rev 
5‘ACGAGGTGAACTTTCTGGTATATCG Tbl1_for 
5‘ATCAGGTTTTTCCCACTCTGCCTTCACG Tbl1_probe 
5‘GGACTGGCTAATGTGACTTTCGA Tbl1_rev 
Table 10.  Oligonuc leot ides for quant itat ive real-t ime PCR 
Table 9.  Oligonuc leot ides for PCR in c loning 
Material 
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5‘AATGGTGCCCTGGTTCCA Tblr1_for 
5‘CCGCTGCACTCATCTCTATCATCCAGAAA Tblr1_probe 
5‘AGGTGCCATCCTCATTTATGCTA Tblr1_rev 
5‘TTGACCTAAAGACCATTTGCACTT Tbp_for 
5‘TGCAAGAATGCTGAATATAATCCCAAGCG Tbp_probe 
5‘TTCTCATGATGACTGCAGCAAA Tbp_rev 
5‘CCTTCCCGCTGGACACTG Ucp1_for 
5‘CAAAGTCCGCCTTCAGATCCAAGGTG Ucp1_probe 
5‘CCTAGGACACCTTTATACCTAATGGT Ucp1_rev 
Mouse TaqMan probe ID Desc r ipt ion 
Mm02524224_s1 Adrb2 (inv) 
Mm02601819 Adrb3 
Mm00803820_m1 Angptl3 
Mm00480431_m1 Angptl4 
Mm01611862_g1 Atp5o 
Mm00432554_m1 Cidea 
Mm00438297_g1 Cox7a1 
Mm00432648_m1 Cox8b 
Mm00662319_m1 Fasn 
Mm00433278_m1 Fgf21 
Mm00434759_m1 Leptin 
Mm00495359_m1 Lipe (Hsl) 
Mm00503040_m1 Pnpla2 (ATGL) 
Mm00440945_m1 PPARgamma 
Mm00445641_m1 Retn 
Mm00772290_m1 Scd1 
Mm00458268_m1 Sdhb 
Mm00481172_m1 Sdhc 
Mm00490758_m1 Sirt1 
Mm00441480_m1 Slc2a1 (Glut1) 
Plasmids 
 
Plasmid name Desc r iption Source 
pGL3/3.1kbUcp1p Luciferase reporter vector containing full length 
Ucp1 promoter 
kindly provided by the Kozak lab 
(based on pGL3-Basic, Promega) 
pdsAAV-LP.1-GFPmut-miR-NC Double stranded AAV vector expressing control 
miRNA under the control of LP1 promoter 
kindly provided by the Herzig lab 
(generated by Tessa Walcher) 
pdsAAV-LP1-GFPmut-miR-TBL1 Double stranded AAV vector expressing Tbl1 
miRNA under the control of LP1 promoter 
kindly provided by the Herzig lab 
(generated by Tessa Walcher) 
pdsAAV-LP1-GFPmut-miR-TBLR1 Double stranded AAV vector expressing Tblr1 
miRNA under the control of LP1 promoter 
kindly provided by the Herzig lab 
(generated by Tessa Walcher) 
 
Table 11.  Plasmids 
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Antibodies 
 
Mus  Musculus  Target Protein Source 
Acety l Coenzyme A Carboxy lase (ACC)  3662, Cell Signalling 
Adipose Tr iglycer ide Lipase (ATGL)  4126, Cell Signalling 
Anti-mouse IgG-HRP (goat)  170-6516, Biorad 
Anti- rabbit IgG-HRP (goat)  172-1019, Biorad 
CD16/32 (FcBlock )  14-0161-82, ebioscience/Natutec  
CD31-biotin 13-0311-81, ebioscience/Natutec  
CD45-biotin 13-0451-81, ebioscience/Natutec  
G lucose Transpor ter  1 (GLUT-1)  ab32551, Abcam 
G lycer inaldehyd-3-Phosphat-Dehydrogenase (GAPDH)  sc-166545, Santa Cruz 
Glycogen synthase k inase 3 beta (GSK3β)  9315 Cell Signalling 
Hormone-Sens it ive Lipase (HSL)  AB3525, Chemicon 
Perox isome proliferator -ac tivated receptor  gamma (PPARg)  H100 sc-7196, Santa Cruz 
Phosphory lated Acety l Coenzyme A Carboxy lase (p-ACC)  3661, Cell Signalling 
phosphory lated G lycogen synthase k inase 3 beta (p-GSK3β)  9336 Cell Signalling 
Phosphory lated Hormone-Sens it ive Lipase (p-HSL)  4126, Cell Signalling 
Phosphory lated PKA subs trate (RRXS/T)  9624, Cell Signalling 
Phosphory lated Protein Kinase B (p-AKT)  9271, Cell Signalling 
Poly  [ADP-Ribose] Polymerase 1 (PARP-1)  9542, Cell Signalling 
Protein Kinase B (AKT)  9272, Cell Signalling 
Ter119-biotin 13-5921-81, ebioscience/Natutec 
Transduc in (beta) -Like 1 X-Linked Receptor  1 (TBL1XR1)  NB600-270, Novus 
Transducin (beta)-Like 1 X-Linked Receptor 1 (TBL1XR1)  [only  dur ing tes ting] ab24550, Abcam 
Transduc in (beta) -Like 1X-Linked (TBL1X)  ab24548, Abcam 
Uncoupling Protein 1 (UCP1)  ab23841, Abcam 
Valos in-Containing Protein (VCP)  ab11433, Abcam 
Enzymes 
 
Res tr ic t ion endonuc lease Source Catalogue number  
AgeI  New England Biolabs R0552 
ApaI New England Biolabs R0114 
BamHI Thermo Fischer Scientific (Fermentas) ER0051 
BglII Thermo Fischer Scientific (Fermentas) ER0082 
HindIII Thermo Fischer Scientific (Fermentas) FD0504 
MluI Thermo Fischer Scientific (Fermentas) ER0561 
NotI  New England Biolabs R0189 
Ps tI New England Biolabs R0140S 
SacI New England Biolabs R0156S 
SalI New England Biolabs R0138S 
XhoI New England Biolabs R0146S 
Cloning Enzyme Source Catalogue number 
T4 DNA Ligase New England Biolabs M0202L 
Table 13.  Enzymes 
Table 12.  Ant ibodies  
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Calf Intestinal Phosphatase (CIP) New England Biolabs M0290L 
Phusion High-Fidelity DNA-Polymerase Thermo Scientific F-530L 
General Enzyme Source Catalogue number 
Collagenase Type II Sigma C6885 
DNase I Roche 11 284 932 001 
Lambda Protein Phosphatase (Lambda PP) New England Biolabs P0753S 
Instruments 
 
Ins trument Source 
0.5-10µl single-channel pipette (ErgoOne) Starlab 
100-1000µl single-channel pipette (ErgoOne) Starlab 
20-200µl single-channel pipette (ErgoOne) Starlab 
2-20µl single-channel pipette (ErgoOne) Starlab 
Analytical scales (M-Power) Sartorius 
Automated cell counter (Countess) Life Technologies (Invitrogen) 
Automatic glucose monitor (Accu-Chek Performa)  Roche 
Bacterial incubator (Function Line)  Thermo Scientific (Heraeus) 
Bacterial shaker  Infors AG  
Bacterial shaker / incubator (Multitron Standard) Infors HT 
Benchtop centrifuge (Microfuge Heraeus Pico) Thermo Scientific (Heraeus) 
Benchtop centrifuge, cooling (Microfuge Heraeus Fresco) Thermo Scientific (Heraeus) 
Blot imager (ChemiDoc XRS) Biorad 
Bunsen Burner Campingaz 
Calorimeter (IKA C7000) IKA 
Centrifuge (Biofuge Prime) (cell culture) Thermo Scientific (Heraeus) 
Centrifuge (Labofuge 400R) Thermo Scientific (Heraeus) 
Centrifuge (Mikro 22R) (cell culture) Hettich 
Centrifuge (Multifuge X3R) Thermo Scientific (Heraeus) 
Centrifuge (Super T21) Thermo Scientific (Heraeus) 
CO2 incubator Sanyo 
Electrophoresis chamber  Steinbrenner  
Electrophoresis power supply (PowerPac™ Basic) Biorad 
Electrophoresis power supply (PowerPac™ HC) Biorad  
Ex tracellular flow bioanalyser (Seahorse XF96) Seahorse Bioscience 
FPLC system (ÄKTA purifier) GE Healthcare Life Sciences 
Freeze dryer (Alpha 1-2) Martin Christ 
Freezer -20 °C (comfort / med line) Liebherr 
Freezer -80 °C (Herafreeze) Thermo Scientific (Heraeus) 
Fr idge 4 °C (comfort / med line) Liebherr 
Fumehood (Airflow RXC 90.1) WALDNER Laboreinrichtungen 
Gel imager (IX) Intas 
Handheld Reader System for Wireless temperature detection (model DAS-
7006/7s) 
BioMedic Data Systems 
Hotplate stirrer (Model 375) VWR 
Labcoat Bierbaum Proenen 
Liquid nitrogen cryogenic tank Thermo Electron 
Table 14.  Ins t ruments  
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Liquid scintillation counter (Tri-Carb® 2100TR or 2900TR) Perkin Elmer 
Manual pipetting system (Liquidator 96) Mettler Toledo 
Micro dismembrator S Sartorius 
Microplate reader (Mithras LB 940) Berthold 
Microplatereader SPECTROstar Omega BMG Labtech 
Microscope (Axio Imager.M2) (histology) Zeiss 
Microscope (Axiovert 40 CFL) (cell culture) Zeiss 
Microwave Bosch 
Mini Trans-Blot® cell (buffer tank, lid, cassettes, electrodes) Biorad 
Mini-PROTEAN Tetra cell (buffer tank, lid, running module) Biorad 
Mini-PROTEAN® Tetra handcast systems (casting module, plates, combs) Biorad 
Multichannel pipette reference 8- and 12-channel variable Eppendorf 
Multistep pipette (Multipette Plus) Eppendorf 
pH meter (GMH350) GHM electronics, Greisinger 
PhenoMaster cages TSE Systems 
Photometer (NanoDrop ND-1000) Peqlab Biotechnology 
Pipette controller (accu-jet® pro) Brandtech Scientific 
Real-Time PCR system (StepOnePlus) Life Technologies (Applied Biosystems) 
Rocking platform (Duomax 1030) Heidolph 
Rotating wheel Neolab 
Rotating wheel (model 2-1184) Neolab 
Scales (EG 2200-2NM) Kern & Sohn Gmbh 
Sonicator (Bioruptor) Diagenode 
Sterile biosafety cabinet (e3 Class II Type A/B) SterilGARD 
Tabletop centrifuge (Mini Spin Plus)  Eppendorf 
Thermomixer comfort Heatblock Eppendorf 
T imer (TR 118) Oregon Scientific 
T issueLyser II Qiagen 
Ultracentrifuge (XL 70) Beckman 
Vacuum pump Neolab 
Software 
 
Software Source 
CLC Sequence Viewer 7 CLCbio 
CustomCDF (version 14) Brainarray 
Geneious Pro 5.3.4 Genious 
GraphPad Prism 5 GraphPad 
I llustrator Adobe 
Image Lab Biorad 
Intas-Capture-Software Intas 
MARS data analysis software Omega 
ND-1000 Nanodrop 
O ffice Microsoft 
SAS JMP7 Genomics (version 4) SAS Institute 
Photoshop Adobe 
Reader Control Omega 
Seahorse XF 96 Seahorse Bioscience 
Table 15.  Sof tware 
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SigmaPlot 12.0 SigmaPlot 
STEP 7 MicroWIN Siemens 
StepOne Life Technologies (Applied Biosystems) 
UCSC Genome Browser http://genome.ucsc.edu 
Kits 
 
Kit Source Catalogue number  
2-D Quant Kit GE healthcare 80-6483-56 
BCA Protein Assay Kit Thermo Scientific (Pierce) 23225 
BLOCK-iT™ Adenoviral RNAi Expression System Life Technologies K4941-00 
Cholesterol (liquid) assay Randox CH200 
Cholesterol Standard Solution Randox 2147CH 
Dual-Luciferase Reporter Assay System Promega E1960 
ECL Western Blotting Substrate Thermo Scientific (Pierce) 32106 
G lycerol Standard Solution Sigma G7793 
Mouse Angiopoietin-like 3 Immunoassay, Quantikine ELISA R&D Systems MANL30 
Mouse/Rat FGF-21 Immunoassay, Quantikine ELISA R&D Systems MF2100 
Mouse Insulin ELISA Alpco 80-INSMS-E01 
NEFA Standard Solution Wako 276-76491 
NEFA-HR Reagent 1 Wako 434-91795 
NEFA-HR Reagent 2 Wako 436-91995 
NE-PER Nuclear and Cytoplasmic Extraction Kit Thermo Scientific (Pierce) 78833 
Plasmid Maxi Kit Qiagen 12163 
QIAprep Spin Miniprep Kit Qiagen 27106 
QIAquick Gel Extraction Kit Qiagen 28704 
QIAquick PCR Purification Kit Qiagen 28104 
Qubit dsDNA HS Assay Kit Life Technologies (Thermo) Q32851 
RNeasy Micro kit Qiagen 74004 
RNeasy Mini kit Qiagen 74104 
Serum Triglyceride Determination Kit Sigma TR0100 
SuperScript II reverse transcriptase Life Technologies 18064014 
XF Calibrant Solution Seahorse Bioscience 100840-000 
XF Cell Mito Stress Test Kit Seahorse Bioscience 103015-100 
XF Glycolysis Stress Test Kit Seahorse Bioscience 102194-100 
Chemicals 
 
Chemical Source Catalogue number  
(+)-sodium L-ascorbate Sigma A4034 
14C glucose D-[14C(U)] Perkin Elmer NEC042X250UC 
14C-Mannitol, D-[1-14C] Perkin Elmer NEC314050UC 
2-Deoxy-D-glucose Sigma D8375 
3,3 ′,5-Triiodo-L-thyronine sodium salt (T3) Sigma T6397 
3,3′-Diaminobenzidine (DAB) Sigma 32741 
30% Acrylamide/Bisacrylamide 37.5:1 (Rotiphorese Gel 30) Carl Roth 3029.1 
Table 17.  Chemicals  
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3H-Deoxy-D-glucose, 2-[1,2-3H (N)] Perkin Elmer NET328001MC 
Acetic acid Sigma 45731 
Agarose Applichem A8963 
Ammonium persulfate (APS) Roth 9592.3 
Ampicillin Sigma A9518 
Anti-Sca-1 MicroBead Kit (FITC), mouse Miltenyi Biotec 130-092-529 
Attractene Transfection Reagent Qiagen 301005 
Bar ium hydroxide solution 0.3 N (Ba(OH)2) Sigma B4059 
Biotin Sigma B4639 
Bor ic acid Sigma 31146 
BSA FA free (for ChIP and lipid assays) Sigma A8806 
BSA fraction V (for WB) Biomol 1400 
BSA in solution (for cell culture) Sigma A9576 
Calcium chloride (CaCl2) Carl Roth CN93.1 
Carbaprostacyclin (cPGI2) Biozol (Cayman) 69552-46-1 
Cesium chloride Carl Roth 7878.2 
Chloroform VWR 22.711.290 
Cy tochalasin B Sigma C6762 
D- (+)-Glucose anhydrous Applichem A0883 
Dexamethasone (Dex) Sigma D-8893 
Dexamethasone water soluable (Dex) Sigma D2915 
Dimethyl sulfoxide (DMSO) Sigma D2650 
Disuccinimidyl glutarate (DSG crosslinker) Proteochem c1104 
Dithiothreitol (DTT) Carl Roth 6908.2 
D-Mannitol Sigma M4125-100G 
DMEM, high glucose, pyruvate Life Technologies (Gibco) 11965-092 
DMEM, low glucose, pyruvate Life Technologies (Gibco) 31885-023 
DMEM, no glucose Life Technologies (Gibco) 11966-025 
DMEM, no glucose,/pyruvate/L-glutamine,/phenol 
red/sodium bicarbonate, powder 
Sigma D5030 
DNase / RNase free water Life Technologies (Gibco) 10977023 
dNTPs (10 mM) Life Technologies R0191 
D-pantothenic acid hemicalcium salt Sigma P5710 
Dulbecco's phosphate buffered saline (PBS) Life Technologies (Gibco) 14190094 
Eosin G Carl Roth 7089.1 
Ethanol 99% DKFZ  
Ethanol absolute for analysis Sigma 32205 
Ethidium bromide (EtBr) Carl Roth 2218.2 
Ethylenediaminetetraacetic acid (EDTA) Sigma E5134 
(+)-Etomoxir sodium salt hydrate (Etomoxir) Sigma E1905 
Eukitt quick-hardening mounting medium Sigma 3989 
Fetal calf serum (FCS) Life Technologies (Invitrogen) 10091-148 
Formaldehyde solution 37% J. T. Baker 7040 
Forskolin Sigma F3917 
Gene Ruler 1kb DNA Ladder Thermo Scientific SM0314 
G lucose Transporter Inhibitor III, STF-31 Calbiochem 351801 
G lycerol 2-phosphate disodium salt hydrate (G2P) Sigma G6251 
G lycerol, 99% Sigma 15523 
G lycine Sigma 33226 
Material 
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GW501516 (Ppar-α agonist) Sigma 43732 
GW7647 (Ppar-α agonist) Sigma G6793 
H-89 (PKA Inhibitor) Calbiochem 371962 
Hematoxylin solution Gill No. 2 Sigma GHS232 
HEPES 1M Life Technologies (Invitrogen) 15630-056 
Histofix 4% Formaldehyde Solution for Histology Carl Roth P087.5 
Huminsulin, 100 U/mL Lilly A10AB01 
Hydrochloric acid 37% (12.1 M) Sigma 30721 
IBMX (3-Isobutyl-1-methylxanthin Sigma I5879-1G 
Indomethacine Sigma I7378 
Insulin human Sigma I2643 
Isopropanol Sigma 190764 
Isoproterenol hydrochloride Merck (Calbiochem) 420355 
L- (-)-norepinephrine bitartrate (NE) Sigma A9512 
Laminin Santa Cruz sc-29012 
LB agar Carl Roth X969.1 
LB Medium Carl Roth X968.1 
L-Carnitine Sigma C0158 
L-glutamine Life Technoligies (Invitrogen) 25030-081 
Lipofectamine 2000 Transfection Reagent Life Technologies (Thermo) 11668027 
Lithium Chloride (LiCl) Carl Roth 3739.1 
Magnesium chloride hexahydrate (MgCl2 *6H2O) Sigma M927 
MEM Non-Essential Amino Acids Solution (NAA) Life Technologies 11140 
Methanol Sigma 32213 
N,N,N',N'-tetramethylethane-1,2-diamine (TEMED) Carl Roth 2367.3 
NP-40 (IGEPAL) Sigma 56741 
O ligo(dT)18 Primer Thermo Scientific SO132 
O live oil Sigma 75357 
One Shot TOP10 Chemically Competent E. coli Life Technologies (Invitrogen) C4040 
Orange G Sigma O3756 
PageRuler Prestained Protein Ladder Thermo Scientific 26616 
Penicillin-Streptomycin (10,000 U/mL) Life Technologies 15140-122 
Phenol/Chloroform/Isoamyl alcohol (25:24:1) Carl Roth A156.2 
Phosphatase Inhibitor Cocktail 2 Sigma P5726 
Polyethylenimin (PEI) Sigma 764647 
Poly-L-lysine Sigma P9155 
Potassium chloride (KCl) Carl Roth 6781.1 
Potassium dihydrogen phosphate (KH2PO4) Carl Roth 3904.1 
Protease Inhibitor Cocktail Sigma P8849 
QIAzol lysis reagent Qiagen 79306 
Recombinant Mouse FGF basic (bFGF) R&D Systems 3139-FB-025 
Recombinant Ribonuclease Inhibitor (RNaseOUT) Life Technologies (Invitrogen) 10777-019 
Rosiglitazone Cayman Chemicals 71740 
Rotiszint scintillation liquid Carl Roth 0016.3 
S.O.C. medium Life Technologies (Invitrogen) 15544-034 
Sk im milk powder extra grade Gerbu 1602 
Sodium acetate (NaAc) Applichem A1522 
Sodium chloride (NaCl) Sigma 31434 
Sodium deoxycholate (NaDOC) Sigma D6750 
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Sodium dihydrogen phosphate (NaH2PO4) Applichem A3559 
Sodium dodecyl sulfate (SDS) Sigma 62862 
Sodium fluoride Sigma S1504 
Sodium hydrogen carbonate (NaHCO3) AppliChem A0384 
Sodium hydrogen phosphate (Na2HPO4) Neolab 4066 
Sodium hydroxide standard solution 8 mol/l Sigma 35255 
Sodium orthovanadate (Na3VO4) Sigma S6508 
Sodium palmitate Sigma P9767 
Sodium pyruvate Life Technologies 11360070 
sodium sulfate (Na2SO4) Applichem A3487 
Solvable Perkin Elmer 6NE9100 
Streptavidin MicroBeads Miltenyi Biotec 130-048-102 
Streptozotocin Axxora LKT-S7870 
Sucrose Sigma S1888 
Sulforhodamine B sodium salt Sigma S9012 
Sunflower seed oil from Helianthus annuus Sigma S5007 
Tamoxifen Sigma T-5648 
TaqMan Gene Expression Master Mix Life Technologies 4369016 
Tr iolein [9,10-3H(N)] Hartmann ART 0199 
Tr is base Sigma T1503 
tr i-Sodium citrate dihydrate Sigma 71405 
Tr iton-X100 AppliChem A1388 
Trypsin-EDTA solution Life Technologies (Invitrogen) 25200072 
Tween 20 Sigma P9416 
Ty loxapol Sigma T0307 
Xy lene Merck 1.08681.2500 
Z inc sulfate solution 0.3 N Zn(SO)4 Sigma Z2876 
Consumables 
 
Consumable Source Catalogue number  
10µl graduated tips Starlab S1111-3800 
1000µl blue graduated tips Starlab S1111-2821 
10ml Disposable Polystyrene Serological Pipet Corning (Falcon) 356551 
15ml tube PP, sterile (cellstar) Greiner Bio One 188271 
200µl yellow tips Starlab S1111-0806 
250mL Vacuum Filter/Storage Bottle System, 0.22µm Pore Sigma (Corning) 430756 
25ml Disposable Polystyrene Serological Pipet Corning (Falcon) 356535 
300 µM nylon mesh (Polyamid Monofil) Neolab 4-1411 
50ml Disposable Polystyrene Serological Pipet Corning (Falcon) 356550 
50 ml syringe BD Biosciences (Falcon) 1404297 
50ml tube PP, sterile (cellstar) Greiner Bio One 227261 
5ml Disposable Polystyrene Serological Pipet Corning (Falcon) 356543 
70µM cell strainer nylon BD Biosciences (Falcon) 352350 
96 Well Black with Clear Flat Bottom Corning (Falcon) 353219 
96-Well Microplates, clear, flat bottom (MicroWell) Thermo Scientific (Nunc) 95029780 
Bench liner (Labmat) VWR 246750000 
Table 18.  Consumables  
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Cell counting chamber slides (Countess) Life Technologies (Invitrogen) C10228 
Cell Culture Dishes 100x20 mm Corning (Falcon) 353003 
Cell Culture Dishes 150x25 mm Corning (Falcon) 353025 
Cell Scrapers Sigma (Corning) CLS3010 
Combitips advanced, 10 mL Eppendorf 30089464 
Combitips advanced, 5 mL Eppendorf 30089456 
Cover Slips Carl Roth H878.2 
Cryo Cardboard Box, White Neolab Feb 01 
Cryogenic vials, 1.8ml Starlab E3110-6122 
Delicate Task Wipes Kimberley Clark 7216 
Dialysis tubing Cellulose Ester  Spectrum Laboratories 131270 
Disposable Scalpels Feather EF7281 (2975-10) 
Disposal bags (Sekuroka) Carl Roth E706.1 
FPLC column (Superose 6, 10/300 GL) GE Healthcare Life Sciences 17-5172-01 
Gas cartridge Campingaz Z00059581 
G loves, Powder Free Textured Latex Exam blossom BM 11226-PF-AV 
G lucose test strips (Acco-Chek Inform II) Roche 473360 
Gr id insert for cryoboxes, 10x10 Neolab Feb 03 
Histology Mega-Cassette System (Tissue-Tek) Sakura 4173 
Insulin syringes (Micro-fine 1ml U-40, 0.33 mm x 12.7 mm) Becton Dickinson 320801 
large volume centrifuge tubes (500ml) Sigma (Corning) CLS431123 
Liquidator96 LTS tips Steinbrenner SL-LT-L20 
Micro haematocrit tubes Brand 7493 11 
MicroAmp® Fast Optical 96-Well Reaction Plate Life Technologies 4346906 
MicroAmp® Optical 8-Cap Strips Life Technologies 4323032 
MicroAmp® Optical Adhesive Film Life Technologies 4311971 
Micro-osmotic pump (model 1002) Alzet 4317 
Microscopy Slides Carl Roth 0656.1 
Mouse Genome 430 2.0 Array (GeneChip) Affymetrix 900496 
MS Columns Miltenyi Biotec 130-042-201 
needles (Neolus 27G,40 x 20 mm) Terumo NN-2719R 
Nitril Gloves, Safeskin Purple Kimberley Clark 52001M 
Nitrocellulose membrane (Protran 0.45 N) GE healthcare (Amersham) 10600002 
Nuclease free SafeSeal Tubes (Mµlti) Carl Roth 7080.1 
Oc to MACS Separator Starter Kit Miltenyi Biotec 130-042-108 
Paper towels comfort Wepa 277200 
Parafilm M Sigma P7793 
Pasteur capillary pipetts long Brand 747720 
Petri dishes, 94x16 mm Greiner Bio One 632 180 
Pre-Separation Filters Miltenyi Biotec 130-041-407 
Prot/Elec Tips (gel loading) Biorad 223-9916 
Rodent Diet with 10% kcal% fat (low fat diet, LFD) Research Diets D12450J 
Rodent Diet with 60% kcal% fat (low fat diet, LFD) Research Diets D12492 
Round Bottom Polypropylene Tube with snap cap 14ml BD Biosciences (Falcon) 352059 
Safe-Lock Tubes 1.5 mL Eppendorf 22363204 
Safe-Lock Tubes 2.0 mL Eppendorf 22363352 
Safe-Lock Tubes, 1.5  ml Eppendorf 0030 120.086 
Safe-Lock Tubes, 2.0 ml Eppendorf 0030 120.094 
sc intillation tubes, 5ml PP tube, PE cap VWR 720-0495 
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Sc intillation vials mini with screwcap Carl Roth 5404.1 
Soft-Ject Disposable Syringes 1ml Henke Sass Wolf 5010.200V0 
Sy ringe Filter Unit, 0.45 µm (Millex-HV) Millipore SLHV033RS 
T ipOne graduated filtertips, 10µl Starlab S1121-3810 
T ipOne graduated filtertips, 100µl Starlab S1120-1840 
T ipOne graduated filtertips, 1000µl Starlab S1126-7810 
T ipOne graduated filtertips, 20µl Starlab S1120-1810 
T ipOne graduated filtertips, 200µl Starlab S1120-8810 
T issue Culture Plates 24 well Corning (Falcon) 353047 
T issue Culture Plates 48 well Corning (Falcon) 353078 
T issue Culture Plates 96 well Corning (Falcon) 353077 
Transponder (implantable thermometer) (model IPTT-300) BioMedic Data Systems  
Whatman cellulose blotting paper Sigma (Whatman) Z763187 
XF96 FluxPak Seahorse Bioscience 102310-001 
XF96 Polystyrene Cell Culture Microplates Seahorse Bioscience 101085-004 
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APPENDIX 
Adenovirus Sequences 
After cloning, the following AAV constructs were retrieved: 
pdsAAV-Ucp1p-GFPmut-miR122site-miR-Tbl1: 
• highlighted in yellow: Ucp1 mini promoter (MluI and PstI sites used for insertion 
underlined) 
• highlighted in grey: miR-122 target site (ApaI and AgeI sites used for insertion 
underlined, repeats of miR-122 recognition sequence in bold) 
• highlighted in blue: miR-Tbl1 hairpin 
• highlighted in dark blue: ITR regions (internal repeat) 
CAGCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGAATTCCAGACGATTGAGCGTCAAAATGTAGG
TATTTCCATGAGCGTTTTTCCTGTTGCAATGGCTGGCGGTAATATTGTTCTGGATATTACCAGCAAGGCCGATAGTTTGAGTTCTTCTACTCAGGCAAGTGATGTTATTA
CTAATCAAAGAAGTATTGCGACAACGGTTAATTTGCGTGATGGACAGACTCTTTTACTCGGTGGCCTCACTGATTATAAAAACACTTCTCAGGATTCTGGCGTACCGTTC
CTGTCTAAAATCCCTTTAATCGGCCTCCTGTTTAGCTCCCGCTCTGATTCTAACGAGGAAAGCACGTTATACGTGCTCGTCAAAGCAACCATAGTACGCGCCCTGTAGC
GGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCAC
GTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTC
ACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATC
TCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGTTTA
CAATTTAAATATTTGCTTATACAATCTTCCTGTTTTTGGGGCTTTTCTGATTATCAACCGGGGTACATATGATTGACATGCTAGTTTTACGATTACCGTTCATCGCCCTGC
GCGCTCGCTCGCTCACTGAGGCCGCCCGGGCAAAGCCCGGGCGTCGGGCGACCTTTGGTCGCCCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGAA
TTCACGCGTGGTACCGAGCTCCTCTACAGCGTCACAGAGGGTCAGCAGTCACCCTTGACCACACTGAACTAGTCGTCACCTTTCCACTCTTCCTGCCAGAAGAGCAGA
AATCAGACTCTCTGGGGATATCAGCCTCACCCCTACTGCTCTCTCCATTATGAGGCAAACTTTCTTTCACTTCCCAGAGGCTCTGGGGGCAGCAAGGTCAACCCTTTCC
TCAGACTCTCGAGATCCGAGTGACGCGCGGCTGGGAGGCTTGCGCACCCAAGGCACGCCCCTGCCAAGTCCCACTAGCAGCTCTTTGGAGACCTGGGCCGGCTCAG
CCACTTCCCCCAGTCCCTCCTCCAGCAAGGGGCTATATAGATCTCCCAGGTCAGGGCGCAGAAGTGCCGGGCAATCTGGGCTTAACGGGTCCTCCCTGCCCGAGCAA
GAGGAAGGGACGCTCACCTTTGAGCTGCTCCACAGCGCCGCCTCTGCACTGGCACTACCTAGCCCAAGCTTCTGCAGAAGTTGGTCGTGAGGCACTGGGCAGGTAA
GTATCAAGGTTACAAGACAGGTTTAAGGAGACCAATAGAAACTGGGCTTGTCGAGACAGAGAAGACTCTTGCGTTTCTGATAGGC ACCTATTGGTCTTACTGACATCCA
CTTTGCCTTTCTCTCCACAGGTGTCCACTCCCAGTTCAATTACAGCTCTTAAGGCTAGAGTACTTAATACGACTCACTATAGGCTAGCCTCGACGGTACCGCGGGCCCG
GGAC ACCATTGTCACACTCCAGTATACACAAACACCATTGTCACACTCCAGATATCAC AAACACCATTGTCACACTCCACCGGTCGCCACTGTAGAAGGGCGAGGAGC
TGTGAACCGGGGTGGTGCCTATCCTGGTCGAGCTGGACGGCGACGTATACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGC
TGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCA
CATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGA
AGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCA
CAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGC
AGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGT
CCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAAAGCGGCCGCGGGAGGTAGTGAGTCGACCAGTGGATCCTGGAGGCT
TGCTGAAGGCTGTATGCTGAAATGAAGCACTTGCTAACATGTTTTGGCCACTGACTGACATGTTAGCGTGCTTCATTTCAGGACACAAGGCCTGTTACTAGCACTCACA
TGGAACAAATGGCCCAGATCTGGCCGCACTCGAGATATCTAGAGCGGCCGCGACTCTAGATCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAA
CCTCCCACACCTCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTT
CACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTAAGGCGGGAATTGATCTGAGGAACCCTAGTGATGGAGTTGGCCAC
TCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCAAAGCCCGGGCGTCGGGCGACCTTTGGTCGCCCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGA
GGGAGTGGCCAACCCCCCCCCCCCCCCCCCGGCGATTCTCTTGTTTGCTCCAGACTCTCAGGCAATGACCTGATAGCCTTTGTAGAGACCTCTCAAAAATAGCTACCC
TCTCCGGCATGAATTTATCAGCTAGAACGGTTGAATATCATATTGATGGTGATTTGACTGTCTCCGGCCTTTCTCACCCGTTTGAATCTTTACCTACACATTACTCAGGC
ATTGCATTTAAAATATATGAGGGTTCTAAAAATTTTTATCCTTGCGTTGAAATAAAGGCTTCTCCCGCAAAAGTATTACAGGGTCATAATGTTTTTGGTACAACCGATTTAG
CTTTATGCTCTGAGGCTTTATTGCTTAATTTTGCTAATTCTTTGCCTTGCCTGTATGATTTATTGGATGTTGGAATTCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCG
GTATTTCACACCGCATATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTT
GTCTGCTCCCGGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGAAACGCGCGAGACGAAAGGGCCTC
GTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAA
ATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCC
TTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATC
TCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGAC GCCGG
GCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGC
AGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTA
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ACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACT
GGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATT
GCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCA
GGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAA
AACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAA
AGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACC
AACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCT
ACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGG
TCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCG
AAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCG
GGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTT
GCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGA
GCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATG 
For miR-Tblr1 and miR-NC constructs, sequence was identical apart from the expressed 
micro RNA: 
pdsAAV-Ucp1p-GFPmut-miR122site-miR-Tblr1: 
TGTTCACTATTCCAATCTAGAGAGTTTTGGCCACTGACTGACTCTCTAGAGGAATAGTGAA 
pdsAAV-Ucp1p-GFPmut-miR122site-miR-NC: 
TGAAATGTACTGCGCGTGGAGACGTTTTGGCCACTGACTGACGTCTCCACGCAGTACATTT 
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Glossary 
(E)p300 (E1A binding protein p300) 
2DOG (deoxy-D-glucose) 
3H-2DOG (3H-2-Deoxy-D-glucose) 
AAV (adeno-associated virus) 
Acaa2 (acetyl-Coenzyme A 
acyltransferase 2) 
ACC (acetyl-coenzyme A 
carboxylase) 
Acsl5 (acyl-CoA synthetase long-
chain family member 5) 
ADP (adenosine diphosphate) 
Adrb3, β3-AR (β3-adrenoreceptor) 
AF (adipocyte fraction) 
AKT (protein Kinase B) 
Angptl3 (angiopoietin-like 3) 
Angptl4 (angiopoietin-like 4) 
aP-2 (adipocyte protein 2, also fatty 
acid binding protein 4, FABP4) 
Apoc3 (apolipoprotein 3) 
APS (ammonium persulfate) 
Aqp7 (aquaporin7) 
AR (androgen receptor) 
ATKO mice (adipose tissue 
knockout mice) 
ATP (adenosine triphosphate) 
Atp5o (ATP synthase subunit O) 
AUC (Area under the curve) 
AV (adenovirus) 
aWAT (intra-abdominal / visceral 
WAT) 
Ba(OH)2 (Barium hydroxide) 
BAT (brown adipose tissue) 
BATF (basic leucine zipper 
transcription factor) 
BATKO (brown adipose tissue-
specific TBLR1 knockout mice) 
bFGF (basic fibroblast growth 
factor) 
BL6 (C57Bl6 mice) 
BMI (body mass index) 
BMPs (bone morphogenic proteins) 
brite (brown in white) 
BSA (bovine serum albumin) 
C/EBPα, C/EBPβ, C/EBPδ 
(CCAAT/enhancer-binding 
protein alpha, beta, delta) 
cAMP (cyclic adenosin 
monophosphate) 
Cav2 (caveolin 2) 
Cfd (complement factor D, also 
known ad adipsin) 
ChIP (chromatin immune-
precipitation) 
ChIPseq (chromatin immune-
precipitation sequencing) 
Cidea (cell death-inducing DNA 
fragmentation factor, alpha 
subunit-like effector A) 
CIP (calf intestinal phosphatase) 
CL (CL316243) 
CO2 (carbon dioxide) 
Cox7a1 (cytochrome c oxidase 
subunit VIIa 1) 
Cox8b (cytochrome c oxidase 
subunit VIIIb) 
cPGI2 (carbaprostacyclin) 
CPM (counts per minute) 
Cpt1b) (carnitine 
palmitoyltransferase 1b) 
CREB (cAMP responsive element 
binding) 
CsCl (cesium chloride) 
Dex (dexamethasone) 
DMEM (Dulbecco's Modified Eagle 
Medium) 
DPM (disintegrations per minute) 
DSG (disuccinimidyl glutarate) 
DTT (dithiothreitol) 
Dusp10 (dual specificity protein 
phosphatase 10) 
Dusp6 (dual specificity 
phosphatase 6) 
early KD (knockdown 2 days prior 
to induction of adipogenic 
differentiation) 
EDTA (ethylenediaminetetraacetic 
acid) 
ELISA (enzyme-linked 
immunosorbent assay) 
Elovl6 (elongation of long-chain 
fatty acids family member 6) 
ER (estrogen receptor) 
EtBr (ethidiumbromide) 
EtOH (ethanol) 
Fabp4 (fatty acid binding protein 4) 
FABP4 (fatty acid binding protein 4, 
also adipocyte protein 2, aP-2) 
FAs, FFAs (fatty acids, free fatty 
acids) 
FCCP (carbonyl cyanide 4-
(trifluoromethoxy)phenylhydraz
one) 
FCS (fetal calf serum) 
Fgf21 (fibroblast growth factor 21) 
Forsk (forskolin) 
FOXA1, 2 (forkhead box A1, 2) 
FPLC (fast‐protein liquid 
chromatography) 
G2P (glycerol-2-phosphate) 
GAPDH (glycerinaldehyd-3-
phosphat-dehydrogenase) 
GATA3 (GATA binding protein 3) 
GC (gastrocnemius skeletal 
muscle) 
Glut1 (glucose transporter 1) 
GPCR (G-protein coupled receptor) 
GR) (glucocorticoid receptor) 
GSK3 (Glycogen synthase kinase 
3) 
GTT (glucose tolerance test) 
H+ (proton) 
HDACs (histone-deacetylases) 
HDL (high density lipoprotein) 
HFD (high fat diet) 
i.p. (intraperitoneally) 
IBMX (3-isobutyl-1-methylxanthin) 
IGF-1 (insulin-like growth factor) 
Iso (isoproterenol) 
ITT (insulin tolerance test) 
iWAT (inguinal WAT) 
kb (kilobasepairs) 
KCl (potassium chloride) 
KD (knockdown) 
kg (kilograms) 
KH2PO4 (Potassium dihydrogen 
phosphate) 
KO (knockout) 
KRB (Krebs Ringer Buffer) 
late KD (knockdown 2 days prior to 
harvest of mature adipocytes) 
Ldlr (LDL receptor) 
LFD (low fat diet) 
LiCl (lithium chloride) 
LPL (lipoprotein lipase) 
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LXR (liver X rexeptor) 
MAP kinase (p38 mitogen-activated 
protein kinase) 
Map4k (mitogen-activated protein 
kinase kinase kinase kinase) 
MAPK (mitogen-activated protein 
kinase) 
MOI (multiplicity of infection) 
MRI (magnetic resonance imaging) 
MSCs (mesodermal stem cells) 
Myf5 (myogenic factor 5) 
N2 (Nitrogen) 
Na2HPO4 (disodium phosphate) 
Na3VO4 (sodium orthovanadate) 
NAA (non-essential-amino-acids) 
NaAc (sodium acetate) 
NaCl (sodium chloride) 
NaDOC (sodium deoxycholate) 
NaF (sodium fluoride) 
NaH2PO4 (sodium dihydrogen 
phosphate) 
NaHCO3 (sodium hydrogen 
carbonate) 
NaOH (sodium hydroxide) 
NCoR (nuclear receptor co-
repressor) 
NE (norepinephrine) 
NEFAs (non-esterified fatty acids) 
NF-κB (nuclear factor κB) 
Nrg4 (neuregulin 4) 
NRs (nuclear receptors) 
o.n. (over night) 
O2 (oxygen) 
P/S (penicillin / streptomycine) 
PARP1 (poly-[ADP-Ribose]-
polymerase 1) 
PBS (phosphate buffered saline) 
PCI (phenol chloroform 
isoamylalcohol) 
PCR (polymerase chain reaction) 
Pdk4 (pyruvate dehydrogenase 
kinase) 
PEB (protein extraction buffer) 
PEI (polyethylenimin) 
pfu (plaque forming units) 
PGC-1α (peroxisome proliferator-
activated receptor gamma 
coactivator 1-alpha) 
Pi (inorganic phosphate) 
PIC (protease inhibitor cocktail) 
PKA (protein kinase A) 
PKCδ (protein kinase C-δ) 
pola1 (DNA polymerase A1) 
Ppara, Pparg / PPARα, PPARγ 
(peroxisome proliferator 
activated receptor alpha, 
gamma) 
PRDM16 (PRD1-BF1-RIZ1 
homologous domain containing 
16) 
PS (polystyrene) 
qRT-PCR (quantitative real-time 
polymerase chain reaction) 
RER (respiratory exchange ratio) 
Res (response elements) 
Retn (resistin) 
RMR (resting metabolic rate) 
RNAseq (RNA sequencing) 
Rosi (rosiglitazone) 
RXRα (retinoid X receptor alpha) 
Scd1 (stearoyl-CoA desaturase-1) 
Sdhb, Sdhc (succinate 
dehydrogenase complex 
subunit B, C) 
SDS (sodium dodecyl sulfate) 
SEM (standard error of the mean) 
shRNA (short hairpin RNA) 
Sirt1 (sirtuin-1) 
Smad6 (SMAD family member 6) 
SMRT (silencing mediator of 
retinoid and thyroid receptors) 
Srebp1c (sterol regulatory element-
binding protein 1c) 
STZ (streptozotocin) 
SV129 (129S6/SvEvTac mice) 
SVF (stromal vascular fraction) 
T3 (thyroid hormone, 3,3′,5-
triiodothyronine) 
TBE (tris-borate-EDTA) 
TBL (transducin (beta)-like 1 X-
linked, also TBL1X) 
TBLR (transducin (beta)-like 1 X-
linked receptor 1, also 
TBL1XR1) 
TBS-T (tris buffered saline with 
tween) 
TEMED (N,N,N',N'-
tetramethylethane-1,2-diamine) 
TF (transcription factor) 
TGs (triglycerides) 
TNFα (tumor necrosis factor alpha) 
UCP-1 (uncoupling protein 1, also 
thermogenin) 
VCO2 (carbon dioxide consumption) 
VLDL (very low density lipoprotein) 
VO2 (oxygen consumption) 
WAT (white adipose tissue) 
ZnSO2 (zinc sulfate) 
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